- Antibiotic/benzoyl peroxide dispenser

Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife and convenient dispensing and application are provided.

- 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives

1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: The 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I) possess cell cycle inhibitory activity and are accordingly useful for their anti cell proliferation (such as anti cancer) activity.

- 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof

The invention relates to the compounds of formula I, their preparation and the pharmaceutical compositions containing the compounds. The invention also relates to the use of the compounds of formula I in preparing medicines, which can treat sexual dysfunction of animals including human (male and female), especially erectile dysfunction of male and the diseases in which the function of phospholipase 5 (cGMP PDE5) is involved.

- Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same

The present invention is related to novel use of 2-oxo-heterocyclic compounds having anticancer activity and the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the cancer disease comprising lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer or cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors, Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lymphocytic lymphonas, cancer of the bladder, cancer of the kidney or ureter, or neoplasms of the central nervous system, therefore, it can be used as the therapeutics for treating and preventing cancer diseases.

- Antibiotic/benzoyl peroxide dispenser

Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife and convenient dispensing and application are provided.

- Medical films and articles prepared from emulsion polymers

Protective film forming compositions useful as medical films and other related wound care and treatment articles, including liquid bandages are prepared from emulsion polymers, including a polymer blend including at least one hard emulsion polymer component and at least one soft emulsion polymer component, having the required dynamic storage modulus and mean Tg of the hard and soft polymer blend components.

- Self-tanning product comprising two components and means for artificially coloring the skin

Self-tanning products for the skin, including compartmentalized kits therefor, comprise at least two components (A) and (B) comprising: a first component (A) containing, formulated into a cosmetically acceptable medium, at least one self-tanning agent, and a second component (B) containing, also formulated into a cosmetically acceptable medium, at least one hydroxyalkylurea of formula (I) in which R.sub.1, R.sub.2, R.sub.3 and R.sub.4 each independently represent a hydrogen atom, a C.sub.1-C.sub.4 alkyl radical or a C.sub.2-C.sub.6 hydroxyalkyl radical containing from 1 to 5 hydroxyl groups, at least one of the radicals R.sub.1-R.sub.4 representing a hydroxyalkyl group, or salt, solvate, or isomer thereof; the components (A) and (B) being present in the same composition or confined separately.

- Sunless tanning products and processes

Sunless tanning compositions are substantially improved by adding methylsulfonyl methane [MSM] and certain glycols to Dihydroxyacetone (DHA).

- Cosmetic/dermatological compositions comprising a derivative of glucose and of vitamin F and A specific surfactant

Topically applicable cosmetic/dermatological compositions suited for improving the condition of human keratin fibers, notably human hair, especially for reducing or stopping loss and/or inducing and/or stimulating growth and/or density thereof, contain a thus effective amount of (a) at least one derivative of glucose and of vitamin F, solubilized in a topically applicable, physiologically acceptable medium therefor which includes (b) at least one nonionic surfactant having a hydrophilic/lipophilic balance (HLB) of greater than 10, (c) at least one C.sub.1-C.sub.4 alcohol and (d) water.

- Skin external agents and drugs

The present invention provides a method for enhancing epidermal permeability barrier function of the aged skin, which includes the step of externally administering to the aged skin an amount of a fumaric acid diester derivative expressed by the following general formula (1) as an active ingredient wherein R.sup.1 represents a C.sub.1-4 alkylene group; R.sup.2 and R.sup.3 each represents a linear or branched C.sub.1-8 alkyl group; and n is an integer of 2 to 5.

- Cleaning composition in solid form

Cleansing composition provided in solid form and containing, in an anhydrous medium, at least one active agent chosen from salicylic acid and its derivatives, at least one pulverulent foaming surfactant, and at least one water-soluble polymer, it being possible for the quantity of water-soluble polymer to be up to 10% of the total weight of the composition. The composition is preferably provided in powdered or tablet form and it may be incorporated into a sponge. The composition may be used in particular for cleansing greasy skin with a tendency towards acne.

- Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 for immune activation or prevention and treatment of cancer and the preparation method thereof

The present invention relates to the soluble glucan oligomer having a M.W. ranging from 1,000 to 10,000 prepared by treating insoluble beta-glucan isolated the cell wall of yeast variant IS2 with commercially available beta-glucan hydrolyzing enzymes. The soluble glucan oligomer showed potent efficacy on promoting immune activity and on inhibiting the growth of cancer cell, therefore, it can be used as the therapeutics or health care food for treating and preventing immunodeficiency and cancer disease.

- Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-.alpha. or combinations thereof.

- Nicotinamide derivatives useful as pde4 inhibitors

This invention relates to nicotinamide derivatives of general formula (I): in which R.sup.1, Z and R.sup.2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

- Eotaxin: eosinophil chemotactic cytokine

A chemoattractant protein called "eotaxin" is capable of attracting eosinophils and of inducing eosinophil accumulation and/or activation in vitro and in vivo. Various types of agents that inhibit or otherwise hinder the production, release or activity of eotaxin may be used therapeutically in the treatment of asthma and other inflammatory diseases.

- Methods for the production of multimeric protein complexes, and related compositions

Improved methods for the production of multimeric-protein-complexes, such as redox proteins and immunoglobulins, in association with oil bodies are described. The redox protein is enzymatically active when prepared in association with the oil bodies. Also provided are related nucleic acids, proteins, cells, plants, and compositions.

- Natural aqueous composition and machine for dry-cleaning textiles and leathers

The present invention relates to an aqueous composition for dry cleaning and/or degreasing textiles and/or leathers, which composition is natural and biodegradable. The dry cleaning composition of the invention comprises in particular essential oils and surface active agents, it is etherizable and micronizable, and its ingredients are exclusively of vegetable origin. The invention also relates to a method of dry cleaning and/or degreasing textiles and/or leathers implementing the above-described aqueous composition, the method comprising a succession of stages of tumbling the textiles and/or leathers in a leaktight enclosure, wherein one of the stages consists in impregnating the textiles and/or leathers with a small quantity of an aqueous composition by means of pneumatic atomization at a size no more than 50 .mu.m, for a limited duration, and at a temperature of about 35.degree. to 45.degree. C., until the total weight gain is about 5% to 70%. The invention also relates to a machine for dry cleaning and/or degreasing textiles and/or leathers by implementing said method.

- Methods for sterilizing biological materials using dipeptide stabilizers

Methods are disclosed for sterilizing biological materials to reduce the level of active biological contaminants or pathogens such as viruses, bacteria, nanobacteria, yeasts, molds, mycoplasmas, ureaplasmas, prions and parasites. These methods involve the use of dipeptide stabilizers in methods of sterilizing biological materials with irradiation.

- Alcoholic pump foam

An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to .ltoreq.99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam stabilizer, e) optionally, at least one member selected from the group consisting of cosmetic auxiliaries, adjuvants, active ingredients, and mixtures thereof, and f) optionally water. The surface tension of component b) lies in the range of .+.15 dyn/cm of the surface tension of component a) or corresponds to the surface tension of component a), and the sum of components a) to f) is 100 wt % relative to the total quantity of the foam composition.

- Water-soluble anti-dandruff compounds and compositions thereof

Water-soluble and water dispersible undecylenic amido propyl dimethyl hydroxyl ethoxy ethyl ammonium undecylenate compounds of formula I having anti-dandruff, preservative and sunscreen activity wherein R1, R2 are from C1-C6 carbon atoms, R3 is undecylenic acid, amino group is selected from dimethyl amino propyl amine. Personal care compositions comprising compounds of formula I

- Prebiotically active plant extracts

The invention relates to plant extracts that have a prebiotic effect on skin, topical cosmetic and pharmaceutical compositions containing said plant extracts, and the use of said plant extracts and compositions, especially for treating the skin.

- Cell preparation and use of the preparation for treating joints and cartilage defects, and methods for the production thereof

The invention relates to a cell preparation for therapeutic and/or cosmetic use in humans and/or animals, containing: a) human or animal cells, which; b) had been cultured while using a substance or substance mixtures that activates) CD44 expression of these cells, and which present an increased CD44 expression of these cells.

- Stabilized protein compositions for topical administration and methods of making same

A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods of administering active agents topically or transdermally.

- Method for the extemporaneous preparation of cosmetic compositions having the texture of a cream and compositions for carrying out said method

The invention relates to a method for the preparation of cosmetic compositions having the texture of a cream. Said preparation is made at the time when the composition is used and includes bringing the following elements into contact with each other: (A) a liquid phase; (B) a powder containing a gelling agent for the liquid phase (A); and (C) an active cosmetic ingredient, whereby the elements are brought into contact by adding phase (A) to phase (B), subjecting a solid powder containing phase (B) and phase (A) in an immobilized form to mechanical stress, said mechanical stress releasing phase (A). The invention also relates to compositions which can be used in the above context, especially (1) compositions containing phase (B) (to which phase (A) is added prior to use); and (2) solid compositions comprising phase (B) and phase (A) in an immobilized form (and which are transformed into a cream when they are applied to the skin).

- Hydrophilic biocompatible adhesive formulations and uses

This invention relates to the use of hydrophilic, biocompatible adhesives in drug delivery systems, wound dressings, bioelectrodes, and other systems in which hydrophilic, biocompatible adhesives are desirable. In particular, the invention relates to water-swellable, water-insoluble polymers that in combination render a composition adhesive upon contact with moisture, wherein a first water-swellable, water-insoluble polymer is cationic, a second water-swellable, water-insoluble polymer is anionic, and the polymers are ionically associated with each other to form a polymer matrix.

- Dermal medicaments application enhancer

A topical medicament for use in treating tissues comprising: an enhancer for facilitating non-invasive, transdermal delivery and/or enhancing metabolic effect of a therapeutic dosage of LEVULAN.RTM. KERASTICK.TM. (aminolevulinic acid HCl) into a tissue. The present invention provides a topical, transdermal medicament for use in treating tissues comprising an enhancer for facilitating non-invasive, transdermal delivery of a therapeutic dosage of comprising LEVULAN.RTM. KERASTICK.TM. (aminolevulinic acid HCl) into a tissue for example wherein the enhancing agent is comprising L.M.X.4.RTM.The enhancer may be selected from the group consisting of lidocaine, benzyl alcohol, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate and water or combinations thereof. The present invention, also, provides a pharmaceutical composition useful for treating tissues in humans and animals which comprises a therapeutically effective amount of LEVULAN.RTM. KERASTICK.TM. (aminolevulinic acid HCl) or pharmaceutically acceptable salt thereof in combination with a synergistically effective amount of at least one enhancer or pharmaceutically acceptable carrier wherein said enhancer is selected from the group consisting of lidocaine, benzyl alcohol, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate and water. The invention, also, provides a method of treating or preventing a human or animal afflicted by a diseases comprising topically administering a pharmaceutical composition which comprises of a therapeutically effective amount of aminolevulinic acid HCl in combination with an enhancer and/or a pharmaceutically acceptable carrier. The invention, also, provides a method wherein the composition further comprises a synergistically effective amount of an enhancer and/or pharmaceutically acceptable salt thereof wherein said enhancer is selected from the group consisting of lidocaine, benzyl, carbomer 940, cholesterol, hydrogenated lecithin, polysorbate 80, propylene glycol, trolamine, vitamin E acetate, water and combinations thereof.

- Stabilized compositions for topical administration and methods of making same

A stabilizing composition that also enhances permeation is provided for the topical or transdermal administration of an active ingredient. The composition preferably comprises collagen, elastin, sphingoside and cerebroside. Also provided are pharmaceutical or cosmetic formulations comprising an effective amount of an active agent and the stabilizing composition as well as methods of administering active agents topically or transdermally.

- Use of galactomannans as an active cosmetic agent

This invention relates to a method for increasing the adhesion of basal keratinocytes to the Dermoepidermal Junction (DEJ) in a subject, comprising administrating an effective amount of a cosmetic or dermatological composition comprising galactomannans on the skin of the subject, in particular for preventing and/or treating skin aging.

- Pharmaceutical composition for delayed hypersensitivity

The present invention provides a pharmaceutical composition by a novel action mechanism without serious side effects for delayed hypersensitivity and a screening method of the same. The invention also provides a novel assay method of inhibitors/suppressive agents of PAR-2. The invention relates to a pharmaceutical composition for delayed hypersensitivity containing one or two or more active ingredients selected from the group consisting of inhibitors of PAR-2 and suppressive agents of PAR-2 gene expression and a pharmaceutically acceptable carrier, and to a method for screening active ingredients for pharmaceutical composition for delayed hypersensitivity by contacting a subject substance with cells expressing PAR-2 and by determining expression or activity of PAR-2. The invention also relates to a method for detecting or quantifying actions of the subject substance for PAR-2 using cells expressing PAR-2 in a culture containing inositol.

- Peptides having a high cysteine content

The invention relates to cysteine containing peptides of the structure XXCCXXXXXXXCXXXCXXXXXXQXXCXXXCXCXXXXXXXCXXXXXX, of the structure XXCCXXXXXXXCXXXCXXXXXXXXXCXXXCXCXXXXTXXCXXXXXX and of the structure XXCCXXXXXXXCXXXCXXXXXXXXXXCXXXCXCXXXXXXXXCXXXXXX, wherein X, independently of one another, represents any naturally occurring amino acid, as well as to nucleic acid sequences encoding said peptides, to vectors comprising said sequences, as well as to pharmaceutical compositions containing said peptides and their use as pharmaceutics, particularly for the treatment of cancers.

- Biologically active oils

A process for the production of fats or oils and their extracts containing biologically-active chemical compounds from a lipid substrate, the process comprising: a) inoculation of a lipid substrate with fungally derived lipolytic enzymes b) incubating the inoculated substrate for a period of between about 7-120 days at a temperature of between about 4-35.degree. C., at a humidity of between about 75-100%, and C) processing said substrate mixture to obtain a biologically active fat or oil.

- Ampholytic copolymer and use thereof

The present invention relates to an ampholytic copolymer, to polyelectrolyte complexes which comprise such an ampholytic copolymer, and to cosmetic or pharmaceutical compositions which comprise at least one ampholytic copolymer or one polyelectrolyte complex.

- Bodywashes containing additives

The invention encompasses bodywashes containing an additive. The additive may contain a sunscreen. The additive may contain 2, 3, or more than three sunscreens. Optionally, one or more of the sunscreens may be encapsulated. The invention further encompasses methods of making and using bodywashes containing an additive, e.g., an additive containing a sunscreen.

- Sunscreen compositions and methods of use

The invention encompasses additives for addition to a bodywash, where the additives contain one or more sunscreens, and where a bodywash which contains the additive imparts to the skin an SPF of at least about 2, in some cases at least about 5, or 10, or 15. Also described are methods of making and using the additives.

- Skin care compositions containing a sugar amine

Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of a terpene alcohol and a safe and effective amount of a retinoid; a safe and effective amount of a terpene alcohol and a safe and effective amount of a peptide; a safe and effective amount of a retinoid and a safe and effective amount of a peptide; a safe and effective amount of tocopherol sorbate; or a safe and effective amount of a vitamin B.sub.3 compound.

- Skin care composition containing a sugar amine

Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of a terpene alcohol and a safe and effective amount of a retinoid; a safe and effective amount of a terpene alcohol and a safe and effective amount of a peptide; a safe and effective amount of a retinoid and a safe and effective amount of a peptide; a safe and effective amount of tocopherol sorbate; or a safe and effective amount of a vitamin B.sub.3 compound.

- Cosmetic and pharmaceutical substances based on polyelectrolyte complexes

The present invention relates to cosmetic and pharmaceutical compositions which comprise at least one polyelectrolyte complex which comprises a copolymer with cationogenic groups based on vinylimidazole and an acid-group-containing polymer. The invention further relates to the use of these polyelectrolyte complexes.

- Delivery of bio-available compounds with anhydrous topical preparations

The disclosed systems and methods for delivery of bio-available compounds in topical preparations generally include anhydrous carrier particles adapted to carry bio-available compounds. The carrier particles may be admixed with anhydrous formulation material that is suitably adapted to suspend and/or separate the carrier particles. Disclosed features and specifications may be variously controlled, adapted or otherwise optionally modified to realize improved production and/or use of carrier particles that may be employed to deliver bio-available compounds in order to achieve a desired purpose. Exemplary embodiments of the present invention generally provide anhydrous carrier particles that may be mixed with substantially anhydrous topical preparations.

- Medical devices employing novel polymers

Medical devices with at least one surface comprising a polymer or polymers on the surface are provided. The polymer or polymers are capable of breaking down (e.g., including, but not limited to, hydrolyzing) in the physiologic milieu to form an active agent or agents under physiologic conditions, and can contain other active agents dispersed within or appended to the polymer matrix. Methods of delivering an active agent to an interior surface of a vein or artery are also provided.

- Transdermal systems having control delivery system

Transdermal delivery systems are disclosed including a backing layer, a polymer membrane within the backing layer, an adhesive layer for attaching the delivery system to the patient's skin or mucosa, and a releasable layer covering the adhesive layer prior to use, the polymer membrane impregnated with sufficient fluid medium to alter the rate of transmission of an active agent through the polymer membrane, with the amount of fluid medium being greater than the amount retained by the fluid membrane upon drying.

- Composite materials and particles

A method or concept for producing a composite material having at least an amphifilic (i.e., surface-active) and polymer component, and the composite material formed thereby, includes providing a mixture of at least one each of polymer and amphifilic compound in a volatile solvent or solvent mixture and providing a phase diagram of the chemical system describing how the components of the chemical system interact in thermodynamic stable phases as a function of temperature, concentration and pressure. The polymer should be a homopolymer, a random block copolymer or a mixture thereof, preferably biodegradable. The amphifilic compound can form a bilayer-containing phase. The solvent is removed from the mixture by a process selected from the phase diagram considering the desired final composite material, whereby a material is formed. The composite material is useful for applications such as encapsulation of therapeutically active components or for applications such as surface coating.

- Dispenser for dispensing three or more actives

Two separate compositions, one containing an effective anti-acne treating amount of a first active ingredient and one containing a second active ingredient that is incompatible with the first active ingredient are packaged within and dispensed from a common dispenser. By packaging these two active ingredients in this manner, long shelflife and convenient dispensing and application are provided.

- Substituted imidazopyrimidines for the prevention and treatment of cancer

Compounds of general formula (I), wherein from A.sub.1 to A.sub.5, and from B.sub.1 to B.sub.5 are H, alkyl, alkoxyl, halogen, carboxylic derivatives or sulfur derivatives, among others; and from P.sub.1 to P.sub.3 are H, halogen, alkyl or alkoxyl, among others. Said compounds may be used for the chemoprevention and treatment of both precancerous lesions and cancer.

- Use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person

The use of urocanic acid or another pharmaceutically acceptable agent being able to acidify the cell cytoplasm, for the manufacture of a pharmaceutical composition useful for causing inhibition or halting of transformed or non-transformed cell proliferation in a person or an animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal. The use of the agent as an enhancer for other therapeutically active agents, and a pharmaceutical composition, are also disclosed.

- Novel anti-proliferative pharmaceutical composition

The use of urocanic acid or another pharmaceutically acceptable agent being able to acidify the cell cytoplasm for the manufacture of a pharmaceutical composition useful for causing inhibition or halting of transformed or non-transformed cell proliferation in a person or an animal, where an effective amount of the agent is administered in an essentially non-dissociated form to the person or animal. The use of the agent as an enhancer for other therapeutically active agents, and a pharmaceutical composition, are also disclosed.

- Active agent delivery method

A method for active agent delivery is provided which includes orchestrating focus groups and clinical studies and the distribution of educational materials and guidelines for counseling patients with regard to what the patients need to know and what the patients must do in order to both avoid adverse side effects while taking doses of active agent and to receive prescriptions for the doses.

- Secure transaction system

The system of the present invention comprises a personal Virtual Safety Deposit Box where users are able to enroll their identification methods, financial accounts and personal information. Once authenticated, this information is transferred to a master file within a central databank. Enrollment enables the user to link each item (collectively referred to as the "stored data") to any one of the plurality of identification methods they enter. Thereafter, the user may employ their enrolled identification methods to select a desired one of the stored data fields. A secure intermediary uses the identification method and a selection method to determine which of the stored data fields the user desires to employ by accessing a database containing each of the stored data fields and the corresponding selection method. The selected field is activated and any relevant outside agencies are notified of the transaction and the transaction is concluded.

- Film forming foamable composition

A foamable composition, includes (1) about 6% to about 70% by weight of at least one organic carrier; (2) about 0.1% to about 5% by weight of at least one surface-active agent; (3) about 0.01% to about 5% by weight of at least one film forming agent; (4) water; and (5) about 3% to about 25% by weight of the total composition of at least one liquefied or compressed gas propellant. The composition is substantially alcohol free and is used in treating, alleviating or preventing a disorder.

- Chroman derivatives as lipoxygenase inhibitors

The present invention is concerned with certain novel derivatives of Formula I: wherein X and R.sup.1 to R.sup.10 are as described in the specification, and where either R.sup.5 is OH, --NR.sup.dOR.sup.a or --NR.sup.d--NR.sup.bR.sup.c, or R.sup.7 is --NR.sup.dOR.sup.a or --NR.sup.d--NR.sup.bR.sup.c, or C.dbd.R.sup.7R.sup.8 is C.dbd.NOR.sup.a or C.dbd.N--NR.sup.bR.sup.c, which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of skin care and/or pharmaceutical compositions for the treatment of lipoxygenase mediated disorders.

- Aqueous Polymer Dispersion

An aqueous polymer dispersion prepared by free-radical polymerization of vinyl acetate in the presence of at least one ionic emulsifier, at least one free-radical initiator and at least one protective colloid, wherein the polymerization is carried out in the presence of a polymerization regulator and wherein the ratio by weight of protective colloid to ionic emulsifier is at least 4:1 and wherein the ratio by weight of vinyl acetate monomer to protective colloid is between 19:1 and 4:1.

- Haircare use of cyclic amine derivatives

The present invention relates to a process for treating human keratin fibers and/or the skin from which the said fibers emerge, in order to induce and/or stimulate the growth of the human keratin fibers and/or to stop their loss and/or to increase their density, comprising at least the application, to the human keratin fibers and/or the skin, of a cosmetic composition comprising an effective amount of at least one piperidine derivative of general formula (I), in which: R.sub.1 denotes a halogen or a radical chosen from a linear or branched C.sub.1-C.sub.6 alkyl radical, a group OR, a group NRR', a CF.sub.3 group, a group NHCOR or a group CONRR'; R.sub.2 denotes a linear or branched C.sub.1-C.sub.20 alkyl or alkenyl radical, the hydrocarbon-based chain of which may be optionally interrupted with a --CO-- function optionally substituted with at least one group OR, COOR, NRR', NHCOR or CONRR' and/or with a phenyl group optionally substituted with one or more radicals R.sub.1; with R and R' denoting, independently of each other, a hydrogen atom or a linear or branched C.sub.1-C.sub.6 alkyl radical, m represents an integer ranging from 0 to 5; and n represents an integer ranging from 0 to 5. or a salt or isomer thereof, leaving the said composition in contact with the keratin fibers and/or the skin from which the fibers emerge, and optionally rinsing the keratin fibers and/or the skin.

- Skin care compositions containing a sugar amine cross reference to related application

Topical skin care compositions containing sugar amines in combination with selected skin care actives and methods of using such compositions to regulate the condition of skin are disclosed. The compositions contain a safe and effective amount of a sugar amine in combination with either a safe and effective amount of a terpene alcohol and a safe and effective amount of a retinoid; a safe and effective amount of a terpene alcohol and a safe and effective amount of a peptide; a safe and effective amount of a retinoid and a safe and effective amount of a peptide; a safe and effective amount of tocopherol sorbate; or a safe and effective amount of a vitamin B.sub.3 compound.

- Composition serving as a carrier for delivery of active ingredients in cosmetic and dermatological applications

The present invention is for a carrier comprising an oil/water emulsion for delivery of active ingredient in a medium of cream or lotion for skin cosmetic and/or dermatological care.

- Controlled delivery system for fragrance comprising a (METH)acrylate/hydroxy (METH) acrylate copolymer

A perfuming composition for application to the skin by means of a roll-on, pump-spray, squeeze bottle or aerosol spray type device. The composition includes a perfuming base and, optionally, a deodorant or antiperspirant base, with at least one of the bases being combined with a film-forming substrate and an emulsifier so as to form an emulsion. The emulsion, once dried on the skin, provides for in-situ encapsulation of the perfuming base so as to prevent release of the latter until a surge of skin perspiration or contact with a moisture source takes place, and for in-situ re-encapsulation of the perfuming base upon the subsequent drying of the skin. The film-forming substrate is preferably an acrylates/hydroxyacrylates copolymer that is used with other components or that is used alone.

- Hydrophilic beads for use in topical formulations

A composition and method for producing hydrophilic beads for use in topical formulations is described as generally including gellan gum, salts of divalent cations and water. Disclosed features and specifications may be variously controlled, adapted or otherwise optionally modified to realize improved production and/or use of hydrophilic beads to achieve a particular desired purpose. Exemplary embodiments of the present invention generally provide hydrophilic beads that may be comixed with cosmetic, cosmeceutical and/or topical preparations for surface abrasion or as carriers for the delivery of other compounds; such as, aloe vera, ascorbic acid, active agents, and/or the like.

- Novel agents for preventing and treating disorders involving modulation of the RyR receptors

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

- [1,2,4]-Dithiazoli(di)ne derivatives, inducers of gluthathione-S-transferase and NADPH quinone oxido-reductase, for prophylaxis and treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular

The present invention relates to 5-imino-5H-[1,2,4]-dithiazol-3-yl-amine and [1,2,4]-dithiazolidine-3,5-diylidene-diamine derivatives as inducers of gluthathione-S-transferase (GST) and NADPH quinone oxidoreductase (NQO), to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said [1,2,4]-dithiazoli(di)ne derivatives. The invention also relates to the use of a compound disclosed herein for the treatment of adverse conditions associated with cytotoxicity in general and apoptosis in particular. The invention relates to compounds of the general formula (I): wherein wherein the symbols have the meanings given in the specification.

- Stand-alone or enhancer composition for oral care

A biological tissue care composition, such as an oral care composition, for enhancing the effects of whitening compositions. A solvent and surfactant is used with an alkaline builder and an optional saponifier. A method of use of such a composition includes use as a tooth cleaning composition. Alternatively the composition may be used as a stand-alone cleaning composition.

- Capsaicinoid decontamination compositions and methods of use

A therapeutic composition for inhibiting physiological responses elicited by exposure of skin to an irritant can be used to treat exposure to capsaicinoids or other chemical irritants. The therapeutic composition can include a carrier being present in an effective amount and form sufficient to be applied to skin and deliver active agents to the skin which has been previously exposed to a capsaicinoid. Also, the therapeutic composition can include a cooling agent in an effective amount within the carrier to provide a cooling sensation to the skin. Further, the therapeutic composition can include a capsaicin receptor antagonist in an effective amount within the carrier to inhibit calcium flux associated with activation of the capsaicin receptor by a capsaicinoid. The therapeutic composition can be part of a kit that also includes a cleansing composition, which is capable of cleaning and/or absorbing capsaicinoids from the skin.

- Topical medicaments and methods for photodynamic treatment of disease

New photodynamic, topically-applicable medicaments and certain medical uses of such photodynamic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene. The halogenated xanthenes constitute a family of potent photosensitizers that become photoactivated upon illumination of the treatment site with visible wavelengths of light. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs; the mouth and digestive tract and related organs; the urinary and reproductive tracts and related organs; the respiratory tract and related organs; various other internal or external tissue surfaces, such as tissue surfaces exposed during surgery; and for treatment of a variety of conditions related to microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid or aerosol delivery vehicles.

- Method and apparatus for skin treatment

Disclosed is a system and method for treatment of skin disorders. More particularly, the disclosed invention is directed toward the use of multiple light sources for treating skin with or without the use of a topical compositions or photomodulation enhancing agents. Dual light emitting diodes may, for example, be used at relatively low power (less than about 10 J/cm2) to photomodulate skin or living tissue to reduce wrinkles, fine lines, acne, acne bacteria, and other skin disorders.

- Use of tyrosine inhibitors for whitening human skin and treating melanocyted dysfunction associated diseases

The present invention relates to a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

- Stable mixed emulsions

Stable mixed emulsion systems containing at least two discrete and distinctly different dispersed particle size ranges, i.e., both nanoemulsion and macroemulsion semisolid dispersions, as well as a method of making the same, are disclosed. The stable mixed emulsions may be used for cosmetic and dermatological applications and provide unique benefits.

- Care and /or Make-Up Cosmetic Composition Structured with Silicone Polymers

Care and/or make-up cosmetic composition comprising: a liquid continuous fatty Phase structured with at least one structuring polymer (homopolymer or copolymer) having a weight-average molecular mass ranging from 500 to 500 000, containing at least one moiety comprising: at least one polyorganosiloxane group consisting of I to 1 000 organosiloxane units in the chain of the moiety or in the form of a graft, and at least two groups capable of establishing hydrogen interactions, Chosen from ester, amide, sulphonamide, carbamate, thiocarbamate, urea, urethane, thiourea, oxamido, guanidino and biguanidino groups, and combinations thereof, the polymer being solid at room temperature and soluble in the liquid fatty Phase at a temperature of 25 to 250.degree. C., the Said liquid fatty Phase comprising at least one compound capable of reducing the enthalpy of fusion of the structuring polymer, and then the liquid fatty Phase, the structuring polymer and the compound capable of reducing the enthalpy of fusion of the structuring polymer forming a physiologically acceptable medium.

- Benzoyl peroxide compositions and methods of use

Solutions of benzoyl peroxide, in one or more solvents are provided that are suitable for direct topical application to the skin of a user or can be formulated into a product that is suitable for topical application to the skin of a user. In embodiments, the solutions include benzoyl peroxide and optionally additional active or inactive ingredients, and a solvent or mixture of solvents in which the benzoyl peroxide is prepared as a clear solution at 25.degree. C. Methods of using the solutions are also described. Product formulations such as emulsion are also described. The solutions and product formulations can increase the efficacy and percutaneous absorption of benzoyl peroxide.

- Device for delivery of TRPV1 agonists

Described here are drug delivery devices including an occlusive backing layer and a drug depot containing a TRPV1 agonist and a non-hydrophilic solvent. The drug depot may take various forms, such as an adhesive polymeric matrix, liquid reservoir, or microreservoir droplets. Methods of making and using the drug delivery devices are also described.

- Method for determining hair cycle markers

The invention relates to a method for determining hair cycle markers in vitro, test kits and biochips which are used to determine hair cycle markers and to the use of proteins, mRNA molecules, proteins or fragments thereof as hair cycle markers. The invention also relates to a test method which is used to detect the effectiveness of cosmetic and pharmaceutical active ingredients which influence the hair cycle, in addition to a screening method which is used to identify cosmetic or pharmaceutical active ingredients which influence the hair cycle and to a method for the production of a cosmetic and pharmaceutical preparation which influences the hair cycle.

- Aryl oximes

Aryl oxime derivatives of the formula (I), in which R.sup.1, R.sup.2, R.sup.3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

- Formulations

The present invention relates to formulations for topical applications comprising pigments obtainable by agitating a suspension comprising one or more inorganic pigments and silver oxide, in order to reduce undesirable side effects caused by microorganisms.

- Fragrance delivery system for surface cleaners and conditioners

We claim a fragrance delivery system consisting of a mixture of various polymers oligomers and stabilizers capable of forming a surfactant complex gel dispersion when combined with a cleansing surfactant base and yielding high levels of fragrance deposition onto the skin, hair or other surface such as a textile, from a cleansing or softening consumer product comprising a micelle forming surfactant. The internal phase or dispersible phase of this surfactant complex gel dispersion (GLPPD) is made of a mixture of various immiscible polymers, oligomers and stabilizers forming a complex gel with the surfactant platform and whose ratio and composition are selected to dissolve preferentially a wide range of fragrance raw materials. The selection criteria are, first, that the fragrance should present a higher fragrance partitioning ratio into the surfactant complex gel phase than into the free micelles of the surfactant, second, that the surfactant complex gel should not be further solubilized by the free micelles, and third, that the polymer mixture selected should complex with the surfactant system. The external or dispersing phase of the GLPPD is made of a single cationic polymer or a mixture of cationic polymers that have been hydrated and associated with the surfactant to form a complex gel structure that cannot be further solubilized by the free micelles.

- Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation

The present invention relates to the use of the alkaloid K252 and its analogues or derivatives to prepare topical drugs for the treatment of disorders characterised by hyperproliferation of keratinocytes.

- Limposomes containing asiaticoside and the uses thereof

This invention belongs to the chemical field, which is related to the fields of pharmaceutical preparations and cosmetic, especially to asiaticoside-liposome and its use for preparing pharmaceutical preparations and cosmetic. In this invention, asiaticoside and lipid components are fused by heating or dissolved in organic solvents, then treated with the rotary thin layer evaporation technique, hydrated by adding aqueous solution under shaking to afford lipid dispersing aqueous solution, and then treated by using the technics of sonication, homogeneous emulsification, microjet and extruding filtration to enwrap asiaticoside in the middle of liposomal bilayer membranes to form the hydrophilic asiaticoside-liposome. Asiaticoside-liposome of this invention can enhance the stability, skin penetrability and hydrophilicity of asiaticoside, it can be used for the preparation of cosmetic and pharmaceutical preparations especially skin-penetrated pharmaceutical preparations, and it is more convenient and easy to prepare skin-penetrated pharmaceutical preparations and cosmetic containing asiaticoside.

- Interleukin-8 homologous polypeptides and therapeutic uses thereof

The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treatment and diagnosis of inflammatory diseases.

- Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression

The present invention relates to the treatment of autoimmune and/or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to the use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. This invention also relates to treating a subject having a disease or condition associated with abnormal Toll-like receptor 3 as well as Toll-like receptor 4 and/or TLR3/TLR4 signaling in nonimmune cells, monocytes, macrophages, and/or dendritic cells in association with related pathologies. The present invention also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. This invention also relates to pharmaceutical formulations capable of inhibiting the IRF-3/Type 1 IFN/STAT/ISRE/IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

- Method for treatment of skin diseases and the like

A disposable swab tipped medication applicator containing one or more pharmacologically active agents in an anhydrous crystalline or powdered form at the swab. A method for use of the swab tipped applicator provides for delivery the pharmacological agent(s) to an area of the skin, such as the external auditory canal, preferably after showering or bathing, so that the dry agent is dampened so as to treat conditions of the skin. A package of the prepared applicators is provided in one embodiment, while in another embodiment applicators having two different medicaments are provided in a single package for treatment of a condition.

- Equipment and method for reducing and eliminating wrinkles in the skin

A mechanism for preparing the area of the skin to be treated and a mechanism for applying energy thereto both being integrated in the same equipment. The mechanism for preparing the are to be treated comprises an ultrasonic emitting device (preferably low frequency ultrasound) and/or dermabrasion device for breaking the lipid lamellar organization and reducing the dispersion of the irradiated energy altering the ultra-structure of the lipid corneal layer. The mechanism for applying energy comprises an emitting device capable to emit several combined forms of energy to the area to be treated. There is provided an atomizing device for applying topical agents and/or drugs to the area to be treated which cooperates with the mechanism for preparing the area to be treated. The method provides emitting laser light and polarized light, intense pulsed light without polarization and polarized light, or intense pulsed light with polarization and polarized light.

- Use of halogenated hydroxydiphenyl ether compounds for the treatment of the skin

The use of hydroxydiphenyl ether compounds of formula (I), wherein R.sub.1, R.sub.2 and R.sub.3 are each independently of the others hydrogen; hydroxy; C.sub.1-C.sub.20alkyl; hydroxy-substituted C.sub.1-C.sub.20alkyl; C.sub.5-C.sub.7cycloalkyl; C.sub.1-C.sub.20alkoxy; C.sub.1-C.sub.6alkylcarbonyl; phenyl; or phenyl-C.sub.1-C.sub.3alkyl; R.sub.4 is hydrogen, C.sub.1-C.sub.20alkyl; hydroxy-substituted C.sub.1-C.sub.20alkyl; C.sub.5-C.sub.7cycloalkyl; hydroxy; formyl; acetonyl; allyl; carboxy; carboxy-C.sub.1-C.sub.3alkyl; carboxyallyl; C.sub.2-C.sub.20alkenyl; C.sub.1-C.sub.6alkylcarbonyl; C.sub.1-C.sub.3alkylcarbonyl-C.sub.1-C.sub.3alkyl; phenyl; or phenyl-C.sub.1-C.sub.3alkyl; and R.sub.5 is hydrogen; C.sub.1-C.sub.20alkoxy; or C.sub.1-C.sub.6alkylcarbonyl; as melanogenesis inhibitors and for lightening the skin.

- Medicinal cosmetical composition with areca catechu seed extract

The present invention relates to a composition for promoting the proliferation of fibroblasts and kerathincytes comprising a mixed extract from Areca catechu seed and Glycyrrhiza glabra and a cosmetic composition for skin-whitening and a remedy of skin wrinkles comprising the same.

- Method of providing sustained analgesia with buprenorphine

A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at least an additional two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

- Ganglionic blocking agents for the treatment of epithelial diseases

Compositions, and methods of making and using a composition, containing a ganglionic blocking agent and water provide increased penetration of the ganglionic blocking agent into and through epithelial surfaces, such as skin and mucosal surfaces, provide increased release from formulations containing such ganglionic blocking agents, and provide increased antiviral effectiveness compared with compositions containing a ganglionic blocking agents and lacking water.

- Composition for cleaning or rinsing hard surfaces

Composition for cleaning or rinsing hard surfaces in an aqueous or aqueous/alcoholic medium comprising at least one polybetaine for contributing to said surfaces antideposition and/or antiadhesion properties with regard to soiling substances capable of being deposited on said surface.

- Methods for regulating inflammatory mediators and peptides useful therein

The present invention includes methods of modulating cellular secretory processes. More specifically the present invention relates to modulating or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from the vesicles or granules in the inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. MANS peptide and active fragments thereof are useful in such methods.

- Compound inhibiting in vivo phosphorous transport and medicine containing the same

An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R.sup.5 represents optionally substituted aryl or the like, Z represents --N.dbd.CHR.sup.6R.sup.7 or the like, R.sup.6 and R.sup.7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R.sup.101 and R.sup.102 together form .dbd.O, and R.sup.103 and R.sup.104 represent H, or R.sup.101 and R.sup.104 together from a bond, and R.sup.102 and R.sup.103 together form a bond.

- Dry products comprising an applicator and a wax phase

This invention concerns products for cleansing and other applications, which products comprise an applicator such as a puff (pouf), pad, sponge, cotton ball, swab, brush, glove, mitt or bar, to which a wax phase has been applied. The invention further concerns the manufacture and use of such products.

- NK1 antagonists

A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK.sub.1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

- Light emitting display

The present invention provides a light emitting display with excellent reliability by preventing degradation by heat such as color changes or luminance reduction, through uniform and quick discharge of heat generated internally.

- Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis

The fluorinated curcuminoid (3,5-bis-(2-fluorobenzylidene)-piperidin-4-one-acetate is about ten times more effective at arresting the growth of tumor cells than cisplatin. The present invention provides methods to deliver a cytotoxic compound, such as a curcuminoid, specifically to cancer cells and to the vascular endothelial cells that nourish solid tumors. The method involves tethering the drug to a protein such as in factor VIIa that retains high affinity for the surface protein tissue factor. Upon complexation, the resulting heterodimer is endocytosed and the drug is subsequently liberated inside the target cell via proteolytic cleavage. The present invention further provides for the synthesis of novel curcuminoid-tether-linker-factor VIIa compositions and for methods of delivery of effective doses of the novel compositions to target tumor or endothelial cells in a patient

- Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions

A liquid which is a perfluorinated compound whose vapor pressure at 25.degree. C. and atmospheric pressure is greater than or equal to 10,000 Pa (100 mbar) and whose boiling point is greater than or equal to 30.degree. C. is used in the manufacture of a pharmaceutical and/or biological composition. The pharmaceutical and/or biological composition essentially only includes this liquid and the pharmaceutical ingredient in powder form and/or the solid biological material. The pharmaceutical ingredient and/or the biological material are insoluble in the liquid. Optionally, a film-forming agent is also included.

- Foam containing unique oil globules

The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable oil in water emulsion composition includes: an oil globule system, selected from the group consisting of oil bodies; and sub-micron oil globules, about 0.1% to about 5% by weight of an agent, selected from the group consisting of a surface-active agent, having an HLB value between 9 and 16; and a polymeric agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients are added to complete the total mass to 100%. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration.

- Non-Endocrine Disrupting Cytoprotective UV Radiation Resistant Substance

Compositions for enhanced UV-protective agents that increase immuno-responsiveness by providing cytoprotective additives for mammalian skin by ensuring avoidance from endocrine disrupting agents are described. A composition comprising: (a) at least one inorganic non-endocrine disrupting sun-blocking agent or organic non-endocrine disrupting sunscreen agent, (b) at least one non-endocrine disrupting emollient or mixtures thereof and (c) an optional oil component comprising a carrier oil, preferably an essential oil of a naturally occuring substance and a method of making this and other embodiments of similar compositions of the same invention is detailed. Inorganic component (a) is titanium dioxide, zinc oxide, silica or silicon dioxide, fluoropolymers or mixtures thereof. Organic component (a) is butylmethoxy dibenzoylmethane. The non-endocrine disrupting component (b) is cold-processed Aloe barbadensis Miller, which contains a glucose-rich mannose-containing oligosaccharide or oligosaccharides, or a fatty acid salt such as sodium stearate. The compositions are shown to be capable of protecting skin and mammalian health from the harmful effects of radiation including ultraviolet light or sunlight by inhibiting the loss of skin immunocompetency and eliminating any known or suspected endocrine disrupting agents normally utilized as sun protective agents.

- Film foaming hydroalcoholic foam

The present invention provides a foam composition comprising an active agent. In particular, the foam composition produces a water resistant, preferably very water resistant, film upon application.

- Cosmetic compositions containing mono-hydroxyl substituted amines and acid derivatives

Disclosed are cosmetic or dermatological compositions that include a mono-hydroxyl substituted amine such as dimethylaminoethanol (DMAE), a sulfonic, phosphoric, or phosphonic acid derivative, and a cosmetically acceptable carrier. Also disclosed are methods for making and using the compositions.

- Composition for promoting production of type 1 collagen and/or elastin

This invention aims to provide a composition that promotes the production of type I collagen and/or elastin in the human skin fibroblast cells, wherein the composition improves the suppleness and elasticity of the skin, is amply effective in preventing and improving wrinkles and sagging, and is also very safe to the skin. The present invention relates to a composition that contains silymarin, which is a general term for flavonolignans such as silybin, silydianin, silychristin and isosilybin, wherein the aforementioned composition has a property to promote the production of type I collagen and/or property to promote the production of elastin. It also relates to a composition containing silymarin derived from a silymarin-containing plant and/or extract of such plant, wherein the aforementioned composition also has a property to promote the production of type I collagen and/or property to promote the production of elastin.

- Skin regeneration system

A cell culture medium and system are provided which eliminate or at least reduce the requirement for exogenous components such as serum and feeder cells. The cell culture medium comprises an IGF and vitronectin or fibronectin and, optionally an IGFBP, and is particularly suitable for propagating keratinocytes for subsequent use in skin growth and regeneration. This invention also relates to compositions and methods for skin growth and regeneration in situ, which utilize aerosol delivery of cultured keratinocytes.

- Topical composition in the form of a gel for treating skin burns

The present invention relates to novel topical compositions for treating burns, grazes, erythema, eczema, herpes infection, evulsion, sores and any skin damage leading to sloughing, including at least three components, namely a first barrier gel, a second barrier gel and an active principle having proteolytic activity. The novel compositions have enhanced pain-killing, protective, debrding and anti-inflammatory effects relative to the conventional products used in the art.

- Bioactive material for use in stimulating vascularization

The present invention relates to a bioactive material, particularly one which comprises SiO.sub.2 and CaO and optionally Na.sub.2O and/or P.sub.2O.sub.5, for use in stimulating vascularisation and pharmaceutical compositions, wound dressings, tissue constructs and delivery systems which include such a bioactive material.

- Treatment of connective tissue diseases of the skin

The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta.sub.2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta.sub.2 adrenoceptor agonist.

- Novel clerodanes and methods for repelling arthropods

A method for repelling arthropods involving treating a subject or an object with an arthropod repelling composition containing an arthropod repelling effective amount of at least one clerodane of the formula in which R.sup.1 is H, halogen, formyl, a straight chain or branched C.sub.1-4 saturated alkyl, a straight chain or branched C.sub.2-4 unsaturated alkyl, or an aryl containing 6-10 carbon atoms in the ring skeleton thereof, wherein R.sup.1 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of oxo (.dbd.O), OR.sup.2, CO.sub.2R.sup.2, and OC(O)R.sup.2, wherein R.sup.2 is H, a straight chain or branched C.sub.1-30 saturated alkyl, a straight chain or branched C.sub.2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof; wherein R.sup.2 is unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, amino, hydroxyl, oxo (.dbd.O), thio, cyano and nitro; optionally a carrier, optionally an arthropod repellant, and optionally an insecticide. Preferably the compound is 13,14,15,16-tetranorclerod-3-en-12-al (callicarpenal), 13,14,15,16-tetranorclerod-3-en-12-ol, 13,14,15,16-tetranorclerod-3-en-12-oic acid, .beta.-epoxycallicarpenal, .alpha.-epoxycallicarpenal, or mixtures thereof. Also a compound of the above formula. Also an arthropod repellant composition containing an arthropod repelling effective amount of at least one of the compounds of the above formula and a carrier.

- Indole-derivative modulators of steroid hormone nuclear receptors

The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, comprising administering to a patient in thereof an effective amount of a compound of Formula I.

- Method of regulating mammalian keratinous tissue

Method for providing a benefit to mammalian keratinous tissue, comprising applying a composition comprising one or more hair growth regulating compounds to the keratinous tissue and delivering energy to the keratinous tissue by means of an energy delivery device.

- Stable transfer-resistant self-tanning gel containing a water-soluble or water-dispersible gelling agent

A self-tanning aqueous gel composition containing: (a) a cosmetically acceptable support; (b) at least one monocarbonyl or polycarbonyl self-tanning agent; (c) at least one aqueous phase gelling agent comprising at least one water-soluble or water-dispersible, crosslinked or non-crosslinked polymer or copolymer; d) at least one tinting agent; and (e) optionally, at least one water-soluble or water-dispersible film-forming agent.

- Cleansing composition

A skin-lightening cleansing composition with a pH below 7.5 comprising 3% to 50% by weight of detergent active wherein nonionic detergent active when present, has a HLB in the range 5-18; and 0.01% to 20% by weight alkyl or cyclo alkyl resorcinol.

- Biliquid foams stable dispersions thereof and a corresponding process of manufacturing

A biliquid foam comprising from 10% to 98% by weight of a non-polar liquid other than a fuel and from 2 to 88% by weight of a continuous phase polar liquid comprising a C.sub.1-C.sub.4 alcohol, a liquid polyethylene glycol, ethylene glycol or propylene glycol, or mixtures thereof, in an amount of at least 65% by weight, relative to the weight of the continuous phase, wherein the biliquid foam is stabilized with an amount of from 0.05% to 2% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, a C.sub.8-C.sub.24 fatty acid or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof. A stable dispersion having a content of at least 65% by weight with regard to C.sub.1-C.sub.4 alcohol, liquid polyethylene glycol, ethylene glycol or propylene glycol which dispersion comprises from 1-80% by weight of a biliquid foam and from 99-20% by weight of an aqueous gel.

- Cosmetic and dermopharmaceutical compositions for skin prone to acne

The invention relates to the use of an extract of olive leaves (Olea europaea) which is titrated in oleanolic acid and which may or may not be associated with a Larrea divaricata extract which is titrated in nordihydroguaiaretic acid (NDGA). Said products are intended for all types of cosmetic and dermopharmaceutical compositions for all forms of skin care, for moisturizing and anti-inflammatory purposes and, in particular, for the prevention and treatment of skin prone to acne.

- Microbial cellulose materials for use in transdermal drug delivery systems, method of manufacture and use

A method for transdermally delivering a biologically active agent to a subject in need thereof, comprising topically applying a composition comprising insoluble microbial cellulose, water, and a therapeutically effective amount of the biologically active agent, wherein the biologically active agent penetrates through the subject's stratum corneum at a substantially constant rate.

- Caspase 10 as target for monitoring and treatment of diseases

The present invention relates to a method of monitoring and/or modulating disease-associated activatory procceses which are mediated by caspase-10 or caspase-10 isoforms.

- Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival

The invention relates to methods for detecting and inhibiting angiogenesis, cell migration, cell adhesion, and/or cell survival in endothelial and non-endothelial cells as well as in normal and tumor cells. The invention further relates to methods for screening test compounds for their ability to inhibit angiogenesis, cell migration, cell adhesion, and/or cell survival.

- Keratolytic composition with anti-allergic anti-inflammatory properties

A product with an enhanced medicinal and cosmetic composition with a specific utility of "Psoriasis, Eczema and like skin disorders application" is characterized by the fact that it comprises active agents and ingredients as vanilla extract, ammonium chloride, potassium chloride and quaternary ammonium compound having formulated at a specific pH value with other specially selected adjuvants and fillers.

- Dispensing device

The present invention relates to a method of dispensing a liquid suspension from a reservoir of a liquid suspension held in a delivery system, wherein the reservoir of liquid suspension is of a type which is normally isolated from atmosphere, comprising the steps of: a) increasing the volume of the reservoir above an initial volume so as to reduce the pressure in the reservoir to below atmospheric; b) agitating the liquid suspension; c) reducing the volume of the reservoir to the initial volume; and d) subsequently dispensing at least a portion of the liquid suspension from the reservoir.

- Sunless tanning composition and methods for using

A sunless tanning composition is provided according to the invention. The sunless tanning composition includes an effective amount of a tanning active component to provide a darkening effect of skin tissue after exposure to the skin tissue, a polymer component, water, an effective amount of an acidifying agent to provide the composition with a pH of less than about 5, and wherein the composition has the viscosity of at least about 3,000 cSt. The polymer component can be characterized as a skin bonding polymer component to hold the tanning active component in exposure to the skin tissue when applied to the skin tissue. The polymer component can be characterized as a polymer having an average molecular weight of about 2,000 to about 500,000. A method of applying a sunless tanning composition to skin tissue is provided.

- Barrier formulation comprising a silicone based emulsion

The present invention provides an improved barrier formulation that is useful in a number of applications, and a method for its manufacture. The formulation comprises an emulsion having at least an oil phase and an aqueous phase wherein the oil phase comprises a silicone compound wherein the viscosity of the formulation is 20000 cps or less.

- Personal care composition

Stable personal care composition comprising hydrophobic modified silica, a particulate material and a dermatologically-acceptable carrier, said carrier comprising about 70% or greater, by weight of the carrier, of at least one water-soluble polyol, said water-soluble polyol having a solubility parameter of from about 11 to about 17.

- Skin collagen production promoter

It is intended to provide a skin collagen production promoter, foods and drinks for promoting skin collagen production and cosmetics for promoting skin collagen production which are useful in preventing skin chapping, wrinkles, worsening in skin fitness, etc. Namely, a skin collagen production promoter, foods and drinks for promoting skin collagen production and cosmetics for promoting skin collagen production which contain as the active ingredient(s) a milk-origin basic protein fraction and/or a basic peptide fraction obtained by digesting the above-described basic protein fraction with a protein digesting enzyme such as pepsin or pancreatin. The above basic protein fraction and basic peptide fraction have an effect of increasing skin collagen level.

- Method of altering cell properties by administering rna

The invention relates to the alteration of cell properties using RNA molecules. In particular, it relates to the alteration of the ability of cells to mobilise, migrate, integrate, proliferate and/or differentiate. For example, it relates to the induction of differentiation of stem cells, including the acquisition of the ability to migrate, integrate, and proliferate. It also relates to the induction of in vivo stem cell mobilisation, migration, integration, proliferation and/or differentiation. Accordingly, it relates to the promotion of stem cell-mediated functional repair. The invention also relates to the reversal of differentiation of differentiated cells. All these effects may be effected by providing isolated RNA comprising a RNA sequence extractable from cells comprising the desired cell type(s) to a population of cells under conditions whereby the alteration of the cell property is achieved.

- Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives

A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and treat bone disorders.

- Polyether urethane containing allyl groups

The present invention relates to a mono- and/or polyallyl-polyether-urethane, to water-soluble or water-dispersible polymers which comprise such a polyether-urethane in copolymerized form, and to cosmetic or pharmaceutical compositions which comprise a water-soluble or water-dispersible polymer based on a mono- and/or polyallyl-polyether-urethane.

- Disposable pads for applying and distributing substances to target surfaces

The applicators, and methods for making them, their use in manually applying controllable amounts of moist, viscous lotions, creams, gels or dry powders onto target skin and hard surfaces. The applicators comprise an impervious backing sheet, a three-dimensional core layer with reservoirs in the shapes of cones or honeycombs wherein active compositions in the form of viscous lotions, gels, creams or dry powders are located, a microporous flow-directing cover sheet and an optional impervious overwrap. The applicator is capable of releasing the active composition in a controlled manner and protecting the user's hands from contacting the viscous material, to prevent potential soiling, cross-contamination and/or skin irritation. The applicators can be made to form hand or finger mitts, gloves, flat or tubular pads, wraps, facemasks, booties, and more.

- Encapsulated fragrance materials and methods for making same

The present invention is directed to novel capsules containing active materials and methods for making capsules with enhanced performance and stability. The capsules are well suited for use in personal care applications, laundry products and perfume and fragrance products.

- Deodorant agent

This invention relates to deodorant agents, which contain ginkgo or Phellodendron Bark or its extract as an active ingredient. According to the present invention, deodorant agents which are high in safety and can radically inhibit the emission of human body malodors typified by sweat odor, especially, axillary odor.

- ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE

This application discloses a composition comprising a malodor compound and an anti-odor ingredient effective for reducing the presence or production of malodor. The composition may be topically applied to a subject and is useful for cosmetic conditions, pharmaceutical indications, or other objectives.

- System for improved percutaneous absorption of skin benefiting agents

Stable topical compositions containing active ingredients that are prone to oxidation, and methods for improving the percutaneous absorption of an active ingredient are provided.

- Employment of rotavirus proteins, derived proteins and peptides for the modulation of tisssue permeability

The present invetnion refers to the use of rotavirus proteins VP4, VP8 and their derived fusion proteins and peptides, for enhancing the delivery of pharmaceutical agents through the paracellular pathway. These rotavirus proteins and derived peptides may additionally be employed to reduce unwanted cellular adhesion that can occur between cancerous cells, or between normal cells as a result of surgery, injury, chemotherapy, disease, inflammation or other pathological conditions.

- Composition comprising an edible acid or its acidic salt and the use thereof

This invention relates to a drug containing edible acid and/or acidic salt as active agent to treat and alleviate hypersensitivity diseases by lowering the humor pH and method; to improve individual hypersensitivity diseases by uses of health care food, which are made from said edible acid and/or acidic salt, or the acidic fruits containing thereof, or their products; foods lowering the risk of hypersensitivity and their preparation methods; drug to lower the humor acidity and to treat or alleviate disease caused by insects bite toxin; that also to be drug for cold or virus infection; drug for inflammation; drug for analgesic; and drug for thrombus disease; method lowers the hypersensitivity risk of clothing or grove and their products.

- Uv stable transdermal therapeutic plaster

The invention relates to a UV stable transdermal therapeutic system (TTS) consisting of a back layer, at least one matrix containing an active substance and, optionally, a withdrawal film and an UV-radiation absorber. An adhesive layer containing said UV-radiation absorber is arranged between the back layer and the matrix containing an active substance which is distant as much as possible from a surface, a separation layer is arranged between the adhesive layer containing said UV-radiation absorber and the matrix containing an active substance, which is as remote as possible from the surface which is impermeable to the active substance and UV radiation absorber. The inventive transdermal therapeutic system exhibits a high stability and is devoid of inconveniences of existing TTS containing a light-sensitive substance.

- Alteration of rab38 function to modulate mammalian pigmentation

The present invention relates to compositions and methods involving melanocytes. In particular, the present invention provides compositions and methods involving RAB38 and mutant RAB38, suitable for use in modulation of pigmentation and for use in determining the means to diagnose and/or treat conditions associated with disorders in pigmentation.

- Preventive and/or trerapeutic drgs for itch

The present invention provides an agent for prevention and/or treatment of itching comprising a substance capable of suppressing the function involved in signal transduction of GPR4 as an active ingredient. It also provides a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof; [wherein R.sup.1 represents substituted or unsubstituted lower alkyl, etc.; R.sup.2 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; R.sup.3 and R.sup.4 are the same or different and each represents hydrogen, lower alkyl, etc.; n represents 0 or 1; X represents --(CH.sub.2).sub.2--, etc.; and Y represents the formula (II); (wherein W represents CH or a nitrogen atom; Z.sup.1 and Z.sup.2 are the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, etc.; and Z.sup.3 represents hydrogen, substituted or unsubstituted lower alkyl, etc.)]

- Compounds for the treatment of inflammatory disorders

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-.alpha. or combinations thereof.

- Apparatus for curing a composite laminate

The present invention is related to a compound of formula (I): A-B-E-D (I), wherein: A is selected from the group consisting R.sup.a-L1-K-L2; and (II) B is either present or absent, but if B is present then B is (III), E is (IV), D is selected from the group comprising --(CR.sup.1R.sup.m).sub.rC(O)H, --(CR.sup.1R.sup.m).sub.rC--N, --CR.sup.1R.sup.m).sub.rNHNHC(O)NR.sup.5R.sup.6, --(CR.sup.1R.sup.m).sub.rC(O)(CR.sup.nR.sup.o).sub.rc(O)OR.sup.7, --(CR.sup.1R.sup.m).sub.rC(O)(Cr.sup.nR.sup.o).sub.rC(O)NR.sup.8R.sup.9, --(CR.sup.1R.sup.m).sub.rCH(OH)(Cr.sub.nR.sup.o).sub.rC(O)U, --(CR.sup.1R.sup.m).sub.rC(O)W--(CR.sup.1R.sup.m).sub.rC(O)CH.sub.2W, --(CR.sup.1R.sup.m).sub.rC(O)haloalkyl, and --(CR.sup.1R.sup.m).sub.rC(O)(CR.sup.nR.sup.o).sub.r--CHN.sub.2, and the use of said compounds as an inhibitor to rotamases.

- Hydroxamic acid derivatives and the method for preparing thereof

The present invention provides hydroxamic acid derivatives represented by the following formula (I), having anti-aging efficacy and a method for preparation thereof: wherein, R.sub.1 is herein, R.sub.5 and R.sub.6 each independently represents a hydrogen atom, a C.sub.1-C.sub.10 alkyl group or a C.sub.3-C.sub.6 cyclic alkyl group; R.sub.2 is CONH, NHCO, CONR.sub.7 or NR.sub.7CO, herein, R.sub.7 represents a C.sub.1-C.sub.10 alkyl group; R.sub.3 is --(CH).sub.n--, herein, n=0 or 1; and R.sub.4 is a hydrogen atom or a C.sub.1-C.sub.10 alkyl group. Further, the present invention provides skin-care external compositions for preventing skin aging, containing said hydroxamic acid derivatives represented by the formula (I) as an active ingredient.

- Use of spermine and/or spermidine against skin ageting in dietary, pharmaceuetical or cosmetic compositions

The invention concerns the use of spermine and spermidine as active ingredients in the preparation of a composition for dietary, pharmaceutical or cosmetic use in humans for health and beauty of the skin and skin appendages, and related compositions for pharmaceutical or dietary or cosmetic use for administration to humans.

- Pharmaceutical compositions

A compound comprising a cyclopentanone, cyclopentenone, cyclohexanone or cyclohexenone group, wherein a first ring carbon atom carries an --SR substituent, R is a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group that, optionally, includes at least one heteroatom in its carbon skeleton, the remaining available ring carbon atoms are optionally substituted, and said compound either:--(a) is more soluble in water at a temperature of 20-40.degree. C.; (b) is less lipophilic; and/or, (c) has a greater therapeutic index; or; (d) is less soluble in water at a temperature of 20-40.degree. C.; (e) is more lipophilic; and/or, (f) has a greater therapeutic index; than an equivalent cyclohex-2-en-1-one or cyclopent-2-en-1-one derivative in which a hydrogen atom replaces said --SR group.

- Biocompatible implant and use of the same

The present invention provides an implant capable of being cellularized in treatment of an injured organ or tissue in organisms. The present inventors found that a biocompatible implant comprising a biological molecule and a support is capable of being cellularized. The implant can be used instead of conventional implants which essentially comprise cells. The present invention provides a biocompatible implant comprising A) a biological molecule and B) a support. The present invention also provides A) a first layer having a rough surface, B) a rough surface; B) a second layer having a strength which allows the support to resist in vivo shock. The first layer is attached to the second layer via at least one point.

- Stratum corneum piercing device

The present invention features a stratum corneum-piercing device including a microprotrusion member having a skin-contacting surface and plurality of stratum corneum piercing microprotrusions thereon, the device being adapted to move the microprotrusion member lateral to the surface of the skin surface upon contact with the skin.

- Cosmetic composition comprising silica particles, reflecting particles, and at least one polymer, preparative processes, and uses thereof

Disclosed herein is a cosmetic skin make-up and/or care composition comprising an oily phase, for example, a gelled or structured oily phase, comprising silica particles and reflecting particles, said oily phase comprising at least one polymer having a weight-average molecular weight of less than 100,000, for example, below 50,000, comprising (a) a polymer skeleton comprising hydrocarbon repeat units including at least one heteroatom, and (b) optionally at least one pendant fatty chain and/or at least one terminal fatty chain which may be optionally functionalized, comprise from 6 to 120 carbon atoms and which are bonded to the hydrocarbon repeat units. Also disclosed herein is a process for the preparation of this cosmetic composition, to a gloss comprising this cosmetic composition and to a method for obtaining a glossy deposit comprising applying this cosmetic composition to a substrate.

- Use of soluble cd164 in inflammatory and/or autoimmune disorders

The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of humans CD164, in particular for treating inflammatory and/or autoimmune disorders.

- A COMBINATION OF MITOCHONDRIAL NUTRIENTS FOR RELIEVING STRESS, PREVENTING AND IMPROVING STRESS-RELATED DISORDERS

A dietary supplement of mitochondrial nutrients is designed for relieving stress, preventing and improving stress-related disorders, such as chronic fatigue syndrome, diabetes, age-associated cognitive dysfunction and diseases (Parkinson's and Alzheimer's disease). The supplement composition has the following nutrients: B vitamins (cyanocobalamin 2-1,000 ug, thiamin 1-1,000 mg, niacin 15-2,000 mg, pyridoxine 1-1,000 mg, Pantothenate 5-150 mg, folic acid 400-40,000 ug), alpha-tocopherol 10-800 mg, ascorbic acid 50-10,000 mg, calcium 20-2,000 mg, vitamin A 200-10,000 ug, alpha-lipoic acid 100-1,000 mg, N-acetyl cysteine 100-3,000 mg, L-carnosine 100-9,000 mg, tyrosine 100-9,000 mg, vanillin 10-100 mg, phosphatidylserine 10-800 mg, resveratrol 10-50 mg, dehydroepiandrosterone 1-50 mg, and melatonin 0.1-3 mg, all of which have been individually used experimentally or clinically for relieving stress, preventing and treating age- and stress-related disorders and diseases but no combination of these compounds has been used. Many embodiments also contain at least one adjunct ingredient such as coenzyme Q 10-200 mg, acetyl-L-carnitine 100-2,000 mg, choline 50-1,000 mg, and creatine 100-2,000 mg.

- Short peptides from the '2nd loop' of 7 transmembrane receptor which selectively modulate signal transduction

The present invention concerns compounds comprising, within short sequences from a specific regions of the 7TM receptor, that can modulate 7TM receptor-associated signal. The present invention further concerns methods for stimulation angiogenesis by administration of peptides derived from the EDG3 7TM-receptor.

- Composition and method for reducing the appearance of cellulite

A topical composition for controlling the metabolism and/or distribution of subcutaneous fat and/or moderating the appearance of cellulite, comprising, as an active ingredient, phosphatidylcholine together with a solvent operative to maintain the phosphatidylcholine in solution, and a buffer which maintains the composition in the range of pH 7.5-9.0. Typically, the composition includes less than 10% by weight water. The composition may include further active ingredients such as xanthines. Also disclosed are methods for using the composition.

- Use of inositol-tripyrophosphate in treating tumors and diseases

Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis.

- 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- Bridged ring NK1 antagonists

A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK.sub.1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

- HISTONE DEACETYLASE INHIBITORS

Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

- Steroid derivatives and use thereof as medicaments

Steroids of the formula wherein R is defined as in the application capable of increasing the synthesis of collagen.

- Compositions comprising a dispersant and microcapsules containing an active material

Compositions for providing controlled-release of an active material comprise a dispersant and microcapsules containing the active material. The compositions contain the dispersant and/or microcapsules at relatively low levels to avoid negatively impacting the surfaces treated with the compositions. The active material is preferably a perfume and the composition provides a controlled-release scent, along with controlling malodor when the compositions fuirther comprise optional odor control agent. Methods of providing a controlled-release of an active material on a surface comprise the step of contacting the surface with a composition comprising a dispersant and microcapsules containing an active material.

- 4-(Methyl sulfonyl amino) phenyl analogues as vanilloid antagonist showing excellent analgesic activity and the pharmaceutical compositions comprising the same

4-(methylsulfonylamino)phenyl analogues as potent vanilloid receptor antagonists and pharmaceutical compositions comprising the same. The compounds are useful as analgesics to prevent, alleviate or treat pain diseases or inflammatory disease including pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease, inflammatory disease and urgent urinary incontinence.

- Proteases, nucleic acids encoding them and methods for making and using them

The invention is directed to polypeptides having protease activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. The polypeptides of the invention can be used in a variety of diagnostic, therapeutic, and industrial contexts. The polypeptides of the invention can be used as, e.g., an additive for a detergent, for processing foods and for chemical synthesis utilizing a reverse reaction. Additionally, the polypeptides of the invention can be used in food processing, brewing, bath additives, alcohol production, peptide synthesis, enantioselectivity, hide preparation in the leather industry, waste management and animal degradation, silver recovery in the photographic industry, medical treatment, silk degumming, biofilm degradation, biomass conversion to ethanol diodefense, antimicrobial agents and disinfectants, personal care and cosmetics, biotech reagents, in increasing starch yield from corn wet milling and pharmaceuticals such as digestive aids and anti-inflammatory (anti-phlogistic) agents.

- Regulation of mammalian keratinous tissue using personal care compositions comprising tetrahydrocurcumin

Personal care compositions containing tetrahydrocurcumin alone, or in combination with tetrahydromethoxycurcumin and/or tetrahydrobisdemethoxycurcumin are provided. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.

- Regulation of mammalian keratinous tissue using personal care compositions comprising ergothioneine

Personal care compositions containing ergothioneine are provided. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.

- Regulation of mammalian keratinous tissue using personal care compositions comprising diethylhexyl syringylidene malonate

Personal care compositions containing diethylhexyl syringylidene malonate are provided. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.

- Treating gastrointestinal diseases with modulators of retinoic acid

T cells are programmed to target the gastrointestinal tract by activation with dendritic cells capable of producing and/or transporting retinoic acid. Methods for using the programmed dendritic cells and/or T and/or B cells to treat a variety of pathogens and infectious agents residing in the intestine are also disclosed. Similarly, inhibitors of retinoic acid synthesis by dendritic cells or other cells in the gut, and inhibitors of retinoic acid receptors in T and/or B cells or other cells in the intestinal mucosa, are disclosed for treating a variety of gastrointestinal autoimmune diseases such as inflammatory bowel disease and celiac disease.

- Gelled oil particles for targeting sebaceous glands and/or hair follicles

The present invention relates to calibrated and spherical oily particles comprising at least one oily phase structured with at least one gelling polymer, characterized in that they have a mean size of less than or equal to 15 .mu.m, in that the said structured oily phase has a melting point of greater than or equal to 40.degree. C. and in that their circularity index is between 0.9 and 1.

- Compositions and methods for the treatment of immune related diseases

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

- Novel endothelial cells, antibodies directed against said cells and use thereof, in particular for screening angiogenesis inhibiting substances

The invention concerns the use of a binary set comprising: endothelial cells of non-angiogenic phenotype and endothelial cells of angiogenic phenotype, for screening substances angiogenic towards endothelial cells of non-angiogenic phenotype, not substantially affecting substantially the of angiogenic phenotype endothelial cells of angiogenic phenotype, or substances angiogenic towards endothelial cells of angiogenic phenotype, not affecting substantially the endothelial cells of non-angiogenic phenotype.

- Mild foaming cleansing composition

A foaming mild liquid cleansing composition that is dispensed as a mousse or foam is described that contains very low levels of surfactant and that can be conveniently wiped off the skin while depositing significant amounts of skin conditioning compounds. In a preferred embodiment, the composition is provided as a transparent microemulsion.

- Stabilized body care products, household products, textiles and fabrics

Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain sterically hindered amine salt compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners and textile-care products.

- Acetylated therapeutic procytotoxins

A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group, and an acetyl group. These agents are useful in treating cancer, especially prostate cancer.

- Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same

The present invention relates to an antagonist against vanilloid receptor and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fevescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

- Treatment of cell-mediated immune diseases

9-cis retinoic acid and pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, 9-cis retinal and pharmaceutically acceptable acetals thereof, and 9-cis retinol and pharmaceutically acceptable hydrolyzable esters thereof as well as metabolites of 9-cis retinoic acid have been found to be efficacious in treating T-helper cell type 1 mediated immune diseases in well tolerated doses. Preferably, the active ingredient is formulated as a medicament for oral or topical administration.

- Dermatological compositions

Topical dermatological compositions comprising urea as an active ingredient, a vegetable oil or a derivative thereof, water, and conventional excipients. These compositions are used for topical medical applications, particularly to treat various skin disorders.

- Compounds, formulations, and methods for ameliorating telangiectasias

Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an .alpha.-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.

- Polyurethane foams comprising oligomeric polyols

The invention relates to polyurethane foams comprising oligomeric polyols. In embodiments of the invention, the polyurethane foams comprise the reaction product of: (a) a polyisocyanate; and (b) an active-hydrogen containing composition comprising an oligomeric polyol having a hydroxyl number of about 45 to about 65 mg KOH/g, a number average hydroxyl functionality (Fn) of less than about 2.7, and about 40% weight or greater oligomers. The polyurethane foams of the invention may be slabstock foams or molded foams. Also disclosed are low odor polyols and polyurethane compositions.

- Device and kit for delivery of encapsulated substances and methods of use thereof

The present invention is of a kit and electricity generating device for delivery of an encapsulated composition or mixture of compositions, including an electricity generating device and at least one composition in an encapsulated carrier vehicle which is contacted or applied to the electricity generating device. In some embodiments the device includes a means for maintaining stability of the encapsulated composition prior to bio-membrane penetration. The present invention also provides methods of use thereof. Furthermore, the present invention provides a device and method for delivering a fixed ratio of compounds from a mixture to a bio-membrane comprising the step of electro-transporting an encapsulated mixture of compounds. Still further, the present invention is of a device and method for delivering each compound of a mixture of compounds to the same penetration depth.

- Apparatus and methods for using self-heating chamber to excite a multi-compound TDP layer to generate infrared wavelength for various pain treatment, and composition of this TDP layer

An apparatus, product formulation, and method for using heat to excite a multi-compound layer to generate infrared wavelength, wherein the apparatus includes 1) a multi-compound TDP layer which can be excited by heat to generate infrared wavelength and 2) a heat-generating chamber separated by a first non-permeable wall, wherein the reservoir and chamber are formed in or supported by a housing. The TDP layer is composed of more than 30 compounds including ZrO, SiO2, SiC2, Al2O3, FeO, MnO2, Cu2O, MgO, ZnO, and Cr2O3. The heat-generating chamber includes a medium for generating controlled heat, preferably a chemical composition made of carbon, iron, water, and/or salt, which is activated upon contact with air (oxygen). The heat can last as long as 16 hours. The function of the heat-generating element is to supply energy to excite TDP multi-compound layer to generate infrared wavelength at 2-18 micrometer (especially at 4-14 micrometer) range, for all types of pain treatment. The apparatus may also include a layer contacting user's skin to store active pharmaceuticals and transdermal system to additionally relieve pain and improve symptoms associated with arthritis, soft tissue damage, neck vertebrate pain, lumber muscle strain, lumber intervertebrate disc herniation, arthritis around shoulder, prostate inflammation, pelvic inflammation, pain of bone hyperplasia, gastroenteritis, and dysmenorrhoea.

- Antibiotic kit and composition and uses thereof

The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

- Alpha hydroxy acid compositions

Pharmaceutical compositions suitable for topical administration comprising an alpha hydroxy acid. In a particular aspect, these compositions exhibit improved tolerance on the skin upon topical application despite the presence of high levels of alpha hydroxy acids in the composition. These compositions are used for topical medical applications, particularly to treat various skin disorders.

- Detergent composition

A cleansing cosmetic composition comprising; i) a cationised silicon delivery system selected from one or more of a) a cationised fatty alkyl silicone copolymer; b) a cationised dimethiconol complex and c) a cationised high viscosity lower alkyl silicone fluid with or without cationised silicone gum blend; and ii) detergent active. Also disclosed is a cationised silicone delivery system comprising: a) 15-50 parts of a cationised fatty alkyl silicone copolymer; b) 5-50 parts of a cationised dimethiconol complex; and c) 1-50 parts of a cationised high viscosity lower alkyl silicone fluid with cationised silicone gum blend.

- Personal care applications of emulsions containing elastomeric silanes and siloxanes with nitrogen atoms

Oil-in-water (O/W) and water-in-oil (W/O) emulsions and microemulsions containing elastomeric silanes or siloxanes preferably having quaternary ammonium groups are generally made by reacting organic quaternary ammonium compounds having epoxide groups or halohydrin groups, with silanes or siloxanes having amino groups. The reaction is carried out in an aqueous polar phase containing a crosslinking agent and surfactant. The emulsions and microemulsions are especially useful for treating hair, skin, or the underarm.

- Feline probiotic bifidobacteria

According to the invention there is provided a strain of lactic acid bacteria of the genus Bifidobacteria obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria of the present invention are also provided.

- Self-assembling recombinant papillomavirus capsid proteins

Recombinant papillomavirus capsid proteins that are capable of self assembly into capsomer structures and viral capsids that comprise conformational antigenic epitopes are provided. The capsomer structures and viral capsids, consisting of the capsid proteins that are expression products of a bovine, monkey or human papillomavirus L1 conformational coding sequence proteins, can be prepared as vaccines to induce a high titer neutralizing antibody response in vertebrate animals. The self assembling capsid proteins can also be used as elements of diagnostic immunoassay procedures for papillomavirus infection.

- IL-17A/F heterologous polypeptides and therapeutic uses thereof

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

- Novel adenoviruses, nucleic acids that code for the same and the use of said viruses

The present invention is related to an adenovirus expressing a first protein which is selected from the group comprising an E1B protein and an E4 protein, priorto a second protein which is selected from the group comprising an E1A protein.

- Feline probiotic Lactobacilli

According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed feline gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.

- Compositions and methods for treating tissue

The present invention relates to the field of bacteriology. In particular, the invention relates to novel compositions and methods for altering (e.g., inhibiting) the growth and virulence of populations of pathogenic microorganisms.

- Use of chalcones for the treatment of viral disorders

The present invention relates to chalcone derivatives and compositions containing such derivatives useful in the treatment of viral disorders, including but not limited to the treatment of viral lesions resulting from viruses such as Herpes Simplex virus.

- Hydrazono-malonitriles

Hydrazono-malonitrile derivatives of the formula (I) in which R.sup.1, R.sup.2, R.sup.3, R.sup.3' and R.sup.4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

- Pyridazine derivatives

Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

- 2-Aminobenzoyl derivatives

The invention relates to 2-aminobenzoyl-alkylamines, -alkylamides and -alkylthioamides, and their application for treatment or prevention of various physiological conditions.

- Ternary and quaternary eutectic mixtures of local anesthetics substances

The present invention describes ternary and quaternary eutectic mixtures composed by active local anesthetic substances. These eutectic mixtures possess melting point inferior to 2O.degree. C. and consist of homogeneous liquid useful in the preparation o pharmaceutical compositions for topical anesthesia or analgesia of tissues as skin or mucous.

- Foamable vehicle and pharmaceutical compositions thereof

A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

- Saccharide foamable compositions

A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

- Skin care compositions containing idebenone

A stable skin care composition, comprising an effective amount of idebenone, at least one additional skin care active, and a dermatologically acceptable carrier. The composition is substantially colorless.

- Skin care active complex and methods of using same

A skin care active complex in accordance with an embodiment of the invention comprises a combination of (1) from about 0.001% to about 10% by weight, preferably from about 0.001% to about 5% by weight, of a vitamin A derivative; (2) from about 0.00001% to about 10% by weight of a hydroxamate derivative; (3) from about 0.01% to about 5% by weight of an anti-inflammatory natural compound; and optionally, (1) from about 0.001% to about 10% by weight of vitamin K.

- Skin care compositions containing idebenone

A stable skin care composition, comprising an effective amount of idebenone, at least one additional skin care active, and a dermatologically acceptable carrier.

- Topical cosmetic formulations for regulating and improving the moisture content of the skin

Cosmetic and/or dermatological formulations for the topical treatment of the skin for regulating and improving the moisture content of the skin, comprising as active ingredient combination a) at least one anionic polyamino acid matrix, b) at least one polysaccharide, and optionally c) one or more osmoprotectants for topical application are provided.

- Depolymerized scleroglucan for regulating and improving the moisture content of the skin

The use of depolymerized scleroglucan alone, or in combination with one or more active ingredients as a moisturizer, and as anti-inflammatory active ingredient for protecting and for restoring a healthy skin barrier in the field of cosmetic or dermatological skincare is disclosed.

- METHOD OF PREVENTION AND TREATMENT OF AGING, AGE-RELATED DISORDERS AND/OR AGE-RELATED MANIFESTATIONS INCLUDING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, CORONARY ARTERY DISEASE, OSTEOPOROSIS, ARTHRITIS, TYPE 2 DIABETES, DEMENTIA, ALZHEIMERS DISEASE AND CANCER

This invention relates to a method for prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, type 2 diabetes, dementia and some forms of arthritis and cancer in a subject comprising administering to said subject, separately, sequentially or simultaneously a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor .kappa.B (NF-.kappa.B) inhibitors/antibodies, I.kappa.B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging, age-related disorders and/or age-related manifestations including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, serine/threonine kinases inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor .kappa.B (NF-.kappa.B) inhibitors/antibodies, I.kappa.B kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and/or inhibition of the signal transduction pathway

- Rapidly absorbing lipophilic skin compositions and uses therefor

Topical compositions, and particularly hydrophobic compositions include an essential oil in an amount effective to achieve substantially complete absorption of the composition in the skin without leaving a greasy residue. Especially preferred topical compositions may also include pharmaceutically active agents (e.g., polyphenol), additional essential oils, stabilizers, etc. In further preferred aspects, contemplated compositions may delay onset, or even prevent viral eruptions on the skin, and where applied as a lipstick, will increase reddening of the lip as well as reduce chapping.

- Multiparameteric method for assessing immune system status

The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.

- Highly concentrated, biocidally active compositions and aqueous mixtures and methods of making the same

The present invention relates to liquid mixtures and compositions having high bromine concentrations that find use as biocides and processes for preparing them.

- Cosmetic preparation

A cosmetic preparation which comprises microparticles distributed in an adhesive solution wherein the microparticles contain a substance affording an esthetic effect.

- Retinoid solutions and formulations made therefrom

Compositions for topical application for treating a skin disorder (e.g., acne) include a retinoid, which is solubilized completely in alcohol only with the aid of cosolvents such as esters (e.g., alkyl benzoate, isopropyl palmitate, isopropyl myristate, diisopropyl adipate and their derivatives). This completely solubilized retinoid can be used to formulate an emulsion system or liquid to powder suspension containing a second active, such as an antibiotic (e.g., clindamycin).

- Method and composition for transdermal drug delivery

The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.

- Disinfecting teat care compositions

The present invention relates to novel compositions which are used to produce nitrous acid, in preferred aspects such compositions comprise a protic acid and a metal nitrite, and to methods for using these compositions, in particular for disinfecting mammalian teat skin.

- Novel compositions and methods for the treatment of immune related diseases

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

- 17SS-HSD1 and STS inhibitors

The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17.beta.-hydroxysteroid dehydrogenase type I (17.beta.-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of these compounds. Furthermore, the invention concerns the therapeutic use of said novel substituted steroid derivatives, particularly their use in the treatment, inhibition, prophylaxis or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of 17.beta.-hydroxysteroid dehydrogenase type I and/or steroid sulphatase enzymes and/or requiring the lowering of the endogenous 17.beta.-estradiol concentration.

- 4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- Combination

The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) an AT.sub.1-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.

- Cleansing pad

A cleansing pad (10) is made of a web of fibers, forming a substrate (11), where the substrate (11) includes a cleansing agent (12) therein. The cleansing agent (12) is a pourable soap. In making the cleansing pad (10), the cleansing agent (12) is initially heated from solid form into molten/liquid form, and distributed essentially throughout one or more portions of the substrate (11) in molten form to coat the fibers in said portions of the substrate (11). After application of the molten cleansing agent (12), the substrate (11) is then allowed to cool such that the molten cleansing agent (12) solidifies and remains solid at a desired range at and above room temperature, forming the cleansing pad (10). Thereafter, in use, the cleansing pad (10) is applied for cleaning an object in conjunction with a solvent such as water. The solvent dissolves the solidified cleansing agent (12). The cleansing pad (10) can be used in this manner multiple times without the need for application of additional cleansing agent (12) to the cleansing pad (10). As such, the cleansing pad (10) is a self-contained, long lasting product that maintains its creamy lather during multiple uses and does not require the user to reapply cleansing agents to the cleansing pad (10) with every use.

- Cosmetic composition comprising a tribochromic compound, process using this composition and uses

The present disclosure relates to a cosmetic composition comprising, in an appropriate cosmetic medium, at least one tribochromic compound. The present disclosure also relates to a process for making up the lips, skin, or integuments using the compostions disclosed herein, wherein the at least one tribochromatic compound has the property of changing coloration or shade when, once deposited onto the integuments, the lips or the skin, it undergoes a conformational change subsequent to a mechanical stress.

- PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PSORIASIS

Pharmaceutical compositions for the treatment of skin disorders such as psoriasis, acne and eczema, methods of making the compositions and methods of use thereof are described herein. The composition comprises psorberine, an alcohol-water extract isolated from the Mahonia aquifolium plant, and one or more additional active agents. In a preferred embodiment, the one or more active agents is a vitamin D3 analog, such as calcipotriol. The compositions may also contain excipients such as emollients, surfactants, emulsifiers and buffers. The compositions are formulated into a cream, lotion or ointment for topical administration.

- Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect

The present invention provides methods for treating tendinopathy providing a durability of effect by administering nitroglycerin. Such methods include methods for relieving pain associated with such tendinopathies. The use of a transdermal patch configured to deliver glyceryl trinitrate at a rate of 5 mcg/hr to about 85 mcg/hr

- Composition containing as the active ingredient componantes from salvia sclarea seed

The present invention concerns a food supplement comprising Salvia sclarea seeds, or flour, oil or pulp or extracts obtained from the seeds as well as finished food products comprising the food supplement. The present invention further concerns a nutraceutical or cosmetic preparation comprising as an active ingredient Salvia sclarea seeds, or flour, oil or pulp or extracts obtained from the seeds.

- 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- Helix 12 directed non-steroidal antiandrogens

Compounds having the structure (or their salts): are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

- 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- 17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- VITAMIN FORMULATION

A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.

- Medicaments

There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterized in that the coarse fraction possesses a greater mass median aerodynamic diameter than the fine fraction. There is also described a method of delivering a therapeutically effective amount of a substantially fine active ingredient to the lung of a patient by co-administration with a substantially coarse active ingredient.

- Composition and method of protection against UV irradiation

The present invention relates to a composition for use in a nutritional product, dietary supplement, or pharmaceutical compound wherein such composition is used to protect the skin against the effects of ultraviolet (UV) irradiation from the sun or other sources, including but not limited to sunburn, skin redness, swelling, immune suppression, photo-aging, photodamage, and skin cancer. The invention relates to a composition containing a variety of antioxidants, vitamins, and herbal ingredients. The present invention further relates to a method of administering a therapeutically effective amount of the composition ingredients to protect the skin against the effects of UV irradiation.

- Topical skin preparations for treatment of skin aging comprising a testosterone ester

The present invention concerns Topical skin preparations for the use in the prevention of atrophy and aging of the skin, comprising a testosterone ester with an esterifying acid having between six to eleven carbon atoms.

- ENCAPSULATED COSMETIC COMPOSITION

The present invention relates to encapsulated cosmetic compositions that are topically applied. The compositions contain at least one frangible capsule that has a seamless shell of a thermo-softening material. The shell is solid at about room temperature and melts upon application to the skin. The shell holds a core cosmetic that is added to a clear gel base. Thus, the color of the capsule is visible and multiple colored capsules can be added to the base for a custom colored composition.

- Gel compositions for topical administration

Pharmaceutical gel compositions containing pharmacologically active agent for topical administration, as well as a method of making the same, are disclosed.

- Pharmaceutical composition

This invention relates to pharmaceutical formulations comprising particles with a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule. The invention also relates to methods of forming particles comprising a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule.

- Active substance combination of licochalcone A and phenoxyethanol

A cosmetic or pharmaceutical preparation comprising licochalcone A and phenoxyethanol. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

- Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them

The invention relates to nitro-substituted 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 4 activity in immunocompetent cells (e.g. macrophages and lymphocytes).

- Cosmetic composition comprising silicone particles

Disclosed herein is a composition comprising concave particles of a silicone material and a fatty phase comprising at least one oil and at least one non-spherical silicone elastomer. The composition may make it possible to obtain a make-up for the skin and/or lips which is non-drying and/or which does not exhibit tightness and/or which is comfortable.

- Composition, method and pharmaceutical preparation for pharmaceutical spray suspensions

A pharmaceutical composition, constituting a spray suspension includes at least one liquid excipient and at least one solid excipient substantially insoluble in the liquid excipient, and at least one pharmaceutical active ingredient. A method of preparing porous suspension particles includes: a) wet-milling or dry-milling the solid excipient(s) or a mixture of at least one active ingredient and a solid excipient(s) in a milling equipment inducing essentially compression and shear forces, resulting in fine particulate quality, where more than 90% by weight is smaller than 5 m; b) drying and aggregating the product of step a) alone or with the addition of at least one active ingredient, in fine particulate form, which will produce essentially isodiametrical aggregate particles. A suspension particles obtainable by the method pharmaceutical preparation, utilising the composition or porous suspension particles and a method for treatment of disorders using the preparation are disclosed.

- Sunless tanning composition and method of sunless tanning

A sunless tanning composition having dihydroacetone and an amphoglycinate (amphoacetate) in an amount effective for sunless tanning is provided. Also provided is a method of sunless tanning having the step of topically applying to the skin an effective amount of a sunless tanning composition having dihydroacetone and an amphoglycinate.

- Method of enhanced benzoyl peroxide application

Methods of treating acne are disclosed comprising applying a benzoyl peroxide solution in one or more solvents to the skin of a user and applying a sealer thereto. The methods are useful to improve the penetration of active drug into the skin in need thereof, and are highly effective in treating P. Acne.

- Preparations containing an extract of eperua falcata and/or constituents of the latter

A cosmetic, pharmaceutical or dermatological preparation containing extract of the plant Eperua falcata, active principles of the plant Eperua falcata, astilbin or engeletin. The preparation is useful to inhibit release of pro-imflammatory mediators and neuropeptides, including CGRP and SP, for skin and hair treatment, including, sensitive skin, acne, scalp itch and neurogenous inflammation.

- Stem cells having increased sensitivity to sdf-1 and methods of generating and using same

The present invention relates to stem cells which exhibit increased sensitivity to a chemoattractant and, more particularly, to methods of generating and using them such as in clinical applications involving stem cell transplantation.

- Microemulsion for cosmetic or pharmaceutical use containing an active ingredient

The invention relates to a transparent microemulsion comprised of a surfactant or emulsifier based on polyethylene glycol, a first cosurfactant (or coemulsifier) based on polyglycerol, a second cosurfactant (or coemulsifier) based on monoesters, an aqueous or hydrophilic phase, and may or may not include an active for delivery that can include vitamins, sunscreens, antiaging agents, or pharmaceutical actives. The said microemulsion is useful in personal care and pharmaceutical products.

- Preparation for oral administration containing physiologically active fatty acids and oligomer proanthocyanidin

Compositions for oral administration of (a) a physiologically active fatty acid containing about 16 to 26 carbon atoms and about 2 to 6 double bonds, and esters or glycerides thereof; and (b) an oligomeric proanthocyanidin or a plant extract containing said proanthocyanidin are disclosed. Methods of using the compositions as additives in food products are also disclosed.

- Extracts obtained from cell line cultures from plants belonging to the Oleaceae family (e.g. Syringa vulgaris), their preparation and use

The present invention refers to the use of extracts from selected and stabilised cell lines comprising phenylpropanoids with high anti-oxidant capacity having a verbascoside titre of between 20% and 90% and a chromophore-free fraction of between 80% and 10%, in human and veterinary medicine, and for nutritional and cosmetic purposes.

- Antiangiogenic agents

Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: wherein R.sub.a is selected from --OCH.sub.3, --OCH.sub.2CH.sub.3 or --CCCH.sub.3; and Z is selected from >C(H)--OH, >C(H)--O-alkyl, >C(H)--O-sulfamate, or >C(H)-dioxolane, where alkyl is a linear, branched and/or cyclic hydrocarbon chain comprising 1 to 10 carbons.

- 2,6-Quinolinyl derivatives, processes for preparing them and their uses

The present invention concerns 2,6-quinolinyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

- Active energy radiation hardenable skin plaster composition and skin plaster

[Problems] A composition curable with active energy beams for use in skin patches is provided, which is liquid at ordinary temperature, has a practical crosslinking property or curability in the absence of photopolymerization initiators even when irradiated with visible or ultraviolet light, and provides cured films that are not discolored and excellent in various pressure-sensitive adhesive performances and have appropriate pressure-sensitive adhesiveness so as not to cause pain or damage to the horny layer in the patch-applied area even when patches are repeatedly applied and peeled off, as well as excellent water resistance. [Means for solving problems] The composition curable with active energy beams for use in skin patches is liquid at ordinary temperature and comprises (A) a compound having two or more maleimide groups and (B) an oil component, or water or a water-soluble compound.

- Photoprotective compositions comprising an aqueous phase and a low melting point apolar wax

Photoprotective cosmetic compositions having at least reduced shine, stickiness, whitening and/or fluffiness and/or enhanced SPF contain an effective amount of at least one UV radiation filtering agent, at least one aqueous phase and at least one apolar wax having a melting point greater than or equal to 30.degree. C. and a fusion enthalpy of less than 250 J/g, formulated into a topically applicable, cosmetically acceptable carrier therefor.

- Pigmented anhydrous cosmetic compostition

The disclosure relates to an anhydrous cosmetic makeup composition comprising at least one volatile oil, at least one pigment in an amount greater than or equal to 25% by weight of pigments, and at least one oil-thickening agent, the composition having a hardness ranging from 0.04 to 0.5 newtons. The disclosure also relates to a makeup kit comprising two compositions, for example anhydrous compositions, of different color. The disclosure also relates to a method of effacing and/or covering skin color inhomogeneties, such as marks, by applying the anhydrous composition, or of a mixture of two compositions of the makeup kit to the skin.

- Personal care compositions and methods for the beautification of mammalian skin and hair

Personal care composition comprising from about 0.05% to about 5% of at least one aquaporin-stimulating compound selected from the group consisting of xanthine, caffeine; 2-amino-6-methyl-mercaptopurine; 1-methyl xanthine; 2-aminopurine; theophylline; theobromine; adenine; adenosine; kinetin; p-chlorophenoxyacetic acid; 2,4-dichlorophenoxyacetic acid; indole-3-butyric acid; indole-3-acetic acid methyl ester; beta-naphthoxyacetic acid; 2,3,5-triiodobenzoic acid; adenine hemisulfate; n-benzyl-9-(2-tetrahydropyranyl)adenine; 1,3-diphenylurea; 1-phenyl-3-(1,2,3-thiadiazol-5-yl)urea; zeatin; indole-3-acetic acid; 6-benzylaminopurine; alpha-napthaleneacetic acid; 6-2-furoylaminopurine; green tea extract; white tea extract; menthol; tea tree oil; ginsenoside-RB1; ginsenoside-RB3; ginsenoside-RC; ginsenoside-RD; ginsenoside-RE; ginsenoside-RG1; ginseng root extract; ginseng flower extract; pomegranate extract, extracts from Ajuga turkestanica; extracts from viola tricolor and combinations thereof; an additional ingredient selected from the group consisting of niacinamide, glycerin and mixtures thereof, and a dermatologically-acceptable carrier.

- Human Endokine Alpha and Methods of Use

The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.

- Composition useful as an adhesive and use of such a composition

A pressure sensitive adhesive composition comprising one or more hydrogel-forming hydrophilic homopolymers or heteropolymers and one or more amphiphilic block-copolymers comprising hydrophobic polymer blocks being incompatible and hydrophilic polymer blocks is useful, for example, in transdermal drug delivery systems and other medical, pharmaceutical and cosmetic products that adhere to the skin or other body surface.

- Monitoring and modulating HGF/HGFR activity

Provided are methods and compositions for the modulation of hepatocyte growth factor activity to regulate lymphatic vessel development and function. Methods and composition for the monitoring and treatment of skin disorders, lymphedema, and metastatic cancers are disclosed. Also described are methods of identifying inhibitors of hepatocyte growth factor dependent lymphangiogenesis.

- Caspase inhibitors and uses thereof

The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be advantageously used as agents against caspase-, interleukin-1-("IL-1"), apoptosis-, interferon-y inducing factor-(IGIF), interferon-.gamma.-("IFN-.gamma."), or TNF-alpha mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to processes for preparing the compounds of this invention. This invention also relates to methods for inhibiting caspase and TNF-alpha activity and decreasing IGIF production and IFN-.gamma. production and methods for treating caspase-, interleukin-1, apoptosis-, and interferon-.gamma.-, and TNF-alpha mediated diseases using the compounds and compositions of this invention.

- Avermectin and praziquantel combination therapy

An antiparasitic combination therapy compising a combination of a 13-monosaccharide 5-oxime avermectin, such as selamectin, and praziquantel in a veterinarily acceptable carrier, diluent or adjuvant. Also provided is a method of treatment or prophylaxis of a parasitic infestation as well as a kit useful in the treatment or prophylaxis of a parasitic infestation of flea, heartworm or tapeworm in a mammal.

- Methods of treating disease states using antiangiogenic agents

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.

- Skin make-up composition comprising a resin

The present invention relates to a skin make-up or care composition containing a liquid fatty phase having at least one resin having a number-average molecular weight of less than or equal to 10 000 g/mol, chosen from rosin, rosin derivatives, hydrocarbon-based resins, and mixtures thereof. The invention also relates to a non-therapeutic use of the invention composition in a process for making up or caring for the skin and for obtaining a deposit on the skin which has good transfer resistance, in particular in the presence of sebum.

- Protein compositions for promoting wound healing and skin regeneration

Methods for stimulating proliferation and inhibiting death of cells in the epidermis and dermis of wounded and non-wounded as well as transplanted mammalian skin and transplanted skin cell suspensions are described. The methods include the steps of administering to an area of wounded or non-wounded skin therapeutically effective amounts of .alpha..sub.1-antitrypsin, alkaline phosphatase (such as placental alkaline phosphatase), transferrin, and .alpha..sub.1-acid glycoprotein in compositions that contain at least two of these proteins, or their active derivatives, as the major active components. The compositions can be administered topically and/or by injection, or both. The invention also provides regimens for restoring or maintaining the strength and thickness of wounded, non-wounded and transplanted skin as well as developing new skin from skin cell suspensions comprising periodically administering one or more compositions topically and/or by injection.

- Extracts from Ajuga reptans cell lines, their preparation and use

The present invention relates to selected and stabilized cell line extracts from Ajuga reptans comprising phenylpropanoids having high antioxidating capacity with a teupolioside titre of between 20% and 90% and a chromophore-free fraction of between 80% and 10%. Said extracts are for use in human and veterinary therapy and for nutritional and cosmetic purposes. Furthermore, the invention relates to a novel phenylpropanoid molecule denominated isoteupolioside.

- HISTONE DEACETYLASE INHIBITORS

Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of: wherein the substituents are as defined herein.

- Lip augmentation device

The present invention is of a method of facilitating lip augmentation, the method comprising treating the lip area with an electricity generating device. The present invention further provides devices and kits for lip augmentation.

- Sunless tanning substrate

The present invention provides a sunless tanning substrate having one or more sunless tanning enhancers, which adjust the rate of color development and/or adjust or customize the color developed on the skin. The present invention further provides a method of sunless tanning comprising the step of using the sunless tanning substrate of the present invention either prior to application, simultaneously with application, after application, or any combinations thereof, of one or more sunless tanning actives or agents to the skin. The present invention also provides a sunless tanning kit that includes one or more of the sunless tanning substrates.

- Photoprotecting/cosmetic compositions comprising benzotriazole and bis-resorcinyltriazine

Topically applicable sunscreen/cosmetic compositions suited for the improved photoprotection of human skin and/or hair against the damaging effects of UV-irradiation, particularly solar radiation, comprise an effective SPF-maintaining and water remanence-enhancing amount of intimate admixture of (a) at least one benzotriazole first sunscreen compound and (b) at least one bis-resorcinyltriazine second sunscreen compound, formulated into (c) a topically applicable, cosmetically acceptable vehicle, diluent or carrier therefor.

- Use of biotin or a biotin derivative for lightening skin and treating age spots

The present invention relates to the use of biotin alone, preferably, however, with vitamin C or a derivative thereof, for the preparation of a cosmetic composition or of a pharmaceutical composition for skin-lightening purposes, for the elimination of skin color irregularities and for the treatment of senile lentigines.

- Foamable composition combining a polar solvent and a hydrophobic carrier

The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least one surface-active agent; (3) water; and (4) at least one liquefied or compressed gas propellant at a concentration of 3% to 25% by weight of the total composition. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering the above-mentioned compositions to an afflicted target site.

- Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride

Personal care composition including a first skin and/or hair care active cetyl pyridinium chloride; and at least one additional skin and/or hair care active selected from the group consisting of tetrahydrocurcumin, sugar amine, vitamin B.sub.3, retinoids, hydroquinone, peptides, phytosterol, dialkanoyl hydroxyproline, hexamidine, salicylic acid, n-acyl amino acid compounds, sunscreen actives, water soluble vitamins, oil soluble vitamins, hesperedin, mustard seed extract, glycyrrhizic acid, glycyrrhetinic acid, carnosine, Butylated Hydroxytoluene (BHT) and Butylated Hydroxyanisole (BHA), ergothioneine, vanillin or its derivatives, diethylhexyl syrinylidene malonate, melanostatine, sterol esters, idebenone, dehydroacetic acid, Licohalcone A, creatine, creatinine, feverfew extract, yeast extract, beta glucans, alpha glucans, their salts, their derivatives, their precursors, and/or combinations thereof; and a dermatologically acceptable carrier. The invention further relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of the personal care composition of the invention.

- Non-flammable insecticide composition and uses thereof

The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%; or about 10% to about 20%; or about 20% to about 50% by weight; about 0.1% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and (5) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

- IL-17 homologous polypeptides and therapeutic uses thereof

The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

- Composition and its Therapeutic Use

A composition having a variety of therapeutic and cosmetic uses comprises: (i) a vitamin; (ii) a metal salt that provides metal ions in vivo; and (iii) insulin or a growth hormone. Such a composition is useful for treating, for example, genetic disorders, skin diseases, cancer and viral infections.

- Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase

A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, bronchoconstriction, lung allergy(ies) or inflammation, and abnormal levels of adenosine, adenosine receptors, sensitivity to adenosine, lung surfactant and ubiquinone, such as pulmonary fibrosis, vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, COPD, RDS, ARDS, cancer, and others. The present treatment is effectively administered by itself for conditions without known therapies, as a substitute for therapies exhibiting undesirable side effects, or in combination with other treatments, e.g. before, during and after other respiratory system therapies, radiation, chemotherapy, antibody therapy and surgery, among others. Each of the agents of this invention may be administered directly into the respiratory system so that they gain direct access to the lungs, or by other effective routes of administration. A kit comprises a delivery device, the agents and instructions for its use.

- Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities

The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.

- Nitric oxide donors and uses thereof

Disclosed are novel NO-donating compounds, designed such that when NO is released from the compound a residue which is a naturally occurring metabolite is formed, and thus a development of tolerance to the compounds upon repetitive administration is prevented or decreased. Also disclosed are methods of preparing such NO-donating compounds, pharmaceutical compositions and medical devices containing such compounds and methods utilizing such compounds in the treatment of various medical conditions.

- Pyrimidine derivatives for the prevention of hiv infection

This invention concerns the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, wherein the compound is a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein the ring containing -a.sup.1=a.sup.2-a.sup.3=a.sup.4- and -b.sup.1=b.sup.2-b.sup.3=b.sup.4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; and pharmaceutical compositions comprising them.

- Secreted protein family

This invention relates to a new family of secreted proteins, termed the SECFAMI family, its family members including the novel proteins INSP113, INSP114, INSP115, INSP116 and INSP117, herein identified as secreted proteins containing epidermal growth factor (EGF) fold-containing domains, ranging from 125-153 amino acids in length and containing eight conserved cysteine residues and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

- Dibenzoilmethane derivative compounds, the use thereof in the form of photoactivable solar filters and cosmetic compositions containing said compounds

The present invention relates to dibenzoylmethane-based compounds of formula 1, and also to salts or solvates thereof, and to the process for preparing them. The invention also relates to the use of a compound of formula (I) as an agent for protecting the skin or the hair against UV radiation and to a cosmetic and/or dermatological product, characterized in that it comprises a compound of formula (I) as active principle.

- Depigmentation method and kit

The present invention relates to a cosmetic kit for depigmenting human skin comprising a multi-unit receptacle containing a first unit containing a microdermabrasion composition; a second unit containing a skin depigmenting composition; a third unit containing ascorbic acid in powder form; a fourth unit containing a skin soothing composition; optionally, a fifth unit containing a maintenance composition, and optionally a sixth unit containing a photoprotective composition. The present invention also relates to a method for treating human skin in need of depigmentation comprising the successive application, to an area of skin, of the compositions contained in the multi-unit receptacle.

- Compositions and kit for alleviating signs of ageing

A cosmetic kit for treating human skin comprising a multi-unit receptacle containing: (a) a unit containing a microdermabrasion composition having at least one type of skin abrading particle; (b) a unit containing a peeling composition having at least one skin peeling agent; (c) a unit containing an anti-ageing composition having at least one anti-ageing ingredient; (d) a unit containing a skin soothing composition having at least one skin soothing ingredient; (e) optionally, a unit containing a maintenance composition; and (f) optionally, a unit containing a photoprotective composition.

- Interleukin-8 homologous polypeptides and therapeutic uses thereof

The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treatment and diagnosis of inflammatory diseases.

- Coumermycin/novobiocin-regulated gene expression system

A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator, which then binds to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.

- Liquid cleansing composition

A mild, aqueous, liquid crystalline structured cleansing and moisturizing composition with low levels of surfactants that include monoalkyl sulfosuccinate surfactant(s) and high levels of hydrophillic emollients is provided that provides a low in-use slip, tight skin feel, and a fast, clean-feel rinse in the absence of substantial levels of soap. Substantial amounts of persistent and fine quality lather are produced with the inventive composition even in the presence of high levels of emollients.

- High alcohol content gel-like and foaming compositions

This invention relates to a "high lower alcohol content" (>40% v/v of a C.sub.1-4 alcohol) liquid composition able to be either dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers or as an alcohol gel composition which does not use thickener and gelling agents that leave undesirable deposits or a sticky after-feel and that has a final viscosity less than 4,000 cps. The liquid compositions comprise an alcohol, C.sub.1-4 (>40% v/v), a fluorosurfactant of at least 0.001% by weight to prepare a foamable composition or from 0-2.0% to prepare a gel-like composition of a final viscosity less than 4,000 cps, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition or a gel-like composition with a viscosity less than 4,000 cps), and the balance being purified water. The compositions may include emulsifier-emollients and mosturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.

- GHRP 2 strips

The products that exist on the market today that produce the same results are with injection. This new product, HGH Strips, is taken orally through strips that are placed on the back of the toungue. HGH Strips is scientifically developed with GHRP-2 (Growth Hormone Releasing Peptide-2), L-Lysine, L-Argenin and L-Valine which amino acids are specifics for increasing the natural production of GH (Growth Hormone) by the anterior pituitary deep inside the brain; also called Somatotropin, it influences in growth of cells, bones, muscles and organs throughout the body. HGH Strips helps to increasing the levels of IGF-1 (Insulin like Growth Factor-1 is a metabolite of human growth hormone) rise; a natural anabolic growth factor molecule. Studies have found that IGF-1 has increased lean body mass, reduced fat, built up bone and muscle tissue, it may even regenerate nerve tissues and boost the immune system.

- Topical skin-protectant and anti-pruritic compositions

Topical skin protectant compositions, and more particularly anti-pruritic skin protectant compositions, comprising a skin protective ingredient, a therapeutically effective amount of a pharmaceutically active agent comprising an anesthetic agent or derivative thereof, an oleaginous solvent comprising a substance other than the skin protective ingredient, and an aqueous solvent. These skin protectant compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, or preventing pruritic skin conditions, as well as other related skin conditions. These compositions are further capable of restoring or repairing a skin lipid barrier of a mammal.

- Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease

Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

- ORALLY ADMINISTERED AGENT FOR IMPROVING SKIN CONDITION

It is desirable to provide a medicament and a nutritional food to improve skin conditions and to create fulfilling life for people who are not satisfactory about their skin conditions. Specifically, one object of the present invention is to provide an orally administered agent, a food and drink, or a food additive which can be used for improving skin condition. An orally administered agent, a food and drink, or a food additive for improving skin condition, comprising ornithine or a salt thereof as an active ingredient can be provided according to the present invention.

- Therapeutic and diagnostic means for papillomas and other diseases involving ped/pea-15

The present invention discloses diagnostic methods and means, as well as medicaments in diagnosis, prognosis and therapy of diseases where PED/PEA-15 plays an etiopathogenetic role, in particular papilloma and diabetes. Said methods are based on the determination of PED/PEA-15 levels and the medicaments are based on antisense oligonucleotides. A non-human transgenic animal, expressing high PED/PEA-15 levels, is also disclosed, being it useful as a model for the study of said diseases and evaluation of their therapies.

- Skin and/or hair treatment agent containing tetrasubstituted cyclohexene compounds

A composition of matter that is suitable for use on skin or hair. The composition comprises one or more compounds of formula wherein R1, R2, R3 and R5 are as defined in the specification, and at least one other component or element.

- Use of A33 antigens and jam-it

The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer.

- Implantable preparations

Implantable preparation comprising a material which can be obtained from globin that has been modified, especially chemically, to be, at least partially, soluble at physiological pH, the material being biocompatible, and biodegradable in the organism. The material may be soluble at physiological pH, or insoluble at that pH. The preparation may be in the form of a solution, suspension, paste, gel, film, sponge, powder or granules, or a solid implant. Application in particular to the healing, protection or filling of external skin wounds, the filling of wrinkles and skin flaws, the filling of tissue, as means for fixing prostheses or biomaterials, or means for preventing adhesion.

- Permeant delivery system and methods for use thereof

Disclosed is a device for causing the transdermal flux of a per meant into a subject via at least one formed pathway through a skin layer of the subject. The device comprises a delivery reservoir comprising: i) a non-biodegradable matrix having a bottom surface and defining a plurality of conduits therein the matrix, at least a portion of the plurality of conduits being in communication with the bottom surface; and ii)an undissolved hydrophilic per meant disposed therein at least a portion of the plurality of conduits of the matrix, wherein the hydrophilic per meant can come in contact with subcutaneous fluid from the subject when the bottom surface of the matrix is positioned in fluid communication with the at least one formed pathway. Also disclosed are systems and methods for causing the transdermal flux of a per meant into a subject via at least one formed pathway through a skin layer of the subject.

- Enriched aqueous components of emblica officinalis

In an extraction process comprising extracting a raw extract from Emblica officinalis the improvement comprising conducting the extraction under conditions of time, temperature and atmosphere, to inhibit the formation of black specks and/or oligomeric and/or polymeric tannins and/or oxidation products thereof.

- Fusion polypeptides, and use thereof in antivascular tumor therapy

The present invention relates to fusion polypeptides, comprising at least two peptides. The invention further relates to the use of these fusion proteins in antivascular therapy of neoplastic diseases and to their use I the production of a drug for the treatment of neoplastic diseases.

- 1,3 Aclyated 24-keto-vitamin d3 compounds and methods of use thereof

The invention provides 1,3 acylated, 24-keto vitamin D.sub.3 compounds of formula I: wherein: X.sub.1 and X.sub.1 are each independently H.sub.2 or .dbd.CH.sub.2, provided X.sub.1 and X.sub.1 are not both .dbd.CH.sub.2; R.sub.1 and R.sub.2 are each independently, hydroxyl, OC(O)C.sub.1-C.sub.4 alkyl, OC(O)hydroxyalkyl, OC(O)haloalkyl, provided that R.sub.1 and R.sub.2 are not both hydroxyl; R.sub.3 and R.sub.4 are each independently hydrogen, C1-C4 alkyl, hydroxyalkyl, or haloalkyl, or R.sub.3 and R.sub.4 taken together with C.sub.20 form C.sub.3-C.sub.6 cylcoalkyl; and R.sub.5 and R.sub.6 are each independently C.sub.1-C.sub.4 alkyl, hydroxyalkyl, or haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof. Methods for using the compounds to treat vitamin D.sub.3 associated states, and phar,aceutical compositions containing the compounds are also disclosed.

- Novel methods for the preparation of dhea derivatives

The invention relates to a method for the production of DHEA derivatives, such as 7-oxo-DHEA and 7-hydroxy-DHEA, from DHEA itself.

- Novel compounds useful for bradykinin B1 receptor antagonism

Disclosed are compounds that are bradykinin B.sub.1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B.sub.1 receptor.

- Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof

The invention relates to novel aminothiol ester compounds having the general formula (I): and to a method for preparing them and to their use in pharmaceutical compositions intended for use in human or veterinary medicine (cancers and precancers, dermatological, rheumatic and ophthalmological complaints in particular) or in cosmetic compositions. The invention also relates to a pharmaceutical or cosmetic composition, characterized in that it comprises, as active agent, a compound of general formula (I) in combination with a pharmaceutically or cosmetically acceptable support.

- Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients

The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives and combinations of said derivatives with other therapeutically active ingredients. The invention also concerns compositions comprising said derivatives or said combinations and uses thereof, for the treatment of cerebrovascular diseases, pathology related to inflammation, neurodegeneration, deregulations of lipid and/or glucose metabolism, cell proliferation and/or differentiation and/or skin or central nervous system ageing.

- Control of power, loads and/or stability of a horizontal axis wind turbine by use of variable blade geometry control

The present invention relates to a design concept by which the power, loads and/or stability of a wind turbine may be controlled by typically fast variation of the geometry of the blades using active geometry control (e.g. smart materials or by embedded mechanical actuators), or using passive geometry control (e.g. changes arising from loading and/or deformation of the blade) or by a combination of the two methods. The invention relates in particular to a wind turbine blade, a wind turbine and a method of controlling a wind turbine.

- Topical Delivery with a Carrier Fluid

Aerosol spray formulations capable of delivering high concentrations of active agent-containing materials and/or excipient are described herein. The formulation contains a carrier fluid, a propellant, and a therapeutic, prophylactic, consmeticeutical and/or inert solid suspended, dissolved, or dispersed in the formulation. The active ingredient may be any pharmaceutically active agent, but is preferably an antibiotic, an antihistamine, an anesthetic, an anti-inflammatory, and/or an astringent. In one embodiment, the active agent is an antifungal agent. In another embodiment, the active agent is a consmeticeutical. The active agent can optionally be dispersed on, or associated with, a carrier powder. The carrier fluid is a highly volatile silicone liquid, which evaporates in less than 10 minutes, preferably less than 5 minutes, after application of the formulation to the patient's skin. The formulation may also contain one or more pharmaceutically acceptable excipients such as antioxidants, stabilizers, perfumes, colorants, viscosifiers, emulsifiers, surfactants, and combinations thereof. The formulation can be packaged in a conventional aerosol spray can.

- Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases

The invention relates to substances which specifically inhibit peptidases splitting ala-p-nitroanilide for use in medicine. The invention further relates to the use of at least one such substance or of a pharmaceutical or cosmetic composition containing at least one such substance for the prophylaxis and therapy of diseases, in particular the prophylaxis and therapy of diseases with an overshooting immune response (autoimmune diseases, allergies and transplant rejections), of other chronic inflammatory diseases, neuronal diseases and brain damages, skin diseases (acne and psoriasis, among others), tumor diseases and special virus infections (including SARS).

- Inhibitors of cancer cell, T-cell and keratinocyte proliferation

The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein Y is --NR.sup.aR.sup.b, --NR.sup.cC.dbd.ONR.sup.aR.sup.b, --NR.sup.cC.dbd.SNR.sup.aR.sup.b, --NR.sup.cC.dbd.NR.sup.dN.sup.aR.sup.b, heterocycle, --C.dbd.ONR.sup.aR.sup.b, heterocycle, or aryl; n is 0 to 8; m is 0, or 1; r is 0 to 3; t is 0 to 3; X is O or N; Z is CH.sub.2, C.dbd.O, C.dbd.S or a single bond; Z.sup.1 is CO--R.sup.2, CS--R.sup.2, (CH.sub.2).sub.t--R.sup.2 or the side-chain of a naturally occuring amino acid;, Z.sup.2 is CO--R.sup.2, CS--R.sup.2 or (CH.sub.2).sub.t--R.sup.3 or the side-chain of a naturally occuring amino acid; Z.sup.3 is CO--R.sup.2, CS--R.sup.2 or (CH.sub.2).sub.t--R.sup.4 or the side-chain of a naturally occuring amino acid; Z.sup.4 is H, alkyl, alkoxy, or cycloalkyl; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently from each other H, OH, SH, NH.sub.2, CN, NO.sub.2, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkylthio, haloalkyloxy, hydroxyalkyl, hydroxyalkylamino, alkylamino, alkylaryl, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxyalkyl, alkoxy, aryloxy, heteroaryl, aryl, or halogen.

- Lipid-containing compositions and methods of using them

Anabolic compositions can be administered to patients with chronic diseases, or who suffer from conditions precipitated by such diseases or long term treatment regimes. The compositions comprise at least one surfactant wherein the total concentration of surfactant in the composition is greater than 1% (w/w or w/v), and can cause weight gain in chronic disease patients as well as reduce or eliminate other disease symptoms or conditions. The anabolic compositions can also provide therapeutic benefit in patients who are candidates for, or who have undergone, organ or tissue transplant procedures.

- Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient

Disclosed are medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups X, R.sup.a, R.sup.b, R.sup.1, R.sup.1', R.sup.2, R.sup.2', R.sup.2'', R.sup.2''', V and n may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

- Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases

The present invention relates to substances capable of specifically inhibiting Gly-Pro-p-nitroanilide cleaving peptidases, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).

- Tricyclic steroid hormone nuclear receptor modulators

The present invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).

- Enhancing the effect of radioimmunotherapy in the treatment of tumors

4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2- -ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used for enhancing the effect of radioimmunotherapy of tumors.

- Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors

The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance; short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake; adipogenesis, adiposity and/or obesity; body weight gain and/or reduction; diabetes, diabetes type I, diabetes type II, tumor cell proliferation; inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

- Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superinfections and fungal recurrances

The present invention is directed to compositions containing ascorbic acid or a physiologically acceptable salt thereof for the preparation of a formulation useful for the prevention of fungal infection recurrences or fungal superinfections in patients at risk.

- Skin cleansing agent, particularly for removing printing inks and/or soiling caused by ink

The invention relates to a skin cleansing agent, particularly for the removal of printing colors and/or inks, comprising the components a) 1 to 70 wt.-% of at least one ethoxylated amine and/or ethoxylated diamine, b) 30 to 70 wt.-% of at least one polyethylene glycol of general formula H--O--(CH.sub.2CH.sub.2--O).sub.nH, wherein n is an integer of from 1 to 150, c) 1 to 30 wt.-% of at least one fatty alcohol polyglycol ether, d) 0.1 to 5 wt.-% of at least one complexing agent, e) 0 to 30 wt.-% of at least one reducing or oxidizing agent, f) 0 to 25 wt.-% of one or more abrasives, g) 0 to 10 wt.-% of at least one polyhydric alcohol, h) 0 to 3 wt.-% water, i) optionally one or more viscosity-building agents, j) optionally further cosmetic adjuvants, additives and/or active substances, the sum of components a) through j) making 100 wt.-%, relative to the composition of the cleansing agent.

- G-csf derivative for inducing immunological tolerance

The invention relates to a method, composition and use thereof for inducing immunological tolerance, in particular transplantation tolerance in a recipient and self-tolerance in a patient. Tolerance is preferably induced by administering a G-CSF derivative, or biologically active fragment, homolog or variant thereof, in particular peg-G-CSF, to a transplantation donor. Transplantation tolerance may reduce or prevent graft versus host disease or graft rejection and self-tolerance may prevent, treat or improve a condition in relation to an autoimmune disorder. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocyte precursors cells and IL-10 secreting T cells.

- Ultrasonic modification of soft tissue matrices

The present invention provides a method of, and apparatus for, utilising ultrasonic energy so as to mechanically disrupt the collagenous architecture of biological matrices in a controlled manner so that the tissue can be rapidly recellularised in continuous form. The present invention also provides for the production of tissue matrices with improved recellularisation properties, cell stratification or patterning.

- Aromatase activating agent

The present invention is directed to an aromatase activating agent containing a plant selected from among mulberry bark, ginseng, cucumber, and phellodendron bark; or chlorella; or an extract of any of these ingredients. The aromatase activating agent of the present invention is highly safe to the human body, and useful as a drug or cosmetic composition for prevention, amelioration, or treatment of various lesions caused by estrogen deficiency.

- Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions

Botanically derived anti-irritants for prophylactic and therapeutic treatment of adverse skin reactions from application of transdermal or topical drug delivery system, permits the effective administration of a drug from a delivery system in which the drug, of a component of the delivery system comprises a skin irritant; and the delivery systems formed thereby.

- Preparation for the application of agents in mini-droplets

The invention relates to a preparation for the application of agents in the form of minuscule droplets of fluid, in particular provided with membrane-like structures consisting of one or several layers of amphiphilic molecules, or an amphiphilic carrier substance, in particular for transporting the agent into and through natural barriers such as skin and similar materials. The preparation contains a concentration of edge active substances which amounts to up to 99 mol-% of the agent concentration which is required for the induction of droplet solubilization. Such preparations are suitable, for example, for the non-invasive applications of antidiabetics, in particular of insulin. The invention, moreover, relates to the methods for the preparation of such formulations.

- Self forming, thermodynamically stable liposomes and their applications

Certain diacylglycerol-polyethyleneglycol (DAG-PEG) lipids are especially useful for forming thermodynamically stable liposomes. Such liposomes are useful for a variety of purposes, including the delivery of therapeutic agents.

- High drug load formulations and dosage forms

The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.

- Medicament for treatment of dermal pigmentation

A medicament for preventive and/or therapeutic treatment of dermal pigmentation and/or development of skin cancer, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula --O-A wherein A has the same meaning as that defined above and the group represented by formula --X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula --O-A wherein A has the same meaning as that defined above and the group represented by formula --X-E wherein each of X and E has the same meaning as that defined above.

- Slimming cosmetic composition

Cosmetic or dermopharmaceutical compositions containing, in a dermatologically acceptable carrier, at least one diterpene among: cafestol, kahweol and chemical derivatives are useful for slimming treatments including prevent and/or treat cellulite or orange peel and/or to refine contours of the face, skin firming, to reduce the steatomery of the thighs, to decrease the volume/fatty overload of the spare tire at the hips, to reduce "love handles", both on men and women.

- Novel compounds

The present invention relates to novel phenylalanine compounds, processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.

- Method of enhanced drug application

Methods of treating skin in need thereof are disclosed including applying a drug or active agent or formulation thereof to the skin of a user and applying a sealer thereto. The methods are useful in actively enhancing penetration of the actives immediately upon application to skin, sealing the skin surface to prevent removal of the drug or active agent, holding the drug or active agent in a reservoir film, and/or enhancing long term penetration of the drug or active agent.

- Cosmetic composition to accelerate repair of functional wrinkles

The present invention relates to a composition consisting of a combination of peptides that regenerate the dermal matrix and a rapid acting muscle relaxant derived from the extract of the plant, Acemella oleracea. By limiting cutaneous deformation caused by the contraction of facial muscles the extract increases the efficiency of the peptides in reducing expression lines.

- Compositions and methods for the treatment of immune related diseases

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

- Non-irritating solvent-borne polymeric coatings for application to the skin

A method and composition for reducing or eliminating stinging that may accompany application of topical solution of a skin-compatible polymeric material to a skin wound, abrasion, burn or other skin injury. The topical solution may contain one or more skin-irritating chemicals, such as diethyl ether, ethanol, ethyl acetate, methyl acetate, acetone, methyl ethyl ketone and combinations thereof. The method includes: (i) providing a composition that contains between 1% and 10% by weight of the skin-compatible polymeric material dissolved in a liquid medium suitable for human topical use in which the liquid medium includes less than 20% combined weight of skin-irritating chemicals, and at least 45% combined weight of at least one volatile solvent and/or volatile co-solvent, in which the molecules constituting this 45% combined weight portion of the liquid medium contain at least 5 carbon atoms, and the liquid medium has an initial boiling point at 1 atmosphere of greater than 35.degree. C. and less than 150.degree. C., and causes little or no stinging when applied to a skin injury, and (ii) applying the composition to the skin of a patient at the site of the skin injury.

- Antimicrobial treatment of nonwoven materials for infection control

A material substrate having at least part of a surface treated with an antimicrobial composition is described. The antimicrobial composition exhibits at least a 3 log.sub.10 CFU reduction within a period of about 30 minutes after contact with various species of a broad spectrum of microorganisms. The substrate can be a nonwoven material that has good fluid barrier properties, which can be used in protective garments and sheets. Methods for manufacturing and imparting the antimicrobial treatment to the substrate are also provided.

- Pharmaceutical compositions with melting point depressant agents and method of making same

The invention relates to the use of chemical fragrance ingredient to lower the melting point of active agents, thereby changing crystalline active agents into an amorphous state. The invention also relates to methods of enhancing the transdermal or transmucosal skin permeation or skin penetration of pharmacologically active agents to patients in need thereof. The compositions of the present invention present the additional benefits of being substantially alcohol-free and having a pleasant olfactory profile.

- Patches and uses thereof

A patch comprising a support having electrostatic properties is provided wherein a periphery of the support is coated with an adhesive material, and all or part of the non-adhesive surface of the support is covered with at least one biologically active substance in the form of particles that is adhered to the non-adhesive part of the support by electrostatic forces.

- Rapid dissolving bar soap with fibrous assembly

A cleansing article composed of a solid or semi-solid foamable composition, a wear promotion agent and a fibrous layer with bonded fibers is described that provides the user with a pleasant personal cleansing experience by revealing sufficient free fibers during personal cleansing to provide both excellent lather and exfoliating properties and which in one embodiment combines cleansing, aesthetic and/or skin benefit with active agents. The batting layer is at least partially encompassed by the solid or semi-solid foamable composition.

- Resonance modulator for diagnosis and therapy

A method and device are disclosed for monitoring and/or altering an immune function. The method uses a resonance modulating compound as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. The resonance modulator has electromagnetic properties that attract immune cells to a target area to which the resonance modulating agent has been applied. Electromagnetic properties (such as a voltage amplitude) of the target region are altered in the presence of the resonance modulator, and serve as an indicator of immune function. An external stimulus (such as an applied electromagnetic field) can also be applied to the resonance modulator to enhance its immune stimulating and attractant properties. Particular examples of the resonance modulator are aryl hydrazones. The described aryl nitrohydrazones have the ability to interact with populations of cells with emergent behavioral characteristics associated with chemical, biological and radiation changes and injury. The disclosure also provides numerous other examples of resonance modulating agents, and provides attributes of these agents and assays for identifying additional resonance modulating agents.

- Novel agents for preventing and treating disorders involving modulation of the RyR receptors

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

- Isoindole-imide compounds and compositions comprising and methods of using the same

This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

- Confocal Raman Spectroscopy for dermatological studies

Use of Confocal Raman Spectroscopy (CRS) for dermatological studies, including a method for determining the thickness of the Stratum Corneum (SC) on a test area of the skin, and to a method for quantifying the effectiveness of a skin care composition. The methods of the invention can be carried in vitro (either artificial skin or a sample of skin) or in vivo (directly on the human skin of a person).

- Method of treating acne with stratum corneum piercing device

The invention features a method of treating acne by piercing the stratum corneum of skin in need of such treatment with a stratum corneum-piercing device that contains at east one stratum corneum-piercing microprotrusion and a compressible cover such that the compressible cover substantially encases the at least one stratum corneum-piercing microprotrusion, and wherein upon contacting the skin with the compressible cover, the at least one stratum corneum-piercing microprotrusion protrudes from the compressible cover and pierces the stratum corneum of the skin.

- Radiofrequency ablation with independently controllable ground pad conductors

A radiofrequency ablation system provides multiple ground pads and active control of current flow through the ground pads to provide improved power sharing at the tissue near the ground pads reducing risk of patient skin burns for higher power ablation generators.

- Business method for generating advertising claims

Business method for generating advertising claims by utilizing Confocal Raman Spectroscopy (CRS) for dermatological studies. The methods of the invention can be carried in vitro (either artificial skin or a sample of skin) or in vivo (directly on the human skin of a person).

- Composition for cushions, wounds dressings and other skin-contacting products

A skin-contacting adhesive composition is described which has improved initial tack, long-term adhesion, water uptake and translucency characteristics and may be prepared by melt extrusion. Uses of these compositions are also described, for example, their use in wound dressings, adhesive cushions, and transdermal drug delivery devices.

- Personal care composition

Personal care composition comprising a vitamin B3 compound, a sugar amine, a hydroquinone compound, and a dermatologically-acceptable carrier.

- Cosmetic composition comprising extract form mallotus japonicus for improving skin wrinkle

The present invention relates to compositions for inhibiting elastase activity, enhancing collagen biosynthesis and improving skin wrinkle, comprising Mallotus japonicus extract as active ingredient. The present compositions exhibit the inhibition effect on elastase activity and promotion effect on collagen biosynthesis at a molecular level, and as a result, excellent efficacy in improvement of skin wrinkles.

- Compound and method for regulating plasminogen activation and cell migration

The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof.

- Method for reducing allergencity in indoor spaces

According to this invention, allergenicity in an indoor space is reduced by denaturing allergens in allergen reservoirs that are capable of producing respiratory or skin reactions and physically removing the allergens from the allergen reservoirs in the indoor space. The allergen reservoirs may also be treated with pesticides and fungicides/fungistats to prevent reinfestation of house dust mites, molds and cockroaches.

- Multiribbon nanocellulose as a matrix for wound healing

The present invention includes compositions and methods for the integration of a non-allergenic nanocellulose into a wound bed. The composition may be formed into a wide variety of implants, e.g., a suture, a sheet, a compress, a bandage, a band, a prosthesis, a fiber, a woven fiber, a bead, a strip, a clasp, a prosthesis, a catheter, a screw, a bone plate, a pin, a bandage or combinations thereof.

- Transdermal drug delivery devices containing O-Desmethyl Venlafaxine (ODV) or its salts

The present invention provides transdermal drug delivery devices (i.e., patches) comprising O-desmethylvenlafaxine (ODV), a selective serotonin and norepinephrine re-uptake inhibitor, or a pharmaceutically acceptable salt thereof, which, among other, offer the advantage of eliminating or reducing the adverse side effects associated with the oral administration of ODV. Also provided are methods of preparing and using these transdermal delivery systems for the treatment of depression, anxiety disorders, vasomotor symptoms and pain.

- Process for co-spray drying liquid herbal extracts with dry silicified MCC

A process for preparing dry extracts from a liquid extract and at least one additional substance by a spray-drying process, characterized in that said at least one additional substance is added to the spray-drying process in a dry form during the spray-drying processes.

- Methods for treatment of headaches by administration of oxytocin

The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.

- 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- Compounds for treatment of lipase-mediated diseases

Novel benzoquinone-derived compounds and polymorphs, prodrugs, geometric or optical isomers thereof, and pharmaceutically acceptable esters, ethers, carbamates, oximes of such compounds, polymorphs, prodrugs and isomers are provided. Process for preparation of compounds of the invention and pharmaceutical compositions containing such compounds and their use for reducing or inhibiting activity of lipase gene family for treatment, amelioration or prevention of lipase gene family mediated diseases and conditions including overweight, obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, diabetes, atherosclerosis, other cardiovascular diseases, metabolic syndromes, and metabolic disorders are provided. Methods of use of the compounds for skin care, hair care and cosmetics are provided.

- Topical formulations containing O-Desmethyl Venlafaxine (ODV) or its salts

The present invention provides topical compositions comprising O-desmethylvenlafaxine (ODV), a selective serotonin and norepinephrine re-uptake inhibitor, or a pharmaceutically acceptable salt thereof. In certain embodiments, the inventive topical formulations contain one or more percutaneous/permucosal absorption enhancers. Also provided are methods of preparing and using these compositions for the treatment of diseases or conditions where a localized therapeutic effect is sought, such as vasomotor symptoms and pain.

- Olfactory patch

An olfactory patch comprises a well 6 formed by a reservoir layer 2, the well sandwiched between a barrier layer 3 and a permeable layer 4. The permeable layer defines a pathway for olfactory fluid flow from the well 6 (B, FIG. 2). The flow of the olfactory may be commenced by an initiator mechanism, the same or another mechanism may control or terminate the flow of olfactory. The olfactory patch may utilise any olfactory fluid or combination of fluids within the same patch. The patch may utilise olfactory fluid which provides aromas or masks odours or has de-deodorising capability or the olfactory fluid contains therapeutic agents which are released from the patch by aromatization or by direct skin absorption or by inhalation.

- Foamable pharmaceutical compositions and methods for treating a disorder

Novel compositions of matter comprising a foamable delivery system are provided. Novel methods for treating a disease, disorder, or condition using the novel compositions are further provided. Novel methods for making and delivering a foamable pharmaceutical composition are also provided. While the novel compositions and foamable drug delivery system may be utilized for administration of a wide variety of drugs to epithelial tissues, to treat a wide variety of diseases, disorders, or conditions, the inventive compositions and foamable drug delivery systems are particularly useful for the dermatological administration of corticosteroids and antifungal agents.

- Solid skin care composition comprising multiple layers

The present invention relates to a solid skin care composition comprising: (a) a first layer which is solid at 45.degree. C. and which is selected from the group consisting of a water-in-oil emulsion, an oil-in-water emulsion and an oil dispersion; and (b) a second layer which is a pressed powder layer; wherein the first layer and the second layer are provided in the same package in a manner such that the first layer and the second layer can be simultaneously applied.

- Solid skin care composition comprising multiple layers

The present application relates to a solid skin care composition comprising: (a) a first layer which is solid at 45.degree. C. and which is a water-in-oil emulsion or an oil-in-water emulsion; and (b) a second layer which is solid at 45.degree. C. and which is an oil dispersion comprising a benefit agent; and wherein the first layer and the second layer are provided in the same package in a manner such that the first layer and the second layer can be simultaneously applied.

- COMPOSITIONS, METHODS AND KITS FOR TREATING ALLERGIC DERMATITIS OF SKIN

The invention includes compositions suitable for removal of urushiol from skin having been exposed thereto, which compositions contain an ethoxylate and sodium lauroyl sarcosinate, methods for treating allergic dermatitis of skin having been exposed to urushiol, and kits suitable for treatment of allergic dermatitis,

- Administration of 8-hexadecene-1,16-dicarboxylic acid for promoting cohesion of the epidermal horny layer

A regime or regimen for promoting cohesion and/or organization of the epidermal horny layer, notably for promoting homogeneity and/or clarity of the complexion, for improving the homogeneity and/or the staying power of makeup compositions on the skin or the lips, for preventing impairment of the horny layer induced by a cosmetic or dermatological active agent, or for promoting cohesion of the horny layer in the preparation of reconstructed epidermis and/or reconstructed skin, entails administering to an individual in need of such treatment, for such period of time as required to elicit the desired effect, a cosmetic/dermatological composition which contains up to 8% by weight of 8-hexadecene-1,16-dicarboxylic acid, formulated into a physiologically acceptable medium therefor.

- COMPOUNDS AND COMPOSITIONS TO CONTROL ABNORMAL CELL GROWTH

Methods and regimens for stimulating proliferation and inhibiting death of skin cells in wounded, non-wounded healthy and unhealthy, or transplanted skin and skin cell suspensions are provided. The methods and regimens include a step of administering to an area of host skin and/or transplanted skin a combination of lactoferrin and alkaline phosphatase such as placental alkaline phosphatase. The active components may be administered topically, by injection, or by other suitable means. In addition to improving the quality of skin, the reported methods may also be effective to reduce inflammation and microbial infection in the skin. Embodiments of the invention also provide compositions suitable for use in the described methods.

- Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods

The present invention is drawn to a transdermal patch for the delivery of a nitric oxide-donor and a second active agent. The patch can comprise a backing layer and an active agent-containing composition which is supported at least in part by the backing layer. The active agent-containing composition can include an amount of a nitric oxide-donor and an amount of a second active agent. The transdermal patch can have a drug delivery zone defined by the area where the composition contacts an intact human skin site, and the transdermal patch can be formulated to deliver a nitric oxide donor, such as nitroglycerin, at from about 5 .mu.g/hour to about 85 .mu.g/hour. The second active agent can be selected from a number of agents including NSAIDS, opioids, local anesthetics, menthol, salicylic acid, salicylic acid derivatives, vanilloid receptor-1 activators, corticosteroids, vasoconstrictors, and combinations thereof.

- Method for demonstrating efficacy of a topically applied active ingredient

A method is disclosed for demonstrating the efficacy of a topically applied active ingredient, which method includes topically applying a composition containing an active ingredient to an area of skin, applying an absorbent material to the area of skin to extract at least a portion of the active ingredient from the skin, thereby incorporating the portion of active ingredient with the absorbent material in a releasable manner, removing the absorbent material from the skin, extracting the active ingredient from the absorbent material, combining the extracted active ingredient with cellular growth media, incubating the cellular growth media with cultured cells for a period of time to produce a biomarker, and measuring the biomarker to indicate efficacy of the active ingredient.

- Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents

The invention concerns an aminoquinoline-antibiotic hybrid compound of general formula (I): Q--(Y.sub.1).sub.p--(U).sub.p--(Y.sub.2).sub.p-A: wherein Q represents an aminoquinoline, (Y.sub.1).sub.p(U).sub.p--(Y.sub.2).sub.p'' is an optional spacer and A is an antibiotic residue. The invention enables the antibiotic residue activity to be unexpectedly enhanced.

- Solid skin care composition comprising multiple layers

The present invention relates to a solid skin care composition comprising: (a) a first layer which is solid at 45.degree. C. and which is a water-in-oil emulsion; and (b) a second layer which is solid at 45 .degree. C. and which is an oil-in-water emulsion comprising a benefit agent; wherein the first layer and the second layer have a different composition; and wherein the first layer and the second layer are provided in the same package in a manner such that the first layer and the second layer can be simultaneously applied.

- Solid skin care composition comprising multiple layers

Disclosed is a solid skin care composition comprising: (a) a first layer which is solid at 45.degree. C. and which is a water-in-oil emulsion; and (b) a second layer which is solid at 45.degree. C. and which is a water-in-oil emulsion comprising a benefit agent; wherein the first layer and the second layer have a different composition; and wherein the first layer and the second layer are provided in the same package in a manner such that the first layer and the second layer can be simultaneously applied.

- High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances

A method of usign a high-aspect ratio microdevice for treating, preventing or ameliorating a medical condition is provided.

- Transgenic mammal with constitutive, tissue-specific cytokine expression and use as a cancer model

The invention is directed to a transgenic non-human mammal with constitutive, tissue-specific cytokine expression and the use of the transgenic mammal as a model for spontaneous development of cancer. Particularly, the invention provides for a transgenic mouse where specific expression of interlueukin-1.beta. in the stomach results in the development of gastric cancer. The invention also encompasses methods using the transgenic mammals for screening compounds for their ability to modulate the development, growth or progression of cancer.

- Skin care composition

Skin care composition comprising a plurality of interference pigments and a dermatologically acceptable carrier. The plurality comprises at least a first interference pigment which reflects a first color, and at least a second interference pigment which reflects a second, complementary color. The total amount of interference pigments is from about 0.1% to about 10%.

- Cosmetic composition comprising at least one active agent and particles containing at least one colored inorganic pigment in a matrix, and skincare use thereof

Disclosed herein is a cosmetic composition for treating and/or caring for the skin, which comprises, in a physiologically acceptable medium, at least one cosmetic active agent and at least one colored particle comprising at least one inorganic pigment arranged inside a matrix, wherein the composition has an opacity of less than or equal to 35%. Also disclosed herein is a cosmetic treatment process comprising applying this composition to keratin materials. Further disclosed herein is a method for lightening and/or unifying the complexion of the skin and/or for correcting the appearance of skin marks and dyschromias comprising applying a composition of the present disclosure to the skin.

- High alcohol content foaming compositions with silicone-based surfactants

This invention relates to a "high lower alcohol content" (>40% v/v of a C.sub.1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise a C.sub.1-4 alcohol, (>40% v/v), a silicone-based surfactant of at least 0.001% by weight for foaming to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and mosturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.

- Use of oligosaccharides in cosmetic, food or dermatological compositions for stimulating the differentiation of epidermal cell

The present invention related to a method for preventing or treating skin disorders comprising administering to a subject a dermatological composition comprising oligogalacturonides.

- Topical compositions containing plant extracts for personal care

A topical composition or a personal beauty care product (e.g., soap, shampoo, rinse, hair conditioner, and the like) comprises chemical or biological substances or plant extracts obtained from certain plants, in particular, plant species of the family Liliaceae or Amaryllidaceae, preferably selected from the following Allium species such as Allium fistulosum, Allium ampeloprasum or Allium porrum, or other Allium species or their relative species having ingredients which can stimulate hair growth and/or reduce hair loss. The plant species can preferably be selected from bunching onion, scallion, Welsh onion, green onion, great green onion, spring onion, leek, wild leek, Egyptian leek, shallot, and Korean or Asian great green onion, or the like.

- Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.

- Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions

The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof.

- Benzyl-1,3-thiazolidine-2,4-dione compounds for stimulating or inducing the growth and/or for reducing the loss of keratin fibers

The benzyl-1,3-thiazolidine-2,4-dione compounds having the structural formula (I), or salt and/or solvate thereof; are useful active agents for inducing and/or stimulating the growth of mammalian keratin fibers and/or reducing the loss and/or increasing the density thereof, particularly of human head hair, beard hair, moustache hair, eyelashes and eyebrows, and advantageously are active agents for caring for or making up the hair or the eyelashes.

- Active substance-doped absorbing polymer particles, composition comprising polycondensate matrix and absorbant polymer for release of a wound treatment substance

A water-absorbing composition, a process for producing a water-absorbing composition, a composite comprising a water-absorbing composition, and the use of a water-absorbing composition for releasing an active substance (e.g., a wound treatment substance, a care substance, or combinations thereof) are disclosed. A water-absorbing composition can include active substance-doped water-absorbing polymer particles comprising: .PHI.1.) an active substance in a quantity in the range from about 0.001 to about 30 wt. %; and .PHI.2.) an absorber matrix in a quantity in the range from about 70 to about 99.999 wt. %. Also, a hygiene article and a wound treatment means, including a water-absorbing composition, are disclosed.

- Self-supporting aerosol cleansing composition

An aerosol cleansing composition that is self-supporting after dispensing is described whose volume does not noticeably shrink with time. The inventive composition can be used in place of toilet bars when it is inconvenient to use such bars and provides the user with substantial lather and optionally warming agents, skin conditioners and/or skin active agents. A method for cleansing the skin without rinsing with water is also disclosed where the inventive aerosol cleansing composition is applied to the skin and wiped off.

- Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels

Methods of treating, preventing and/or managing disorders associated with low plasma leptin levels are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent.

- Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids

Compositions and methods for preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid comprised in a solid or semi-solid formation or in a transdermal or transcutaneous delivery device are disclosed. Also disclosed are compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include an adhesive. Compositions of a nucleic acid capable of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that include a nucleic acid uptake enhancer are also disclosed. Methods of preventing or inhibiting the growth of a hyperproliferative lesion in a subject that involve these therapeutic compositions and devices are also disclosed.

- Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof

This invention is directed to inhibitors of copper-containing amine oxidases (E.C. 1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-1), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.

- QUALITY ASSURANCE SYSTEM AND METHODS OF USE

A quality assurance system having an ambient condition indicator provides a current visual indication of the cumulative exposure over time of a host product to an ambient condition such as temperature or humidity. The indicator's visual response is correlated with the response characteristics of any one of a wide range of specific host products including foods, drugs and vaccines, industrial and other products whose quality is related to condition-exposure over time. The system includes a historical record with one or more historical visual indications of past cumulative exposures. An airline meal can be accompanied by a novel freshness certification document which can simulate a travel document and provide, in a graphically appealing manner, a verified indication of the freshness of the meal served. Also disclosed are a novel quality assurance document and method and a cold chain monitor.

- Dual variable domain immunoglobulin and uses thereof

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

- Pharmaceutical compositions for transdermal administration of anti-inflammatory agents

A pharmaceutical composition for transdermal administration comprising a polymeric release matrix capable of forming a supple film after drying, selected among cellulose polymers or copolymers; an active principle selected among the group of non-steroid anti-inflammatory agents comprising at least one carboxylic or metal carboxylate group; a transcutaneous absorption promoter; water; and a physiologically acceptable non-aqueous solvent capable of dissolving the release matrix, the active principle and the transcutaneous absorption promoter and to be rapidly eliminated by evaporation on contact with the skin.

- EXTRACT OF VANILLA PLANIFOLIA

The invention relates to an extract of vanilla originating from at least one species of vanilla plant (family Orchidaceae), to the method for obtaining it, to a cosmetic or dermatological composition containing it, and to its use as a polyfunctional active agent in a cosmetic or dermatological composition, for the prevention and/or treatment of alterations of the skin due, in particular, to aging, to physiological mechanisms related to aging, or to conditions related to these mechanisms.

- Dermal fillers for biomedical applications in mammals and methods of using the same

A method of tissue augmentation in mammals comprising implanting or injecting into the tissue of a mammal elastic material derived from solar elastosis or other sun-damaged sites in humans is disclosed. The method further comprises injecting into the tissue of a mammal, alone, or in combination with the solar elastosis, at least one filler material, such as fibrillin, recombinant fibrillin, fibulin, and recombinant fibulin. A method of treating various skin conditions, such as wrinkles, photoaging, acne scarring, scars, and HIV-associated lipoatrophy, by injecting into the tissue elastic material derived from solar elastosis and/or filler material is also disclosed.

- Cosmetic Composition Containing Thermoplastic Microspheres and Skin Beneficial Agents

The invention relates to thermoplastic hollow microspheres containing one or more skin benefit agents entrapped therein. The microspheres are useful in the topical delayed release of the skin benefit agent.

- C1q related protein

This invention relates to the novel protein, termed INSP163, herein identified as a secreted protein containing a jelly-roll fold, in particular, as a member of the TNF (tumor necrosis factor)-like family of cytokines, specifically as a C1q-like protein and to the use of this protein and nucleic acid sequence from the encoding gene in the diagnosis, prevention and treatment of disease.

- Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same

This invention relates to the therapeutic, diagnostic and pharmacogenetic use of nucleic acids and proteins involved in human proteolytical system such as serine and cysteine proteases and their inhibitors and pharmaceutical agents and other therapies affecting these. This invention discloses methods for the treatment and prevention of cardiovascular diseases such as coronary heart disease (CHD), acute myocardial infarction (AMI), chronic CHD, arterial hypertension (HT) and cerebrovascular stroke and metabolic disorders such as the metabolic syndrome (MBO) and obesity and methods for detecting or diagnosing a risk of, or predisposition to the said diseases in a subject, for selecting treatment in a subject and for selecting subjects for studies testing cardiovascular, anti-diabetic and anti-obesity drugs, as well as to transgenic animals.

- Peptide nucleic acid based guanidinium compounds

Disclosed herein are transmembrane transporter compounds containing guanidinium groups to enhance transport of a polymer backbone across biomembranes. Therapeutic and other biologically active moieties may be attached to the compounds. The polymer backbone may include peptide nucleic acid monomer units.

- Antimicrobial and anticancer lipopeptides

The invention provides lipophilic conjugates comprising a peptide coupled to a fatty add, the peptide comprising at least two positively charged amino acid residues, said peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by pathogenic organisms such as bacteria and fungi. The lipophilic conjugates are also suitable for sanitation, as disinfectants, or for food preservation.

- Use of quinol derivatives thereof for cosmetic, dietary supplement or pharmaceutical compositions and compositions thereby obtained.

The present invention relates to a cosmetic, dietary supplement, or pharmaceutical composition for oral ingestion or topical application to the skin comprising effective amounts of a tocopherol quinone, tocopherol quinol, plastoquinol, menaquinol, or phylloquinol compound, or any combination thereof as a method for preventing free radical oxidation or preventing or treating environmental skin damage including photoaging, trauma, discoloration, dryness, thickness, elasticity, or wrinkles.

- Wound dressing and adhesive wound dressing comprising a vasoconstrictive ingredient, and processes for the production thereof

A wound dressing provided as a ready-made product for covering bleeding wounds. The wound dressing comprises a carrier material containing at least one vasoconstrictive medicinal substance.

- PHARMACEUTICAL FOAM

The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized contained comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.

- MICROFABRICATED NANOPORE DEVICE FOR SUSTAINED RELEASE OF THERAPEUTIC AGENT

A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device.

- Spray dry capsule products and methods for preparing and using same

The present invention relates to spray-dried compositions comprising encapsulated active materials and a spray-dry carrier, to methods for imparting an effective amount of active materials to spray-dried products and to products incorporating the spray-dried compositions.

- Cell permeable conjugates of peptides for inhibition of protein kinases

The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a linker or a spacer. The complex molecules are preferably peptide conjugates having improved cell-permeability, serum stability and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed.

- Guanidinium delivery carriers

Disclosed herein are transmembrane transporter compounds containing guanidinium groups. Also disclosed herein are methods for transporting a biologically active moiety across a biological membrane using the transmembrane transporter compounds. Particularly, this invention provides a method for the delivery of a biologically active moiety across the biological membranes of such membranes as endothelial tissues.

- Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological inflammatory, neuronal and other diseases

The present invention relates to substances capable of specifically inhibiting Ala-p-nitroanilide-cleaving peptidases and Gly-Pro-p-nitroanilide-cleaving peptidases as well, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).

- Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof

Novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds having the following formula and the salts or their solvates thereof: are useful for stimulating or inducing the growth of keratinous fibers and/or slowing down their loss and/or increasing their density and/or improving their appearance, and also for caring for or making up keratinous fibers, e.g., for caring for or making up the hair or eyelashes.

- Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders

The present invention is directed to novel compounds according to formulae wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease treatment utilizing pharmaceutical compositions comprising these compounds. The compounds of this invention are novel therapeutic agents for the treatment of cancer, diabetes, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful modulators of gene expression. They exert their activity by interfering with certain cellular signal transduction cascades. The compounds of the invention are thus also useful for regulating cell differentiation and cell cycle processes that are controlled or regulated by various hormones or cytokines. The invention also discloses pharmaceutical compositions and methods of treatment of disease in mammals.

- Adhesive composition and use of such composition

The present invention relates to a pressure sensitive adhesive composition comprising a rubbery elastomeric matrix, said composition comprising one or more amphiphilic block copolymers and the use thereof for application in the medical field for instance for adhering of medical devices to the skin, in wound dressings or ostomy appliances and provides a quick and safe means for managing perspiration from the skin also when occluded with medical appliances.

- Indications For Local Transport of Anaesthetic Agents By Electrotransport Devices

The use of an iontophoresis electrode assembly for delivery of a drug formulation is described. The drug formulation includes an anaesthetic and a vasoconstrictor. It is administered to a patient prior to a procedure to produce clinically acceptable depth and duration of dermal anaesthesia at the portion of skin to subject to a painful procedure or to reduce or eliminate pain. The procedure is one selected from the group consisting of venipuncture, IV cannulation, needle aspirations, body piercings, blood donations, electrolysis, tattoo removal, tattoo application, injections, dermabrasion, skin peeling, high velocity particle ablation, pace maker implantation, pace maker replacement, epidural puncture, lumbar puncture, regional nerve blocks, skin harvesting, small skin incisions, skin biopsies, circumcisions or excisions. The iontophoresis electrode assembly may also be used to reduce or temporarily eliminate neuropathic pain.

- Stabilized body care products, household products, textiles and fabrics

Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds and selected organic UV filters. The stabilized products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products, household cleaners and textile-care products.

- Iontophoresis apparatus and method for the diagnosis of tuberculosis

An iontophoresis device includes an active electrode assembly including an active electrode element and at least one active agent reservoir. Active agents include one or more polypeptides, or fusion polypeptides, having antigenic determinants derived from or related to M. tuberculosis antigens and suitable for detection of tuberculosis.

- Surfactant mixtures for improving the deposition of active substances and for reducing the skin irritant action

A use of mixtures of surfactants which form multilamellar liquid-crystalline structures, where the surfactants are chosen from at least two of the following groups formed from isethionates, taurates, sarcosinates, acyl lactylates, acyl glutamates, fatty acid-protein condensates, PEG stearates, PEG distearates with an HLB value of less than 10, alkyl polyglycosides and betaines for reducing the skin irritant action of cosmetic and/or pharmaceutical formulations which are applied to the skin, and for improving hair structure is described.

- Dispersion of polymer particles, composition comprising it and cosmetic treatment method

The present patent application relates to novel dispersions of particles of a polymer which is stabilized at the surface, in a nonaqueous medium, in which dispersions the polymer exhibits a specific glass transition temperature. Another aspect of the present disclosure is a cosmetic or pharmaceutical composition comprising the said dispersion in a cosmetically or pharmaceutically acceptable medium. The present disclosure also relates to a method for the cosmetic treatment of keratinous substances employing the presently disclosed composition.

- COMPOSITION FOR IMPROVING SKIN CONDITIONS COMPRISING HUMAN GROWTH HORMONE AS AN ACTIVE INGREDIENT

Disclosed herein is a skin condition-improving composition for topical application to the skin, comprising human growth hormone as an active ingredient, and a method for improving skin conditions using the same. The disclosed composition exhibits various skin conditioning effects, such as acne treatment, wrinkle improvement, dark spot removal, skin elasticity improvement, hair growth stimulation, skin aging prevention, skin moisturization and the proliferation of skin epidermal stem cells.

- Use of polymers based on n-vinyl caprolactam in hair cosmetics

Use of polymers of 30-65% by weight of N-vinylcaprolactam, 35-65% by weight of a monomer mixture of N-vinylimidazole and vinylpyrrolidone, where the weight ratio of N-vinylimidazole to vinylpyrrolidone is between 0.085 and 0.30, 0-15% by weight of a nitrogen-containing quaternizable monomer (A), which is different from N-vinylimidazole, where the sum of monomer (A) and N-vinylimidazole is less than 18% by weight, in cosmetic preparations.

- Device for transdermal administration of active substances

A device for transdermal administration of active substances, comprising a backing layer and an active substance-containing reservoir connected to the backing layer. The skin-facing contact surface of the device has a plurality of microprotrusions which are suitable for penetrating the skin and which are equipped with structures that make extracting the protrusions from the skin more difficult.

- Lipid compositions and methods of use

The present invention relates to a composition comprising: a C12 to C24 branched or unbranched hydrocarbon; a mid-chain triglyceride; a C26 to C36 branched or unbranched hydrocarbon; a cholesteryl ester; an ester of a C10 to C24 fatty acid and a C10 to C20 alcohol; an ester of a C10 to C24 fatty acid and a C21 to C34 alcohol; glycerol; and a polar lipid; and to methods of making and methods of using the composition to treat lipid tear deficiency (LTD), aqueous tear deficiency (ATD), a combination of LTD and ATD, and other dry eye conditions. The composition is substantially free of water and substantially free of an artificial surfactant. A method of administering an ointment comprising a lipid composition to treat dry eye, while achieving sustained release of the ointment and preventing a blurring of vision by the ointment, comprises applying the ointment to the inferior lid margin of the outside skin of the lower eyelid or to the superior lid margin of the outside skin of the upper eyelid, and allowing the ointment to diffuse onto the eye. Also disclosed is the use of kinetic analysis of tear interference images to analyze an individual's precorneal lipid film spread to identify LTD or to evaluate response to LTD treatment in order to adjust percentages of lipids in the composition.

- Topical delivery of codrugs

The present invention provides pharmaceutical compositions for topical delivery comprising a suitable carrier and a codrug capable of penetrating, or being transported across, the dermis. The codrug according to the invention comprises a first constituent moiety linked to a second constituent moiety, wherein the second constituent moiety is the same as, or different from, the first constituent moiety. The first and second constituent moieties are so linked that they are easily transported into or across the dermis, into the skin, or into the blood or lymphatic system, and are reconstituted in vivo to form the first and second constituent moieties.

- Dispenser for personal care composition

An apparatus for dispensing a personal care composition to the skin includes a container with a reservoir containing the composition. The apparatus has an application end having fibers, with free ends, that provide an application surface.

- Cosmetic product containing mineral water for remineralising and rejuvenating the skin

The invention relates to a cosmetic composition that can be used to remineralise human skin and to counteract the effects of ageing on the latter. According to the invention, said composition contains 0.5-3% water of volcanic origin containing 0.01-0.05 mg/l Fe, 100-300 mg/l K, 1,000-2,000 mg/l Na, 80-200 mg/l Mg, 50-150 mg/l Ca, 50-150 mg/l Si, 0.01-0.1 mg/l P, 0.001-0.005 mg/l Se, 0.01-0.03 mg/l Zn. In addition, the composition optionally contains 0.2-0.8% of an extract from samphire Crithmum maritimum, 0.3-0.9% of the peptide palmitoyl-gly-his-lys and 0.8-1.25% hydrolysed soy protein.

- Delivery peptides, their constructs with active agents and use

The present invention refers to delivery proteins, protein-cargo complexes, methods, and means for the enhanced delivery or transport of drugs, biologically active agents or other compounds as cargo or cargo molecules onto, into, or across biological membranes or tissues forming a biological barrier.

- Tricyclic steroid hormone nuclear receptor modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).

- Active substance combination comprising a carbinol combined to at least an NSAID

The present invention relates to an active substance combination comprising at least one substituted carbinol compound and at least one non-steroidal anti-inflammatory drug (NSAID), a medicament comprising said active substance combination, a pharmaceutical formulation comprising said active substance combination for the manufacture of a medicament.

- 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- Fluorinated 4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- Novel HDAC inhibitors

The present invention relates to novel compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions. The present invention more particularly provides novel HDAC inhibitors of the general formula (1). Also included is a method for treatment of cancer, psoriasis, proliferative conditions and conditions mediated by HDAC, in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

- 21-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators

Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive impairment, decreased libido, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

- Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands

The present invention relates to the use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is H or OH; R1, R2, R3, R4 and R5 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and the pharmacologically active salts thereof.

- Novel Hydroxy Acid Complexes for Antiaging and Skin Renovation

This invention relates to certain divalent and polyvalent d-orbital metals of first transition series of the Periodic Table of Elements, from Group IV to Group VI, and including Molybdenum, complexed concurrently with an amino acid, or an equivalent of an amino acid, and a hydroxy acid in a novel spirocyclic bidentate chemical complex form (FIG. 1). Upon topical application said metal complexes undergo enhanced skin penetration without causing skin irritation. The said metal complexes are useful for topical conditions that include dry skin, xerosis, ichthyosis, dandruff, brownish spots, keratoses, melasma, lentigines, age spots, dark circles around eyes, skin pigmentation, topical inflammation, liver spots, pigmented spots, wrinkles, blemishes, skin lines, oily skin, acne, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, disturbed keratinization, dandruff, bacterial infection, fungal infection, wound healing, body odor, and skin changes associated with aging.

- Compositions and Methods for Treating Hair Loss Using C16-C20 Aromatic Tetrahydro Prostaglandins

A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.

- Oxyacetamide compounds useful for stimulating or inducing the growth and/or retarding the loss of keratin fibers

Oxyacetamide compounds that are inhibitors of type-1 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and which have the formula (I), or salts and/or solvates thereof: are useful for inducing and/or stimulating the growth of human keratin fibers, e.g., human head hair and/or eyelashes, and/or for retarding the loss and/or increasing the density thereof and/or for caring for and/or making up such keratin fibers.

- Composition for the oxidative treatment of hair or skin fixative compostion and method for permanent deformation of hair

Cosmetic composition for the oxidative treatment of hair or skin, prepared by mixing of at least two components, in which dehydroascorbic acid or a dehydroascorbic acid salt or a dehydroascorbic acid derivative is generated from ascorbic acid, ascorbic acid derivative and ascorbic acid salt prior to application by an enzyme that catalyzes the enzymatical oxidation of said of ascorbic acid as well as a process for carrying out the oxidative treatment of keratin, particularly for the oxidative post-treatment of reduced hair in the process of permanent deformation of hair using said composition.

- Compounds and use to reduce the formation of malodour

Malodour formation reducing compounds alpha-N-(3-Methyl-5-phenylpentanoxycarbonyl)-L-glutamine, alpha-N-(2-Methyl-5-phenylpentanoxycarbonyl)-L-glutamine, and alpha-N-(2,4-Dimethyl-4-phenylbutanoxycarbonyl)-L-glutamine, and their salts, compositions comprising such compounds, including cosmetic products, personal care products, and deodorant products, and methods forming such products and their use. The compounds are useful to reduce the formation of human malodour resulting from bacterial degradation of compounds naturally present in sweat, in particular axilliary malodour.

- Natural insect repellant

Disclosed is a pesticide method and composition utilizing a mixture of cedar and cinnamon oils as active pesticide agents in an inert carrier. The composition may also utilize a surfactant. Exemplary embodiments disclosed herein may include up to 8.5% by volume of cedar oil, up to 8.5% cinnamon oil, lemon juice, water, and other ingredients, as desired. Exemplary embodiments may be utilized to repel insects, rodents and other things from humans and animals as well as surfaces and areas that people and pets may be near. The exemplary embodiments may provide this repellant without the harmful effects of other chemicals and repellants.

- Thiamin based insect repellant

The present invention provides a topical application of thiamin to human skin or mammalian coats to provide effective insect repellency. Any commercially available thiamin compounds such as thiamin hydrochloride or thiamin mononitrate can be combined with a pharmaceutically or cosmetically acceptable carrier for preparing a composition for topical application. This composition and method of application can further be combined with sun-block or sunscreen agents to provide protection against insects as well as the harmful effects of UV radiation. This composition may also contain botanical oils or extracts to mask the thiamin odor and provide repellant synergy.

- Non-irritating formulation and method for the intradermal delivery of substances

This invention describes a composition of matter to facilitate intra-dermal delivery of a great variety of active substances, especially including high molecular weight cosmicuticals. Also disclosed is a method of forming the composition of matter and applying topically to patients, especially using a cream or patch. The active substance is initially combined with a biopolymer, which combination is subsequently linked to a base formulation whereby the base formulation aids in the intra-dermal delivery of the active substance without the skin irritation limitations of other formulations and dermal transmitting methods. The use of a combination of natural herbal, vegetable and animal products combined in this invention with biopolymers permits molecules of higher molecule weight to penetrate into the skin in a bioactive form by passive delivery means. The invention includes a product for the improvement of skin health and wrinkle reduction.

- Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites

A composition and method for producing a beneficial effect on a subject's nerve associated with at least one of a cosmetic condition, a dermatological indication and a dental indication and another condition. The composition comprises a hydroxy-oligocarboxylic ester and is formulated for topical administration of the product to a subject to produce the beneficial effect. The method includes topically applying to the subject in a region where the beneficial effect is desired a hydroxy-oligocarboxylic ester in an amount effective to produce the beneficial effect.

- Crystalline vap-1 and uses thereof

The present invention relates to crystalline vascular adhesion protein-1 (VAP-1) and in particular to methods for the use of structural information of crystalline human VAP-1 for ligand and/or inhibitor identification, design and production, as well as screening assays for detection of same. The invention further relates to inhibitors identified by the assays according to the present invention.

- Iontophoresis method and apparatus for systemic delivery of active agents

A method and an iontophoretic device are provided for delivery of one or more active agents via a circulatory system of a subject to a site of pain in the subject. In certain aspects, systemic delivery of active agents may alleviate pain at a site in a subject. Active agents may be selected from -caine-type anesthetics or painkillers. The device for delivery of an active agent may include a control unit.

- SKIN CARE PRODUCTS

The invention relates to a formulation comprising an aqueous emulsion and a propellant gas for a foam skin cream, wherein the emulsion comprises urea and hyaluronic acid, at least one free fatty acid and at least two emulsifiers, wherein the hyaluronic acid has a molecular weight of at least 1.times.10.sup.5 Da.

- Cosmetic composition textured with a bis-urea derivative with a liquid fatty phase textured with a bis-urea compound

A cosmetic composition textured with a bis-urea derivative with a liquid fatty phase textured with a bis-urea compound includes, in a physiologically acceptable medium, at least one liquid fatty acid phase, textured with at least one compound of general formula (I): in which A is a phenylene radical.

- Cosmetic application of rod-coil copolymers

The present invention relates to a cosmetic composition containing, in a physiologically acceptable medium, at least one rod-coil type block copolymer comprising at least one "coil" polymeric block structure of variable conformation bonded to at least one "rod" block structure of restricted conformation, the composition being characterized in that said rod block structure is of polymeric nature and is constituted in full or in part of peptide motifs or the like with some or all of the free hydrogen atoms of said peptide motifs participating in non-covalent hydrogen bonds within the rod structure.

- Tissue augmentation devices and methods

Tissue augmentation devices, as well as methods of manufacturing and using the same, are disclosed. In certain embodiments, a tissue augmentation device comprises an elongate tissue penetrating member and an amount of remodelable material, wherein at least a portion of the elongate member is cannulated, and at least a portion of the amount of material is received within at least a portion of the cannulated portion of the elongate member. The elongate tissue penetrating member may provide at least one deformation that is configured to constrict portions of the amount of remodelable material received within the elongate member. In alternate embodiments, a flexible covering over an implantable biomaterial provides protection and allows an easier delivery of the biomaterial to a tissue tract.

- Methods of making and using novel griseofulvin compositions

The present invention is directed to nanoparticulate compositions comprising griseofulvin. The griseofulvin particles of the composition preferably have an effective average particle size of less than about 2 microns.

- Compositions containing cis-isomers of a carotenoid compound and process

The present invention relates to a primary composition that includes at least one carotenoid-containing extract, concentrate or oleoresin enriched in cis-isomers of the carotenoid compound, and process of forming the same. It also relates to an oral composition that contains the primary composition in a foodstuff, in a food supplement, in a cosmetic preparation or in a pharmaceutical preparation.

- Tripeptides and derivatives thereof for cosmetic application in order to improve skin structure

The invention relates to compounds and to the cosmetically acceptable salts thereof, which correspond to general formula (I), wherein: R.sup.1 represents H, --C(O)--R.sup.6, --SO.sub.2--R.sup.6 or --C(O)--XR.sup.6; R.sup.2 and R.sup.4, independent of one another, represent (CH.sub.2).sub.n--NH.sub.2 or (CH.sub.2).sub.3--NHC(NH)NH.sub.2; n equals 1 4; R.sup.3 represents linear or branched C.sub.1-C.sub.4 alkyl that is optionally substituted by hydroxy; R.sup.5 and R.sup.6, independent of one another, represent hydrogen, optionally substituted (C.sub.1-C.sub.24) alkyl, optionally substituted C.sub.2-C.sub.24 alkenyl, optionally substituted phenyl, optionally substituted phenyl-C.sub.1-C.sub.4 alkyl or 9-fluorenyl-methyl; X represents oxygen (--O--) or --NH--; or XR.sup.5 with X=O also represents the esters of a-tocopherol, tocotrienol or retinol, with the provision that R.sup.1 and R.sup.5 do not represent hydrogen and X does not represent oxygen at the same time. The invention also relates to the production of the compounds of general formula (I) and to a cosmetically active composition that contains at least one compound of formula (I).

- Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.

- Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging

Provided, among other things, is a compound of the formula:

- Method and apparatus for body fluid sampling and analyte sensing

A body fluid sampling system is provided for use on a tissue site. In one embodiment, the system comprises a cartridge; a penetrating member driver; a plurality of penetrating members arranged in a radial configuration on the cartridge wherein sharpened distal tips of the penetrating members point radially outward; wherein an active one of the penetrating members may be operatively coupled to the penetrating member driver, the penetrating member driver moving the active one along a path out of a housing having a penetrating member exit, into the tissue site, stopping in the tissue site, and withdrawing out of the tissue site; and a plurality of analyte detecting members, wherein at least one of the analyte detecting members is positioned to receive fluid from a wound created by the active one of the penetrating members, wherein the detecting members are not pierced by the active one of the penetrating members.

- SURFACTANT-FREE DISPERSIONS, COMPOSITIONS, AND USE IN TOPICAL FORMULATIONS

The present invention provides for the preparation of stable surfactant-free dispersions of hydrophobic substances in low viscosity hydrophilic glyceryl polyacrylate or glyceryl polymethacrylate fluids, and topical vehicles formulated with the dispersions.

- Synergistic phytoceutical compositions

Phytoceutical compositions for the prevention and treatment of circulatory disorders, feminine endocrine disorders, and dermal disorders. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from each group. Such combinations have synergistic effects, with minimal side effects.

- Devices for the delivery of molecular sieve materials for the formation of blood clots

An apparatus for promoting the clotting of blood comprises a substrate and a zeolite in powder form deposited on the substrate. At least a portion of the substrate is selected from a group consisting of paper, polymer matrix, polyethylene sheet, hydrophilic macromolecules, and cloth. An agent for promoting the clotting of blood comprises a porous web structure and a compound capable of providing hemostasis incorporated into the porous web structure. The compound capable of providing hemostasis comprises at least one cationic species interspersed throughout and coulombically bound to the web structure such that the cationic species provides a positive charge to the web structure. A method of fabricating a blood clotting apparatus comprises the steps of providing a cellulose-based substrate; providing a zeolite; incorporating at least one cationic species into a structure of the zeolite to impart a positive charge thereto; and impregnating the cellulose-based substrate with the zeolite.

- Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds

A subject with symptoms of chronic kidney disease (CKD), who does not have end-stage renal disease (ESRD), can be treated by orally administering a pharmaceutical composition as an active ingredient a therapeutically effective amount of a non-toxic lanthanum compound. Administration of a lanthanum compound can prevent the progression of CKD, treat soft tissue calcification, and treat secondary hyperparathyroidism.

- Kneadable Hand Putty as a Delivery System for Skin Conditioning and/or Thermal Therapy Agents

A kneadable putty-like material that is used as a delivery system to deliver skin conditioning agents, and/or essential oils, and/or medicinal agents, and/or antimicrobial agents, and/or thermal therapy agents to the surface of the skin, in particular to the hands, in appropriate concentrations, is disclosed.

- GASTROINTESTINAL APPLICATOR AND METHOD OF USING SAME

A method and apparatus for dispensing a relatively viscous composition to a wound site at a location within a mammalian body requiring a relatively long and thin catheter for access includes filling a distal tip of the catheter with the composition, directing the distal tip to the wound site, dispensing the composition onto the wound site and then inflating a balloon against the applied composition to enable same to congeal enough so that the composition remains fixed to the wound site after the catheter is removed from the body. In an embodiment the balloon is secured to the catheter such that when air is applied through the catheter to the balloon, the balloon expands longitudinally and distally past a distal end of the catheter.

- Shampoo containing a gel network and a non-guar galactomannan polymer derivative

Shampoo compositions comprise (a) from about 5% to about 50% of one or more detersive surfactants; (b) a dispersed gel network phase comprising: (i) at least about 0.05% of one or more fatty amphiphiles; (ii) at least about 0.01% of one or more secondary surfactants; and (iii) water; (c) at least about 0.05% of a galactomannan polymer derivative with a net positive charge and having a mannose to galactose ratio of greater than 2:1 on a monomer to monomer basis, wherein the galactomannan polymer derivative has: (i) a molecular weight from about 1,000 to about 10,000,000; and (ii) a cationic charge density from about 0.7 meq/g to about 7 meq/g; and (d) at least about 20% of an aqueous carrier; all by weight of the shampoo composition.

- Shampoo containing a gel network

Shampoo compositions comprise (a) from about 5% to about 50% of one or more detersive surfactants, by weight of the shampoo composition; (b) a dispersed gel network phase comprising, by weight of the shampoo composition, (i) at least about 0.05% of one or more fatty amphiphiles; (ii) at least about 0.01% of one or more secondary surfactants; and (iii) water; and (c) at least about 20% of an aqueous carrier, by weight of the shampoo composition. A process for preparing a shampoo composition comprises the steps of: (a) combining a fatty amphiphile, a secondary surfactant, and water at a temperature sufficient to allow partitioning of the secondary surfactant and the water into the fatty amphiphile to form a pre-mix; (b) cooling the pre-mix below the chain melt temperature of the fatty amphiphile to form a gel network; (c) adding the gel network to one or more detersive surfactants and an aqueous carrier to form a shampoo composition.

- Combination of 2,3-dibenzylbutyrolactone and licochalcone-a

Active ingredient combinations of (a) one or more 2,3-dibenzylbutyrolactone derivatives and (b) licochalcone A or an aqueous extract of Radix Glycyrrhizae inflatae containing licochalcone A.

- Integument Cell Regeneration Formulation

The invention relates to a composition-of-matter and method of using a topical composition having 10-99 999% by weight of a topical base formulation and other active ingredients including stem cell or growth factors and/or antioxidants, as well as others for the purpose of regenerating integument cells

- Therapeutic agents for solid tumors

A therapeutic agent for solid tumors, said agent comprising as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 2 or an antibody fragment that maintains the antibody activity.

- Cosmetic or dermatological article comprising a medium that is soluble in water

A cosmetic or dermatological article may include: a medium in the form of at least one sheet of a material that is soluble in water at a temperature lower than 20.degree. C.; and at least one cosmetic or dermatological compound carried by the medium.

- Extended release osmo-microsealed formulation

The extended release osmo-microsealed formulation includes three controlled release systems associated in series. First, there is an inner solid particulate phase containing Venlafaxine Hydrochloride (Active), and one or more hydrophobic polymers, one or more diluents required to increase the bulk one or more osmogen (agents which can generate osmotic pressure across the hydrophobic coating) and one or more binder polymers essentially to provide strength/hardness to the particle. Second, there is an outer solid continuous phase including one or more hydrophilic polymers, that is further compressed into a tablet. Third, there is an optional functional coat surrounding the tablet. The process/method for forming the Osmo-microsealed extended release delivery system and the process for using such system for treating human ailment/depression are also provided.

- Biological active blood serum obtained by electrostimulation

The present invention relates to a method for preparing a blood serum product, the blood serum product and a pharmaceutical composition comprising said blood serum product as well as uses thereof in the treatment of various diseases and conditions, including epileptic seizures and apoplexy.

- Milk fractions and milk preparations for treating and/or preventing cox-2 mediated diseases

The present invention pertains to nutritional and pharmaceutical compositions for treating and preventing cyclooxygenase-2 mediated diseases and to a process for increasing the cyclooxygenase-2 inhibiting activity of a product. In addition thereto, the present invention relates to the use of one ore more milk protein fractions and/or one ore more milk protein preparations for inhibiting the activity of cyclooxygenase-2 (COX-2), in particular for the preparation of a medicament or a functional food for treating and preventing cyclooxygenase-2 mediated diseases.

- Container closure with a multi-layer oxygen barrier liner

A container closure with a multiple layer liner. The liner comprises a nylon gas transmission barrier and a non-nylon layer bonded by an adhesive layer. The nylon gas transmission barrier may contain an additional passive gas transmission component comprising an in-situ polymerized inorganic clay. An additional active gas transmission component comprising a chemically reactive scavenger may be incorporated into at least one layer of the multiple layer liner. Materials of the liner are selected for their process conditions and resulting resistance to degradation.

- SYSTEMS AND METHODS FOR SELECTION AND MAINTENANCE OF HOMOGENEOUS AND PLURIPOTENT HUMAN EMBRYONIC CELLS

A number of human disorders are characterized by degeneration or loss of specific cells, resulting in pathology associated with reduction or absence of cell function. Such diseases include neurodegenerative diseases and diabetes. Methods are described for obtaining a substantially homogeneous population of undifferentiated human embryonic stem cells including incubating a population of human embryonic stem cells with an amount of a selection agent. The selection agent is effective to reduce or eliminate differentiated embryonic stem cells from the population of cells such that a substantially homogeneous population of undifferentiated human embryonic stem cells is obtained. The substantially homogeneous population of undifferentiated embryonic stem cells may be produced without use of feeder cells.

- Antimicrobial compositions comprising polymeric stabilizers

Antimicrobial composition comprising iodide and thiocyanate anions, periodic acid, and nitrogen and/or phosphorous containing polymers.

- Topical agent for application to the skin prior to luminous treatment

There is disclosed a topical agent in the form of a topical vasodilator for the application to the skin prior to luminous treatment, e.g. laser treatment, wherein said topical vasodilator in a suitable vehicle includes the active substance consisting of nicotinic acid (Niacin) in the range of 0.5-10.0% by weight Preferably, the topical vasodilator is a skin cream containing the active substance, Niacin, in the range of 5% by weight.

- Copolymers based on tertbutyl(meth) acrylate and use thereof

Copolymers which contain tert-butyl (meth)acrylate, at least one .alpha.,.beta.-ethylenically unsaturated amido-containing compound and acrylic acid incorporated in the form of polymerized units, cosmetic and pharmaceutical compositions which contain at least one such copolymer and the use of these copolymers are described.

- Antiperspirant/deodorant compositions

Disclosed herein is a composition for topical. application to human skin, comprising a biologically active material and a cosmetically suitable carrier, wherein the cosmetically suitable carrier comprises 5-95 wt % of a mixed feed polyolefin based on the total weight of the composition, wherein the mixed feed polyolefin comprises two or more C.sub.6-C.sub.20 copolymerized monomers, and wherein at least two of the copolymerized monomers are each present in the mixed feed polyolefin at 10 wt % or more, based on the total weight of the mixed feed polyolefin. A method of making a composition for topical application to human skin is also disclosed.

- Conditionally immortalized long-term stem cells and methods of making and using such cells

Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.

- Dermatological cream-gels containing avermectin compounds

Pharmaceutical cream-gel compositions useful for the treatment of a variety of dermatological conditions, disorders and afflictions, in particular of rosacea, contain at least one avermectin compound active principle, and which also contain an oily phase dispersed in an aqueous phase by means of a non-surfactant polymeric emulsifier, the oily phase comprising oils having a melting point below 30.degree. C. and being free of solid fats having a melting point above 30.degree. C., formulated into a physiologically acceptable medium therefor.

- Medical active substance patch with reduced optical conspicuousness on the skin

A medical active substance patch comprising a matrix of monolayer or multilayer configuration with at least one active substance-containing layer and comprising a backing layer connected with the matrix. The active substance patch is transparent or at least translucent, and in the state of having been applied to the skin of a first person, the patch has a lightness colour value L.sub.1 at a place of the skin covered by the patch which is not less than 50% and not more than 200% of a lightness colour value L.sub.2, L.sub.2 being the lightness value of the region of the skin of the same person which surrounds the applied patch. The same is true of the skin of a second or any other person, provided that for all the persons mentioned L.sub.2 is in the range from 5.degree. to 100.degree., namely from 20.degree. to 90.degree..

- Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease

This invention discloses a comprehensive nutraceutical designed to antagonize major mitigating factors specific to the degenerative process that occurs in Parkinson's disease (PD). The formulation is comprised of pyruvate, succinate and/or oxaloacetate further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The formula is based on means to attenuate the loss of ATP/toxicity by PD model toxins: 1-methyl-4-phenylpyridinium and rotenone, scavenge hydrogen peroxide/O.sub.2, augment antioxidant enzymes, prevent dopamine oxidation to DA-quinone via inhibition of COX, PLA.sub.2, LOX, xanthine oxidase, tyrosinase, prevent hyperhomocysteinemia, antagonize PARP-1 apoptosis, increase blood flow, glucose and oxygen delivery to the brain, potentiate mitochondrial function, antagonize glia iNOS and MAO or its products, chelate redox-active iron, inhibit hemeoxygenase-1, inhibit alpha-synuclein aggregation, augment ATP storage, mediate anti-inflammatory effects via inhibition. of PDE, MAPK p38/c-Jun NH2-terminal kinase/PGE2, antagonize excitotoxicity and downregulate N-methyltransferase, all of which contribute toward PD pathology.

- Sparc and methods of use thereof

The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.

- Parathyroid hormone-like polypeptides

Novel parathyroid hormone polypeptides and biologically active fragments thereof are disclosed along with nucleic acid molecules encoding same. In particular, parathyroid hormone polypeptides and biologically active fragments (and encoding nucleic acid molecules) derived from fish species (eg Japanese pufferfish (Fugu rubripes)) are disclosed. Such polypeptides and fragments may be used for treatment of diseases associated with abnormal calcium homeostasis (eg osteoporosis, osteopenia, Paget's disease, bone cancer, hyperparathyroidism, hypoparathyroidism, hypercalcemia, psoriasis and other skin-related conditions).

- Radiation exposure history indicator

A radiation exposure history indicator sheet comprises a base material sheet which has a color-changing layer on at least a part of the surface comprising: a polymer compound having a hydroxyl group and at least one group selected from a halogen group and an acetal group; a coloring organic electron donor compound; an active species-generating organic compound for making the organic electron donor compound colored by a radiation; and a radiation absorbent and/or a radiation-excite fluorescent agent.

- KINASE INHIBITORS

Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

- User Interface For Infusion Pump Remote Controller And Method Of Using The Same

A control system for controlling an infusion pump, including interface components for allowing a user to receive and provide information, a processor connected to the user interface components and adapted to provide instructions to the infusion pump, and a computer program having setup instructions that cause the processor to enter a setup mode upon the control system first being turned on. In the setup mode, the processor prompts the user, in a sequential manner, through the user interface components to input basic information for use by the processor in controlling the infusion pump, and allows the user to operate the infusion pump only after the user has completed the setup mode.

- ANTIMICROBIAL COMPOSITIONS AND WOUND DRESSINGS

A wound dressing and an antimicrobial composition are provided. The wound dressing comprises a carbonaceous material, a noble metal carried on the carbonaceous material, and, optionally, a flexible base layer, wherein the carbonaceous material is selected from a group consisting of activated carbon, graphite, carbon, and a combination thereof, while the noble metal is selected from a group consisting of Ag, Au, Pd, Pt, Cu, Zn, and a mixture thereof. The antimicrobial composition is for topical use on skins and comprises the aforementioned carbonaceous material as well as the noble metal carried on the carbonaceous material.

- Herbal composition for treatment of immunocompromised conditions

According to the present invention there is provided pharmaceutical or medicinal preparation comprising a combination of two herbal compositions to be administered together. The first herbal composition comprises a mixture of the following herbs: Asparagus racemosa, Curcuma longa, Glycyrrhiza glabra, Momordica charantia, Tinospora cordifolia, Withania somnifera, Spirulina, Allium sativum, Emblica officinalis, Terminalia belerica, and Terminalia chebula, or a mixture of the active ingredients that have been extracted from those herbs or chemically synthesized. The second herbal composition comprises a mixture of the following herbs: Moringa oleifera, Boerhavia diffusa, Onosma bracteatum, Bauhinia variegata, Spheranthus indicus, Tecomella undulata, Chlorophytum borivilianum, Ficus racemosa, and Cyperus rotundus, or a mixture of the active ingredients that have been extracted from those herbs or chemically synthesized. The herbal preparation is effective for the treatment a wide range of physiological and pathological conditions in the human body resulting from a weakened or deteriorating immune system.

- Cosmetic compositions in particular with anti-ageing activity comprising an extract of aframomum angustifolium or longoza plant

The present invention relates to a cosmetic composition. This composition is characterized in that it comprises, as active ingredient, an extract of seeds of the Aframomum angustifolium or Longoza plant, optionally in a cosmetically acceptable excipient. This cosmetic composition exhibits a good anti-ageing activity.

- Natural antioxidant additive for feed and drinking water

A natural intestine-functional additive with antioxidative properties for utilization as an additive in animal feed containing natural and/or nature identical active substances. The substance include a first active component containing antioxidative active substances derived from plant material from olive plants (Olea europaea L) and a second active component containing antioxidative active substances derived from plant material from grape plants (Vitis vinifera L).

- ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS AND METHODS FOR MAINTAINING HEALTHY SKIN

Compositions and methods for maintaining healthy skin and alleviating skin conditions such as redness, inflammation, irritation and skin aging, as well as for maintaining healthy scalp and hair are disclosed. The oral compositions disclosed comprise antioxidants including lycopene, gallic acid and ascorbic acid. Preferably lycopene containing tomato compositions has been water-extracted, more preferably under acid conditions. In the method of treatment aspect of the invention, an oral composition containing antioxidant(s) is administered to a person concurrently with a topical treatment for said skin conditions. Preferred topical compositions comprise cyclohexane polyols, such as cyclohexanediol or cyclohexanetriol.

- METHODS AND REAGENTS FOR TREATING INFLAMMATION AND FIBROSIS

Methods are provided for providing anti-inflammatory activity and inhibiting a fibrotic disease, such as pulmonary fibrosis, in an individual. The methods comprise administering a biologically effective amount of latency-associated peptide (LAP) to the individual. Also provided are pharmaceutical compositions comprising LAP for use in accordance with these methods.

- Water in oil emulsion compositions containing siloxane elastomers

The present invention relates to water in oil emulsion compositions comprising: from about 0.1% to about 15% of a non-emulsifying crosslinked siloxane elastomer; from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of a solvent for the non-emulsifying and emulsifying crosslinked siloxane elastomers; optionally, from 0% to about 5% of an additional emulsifier; and from about 50% to about 99% of aqueous phase; wherein when shear stress is applied to the composition during spreading on skin, aqueous phase is released from the emulsion.

- SOLUBLE COSMETIC ARTICLE WITH A THERMAL EFFECT

An article having a support in the form of at least one sheet containing fibers that are water-soluble at a temperature of 0-30.degree. C., the support having a density less than or equal to 0.1 g/cm.sup.3, and a composition carried by the support, containing at least one compound with a thermal effect. The article can have a hot or cold effect depending on the nature of the compound(s) with thermal effect that is(are) present.

- TRANSDERMAL THERAPEUTIC SYSTEM

The present invention relates to Transdermal Therapeutic Systems having a silicone adhesive layer, to Transdermal Therapeutic Systems providing specific plasma concentrations, to their manufacture and use.

- Regulation of cell proliferation and differentiation using topically applied peptides

Methods are disclosed for the regulation of cell differentiation and proliferation, e.g., for treating hyperproliferative skin disorders, such as psoriasis, for enhancing wound healing, for stimulating hair growth and inhibiting hair growth, by topical administration of parathyroid hormone (PTH), parathyroid related peptide (PTHrP), or fragment, analog or derivative thereof, and salts thereof, encapsulated by liposomes.

- Composition containing an extract of the fruit of schisandra chinensis and process for producing same

A composition including (a) an extract from the fruit of Schisandra chinensis; and (b) at least one auxiliary and/or additive is provided. A composition also provided includes (a) a component selected from the group of an extract of the fruit of Schisandra chinensis, schizandrin, deoxyschizandrin, schisandrin C, gomisin A, gomisin N, pregomisin, and nordihydroguaiaretic acid; and (b) at least one auxiliary and/or additive. A process for producing an extract from the fruit of Schisandra chinensis is also provided, and includes the steps of (a) extracting of the fruit of Schisandra chinensis with a solvent selected from the group consisting of water, alcohols, esters, hydrocarbons, ketones, halogenated hydrocarbons and supercritical fluids to obtain a mixture comprising the extract and the solvent; and, (b) removing the solvent from the mixture.

- Method for improved diagnosis of dysplasias

The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterising the proliferation properties of the respective cell. The characterisation of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.

- 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof

Compounds of formula: and pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5, have the meanings given in the description; pharmaceutical compositions comprising said compounds; and processes for preparing said compounds and methods of use thereof.

- Compounds for the treatment of inflammatory disorders and microbial diseases

This invention relates to compounds of the Formulae (I)-(IX): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-.alpha. or combinations thereof.

- Composition for improving skin, hair and coat health containing flavanones

The present invention pertains to a composition for preventing, decreasing and/or treating skin and hair/coat disorders, such as is effected by inflammatory reactions, environmental factors, ageing or cancer. In particular, the present invention relates to the use of flavanones compounds or their derivatives in nutritional, cosmetic or pharmaceutical compositions for improvement of human or pet animal skin and coat conditions.

- Use of fepradinol for the production of a pharmaceutical composition for the treatment of rosacea

The invention relates to the use of fepradinol for the production of novel pharmaceutical compositions, in particular, dermatological compositions, of use for the treatment of rosacea.

- Flavonoid derivative

The invention relates to a novel flavonoid derivative, to an extract comprising the flavonoid derivative, to the cosmetic and pharmaceutical use thereof, to preparations comprising the flavonoid derivative or extract, and to a process for the preparation of the flavonoid derivative or extract.

- Personal care composition

Personal care composition comprising from about 5% to about 75% of an oil phase; an aqueous phase; from about 0.1% to about 2% of a polymeric thickener; and a skin care active; wherein said composition comprises at least two separate phases, and after agitation and dispensation from a suitable container containing a suitable propellant, forms stable foam.

- Panthenol and natural organic extracts for reducing skin irritation

Panthenol combined with natural organic extracts are well suited for reducing skin irritation that is normally elicited by exposure to irritant active agents or compounds, particularly found in hair permanent and relaxing compositions, hair colorants and depilatories.

- Skin lightening complex

A skin lightening complex having a skin lightening agent such as hydroquinone. The complex can be formulated in a concentrate form for later dilution as a product for topical application. The concentrate can be diluted such that the product is available as a pharmaceutical product with a high coincentration of active ingredients or as an over the counter product with a lower concentration. The concentrate is diluted with suitable carriers for the particular product. The formulation allows dilution of a high concentration of active skin lightening ingredient and has antioxidants and other ingredients for stable shelf life.

- Cosmetic compositions with encapsulated pigments and a method for using

There is a pigmented cosmetic composition. The composition has a cosmetically acceptable vehicle, a cosmetic active, and a plurality of encapsulated pigment particles. The particles have an encapsulant and an entrapped pigment within the encapsulant. The encapsulant has silicon dioxide and exhibits a refractive index of about 1.4 to about 1.6.

- Aminosulfonic acid compounds for promoting desquamation of the skin

Aminosulfonic acid compounds having the structural formula (I): are suited for promoting desquamation of the skin and/or stimulating epidermal renewal and/or combating aging of the skin.

- Cosmetic and/or pharmaceutical preparations

A cosmetic or pharmaceutical composition containing an extract of a resurrection plant.

- SOLUBLE PATCH

An article, preferably a patch, containing: a support in the form of at least one sheet containing fibres that are water-soluble at a temperature of 0-30.degree. C., and a composition carried by the support, containing at least one water-soluble gelling agent which swells in less than 30 seconds in water at a temperature of 20.degree. C. to 30.degree. C.

- Anhydrous pharmaceutical composition associating a siliconated agent and solubilised active principle

The invention relates to an anhydrous pharmaceutical composition associating at least one type of active principle and one type of siliconated agent which comprises at least one type of organopolysiloxane elastomer, wherein said active principle is embodied in the solubilised form thereof in said composition.

- Method of treating tumors with azaxanthones

The use of azaxanthones for treating diseases associated with tumor cells which express one or more protein of S100 family, and in treating patients that have malignancies consisting of tumors of an epithelial or mesenchymel nature, where these compounds are effective in retarding the progression and/or metastasis of these tumors.

- Aralkyl ester soft drugs

The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is administered. The parent drug compound is modified by forming one or more of a predetermined chemical arrangement within the parent drug structure where the chemical arrangement is A-.PHI.-R--X--R'; where A is absent or is a tether moiety which allows for a metabolically stable chemical connection to be made to the parent drug compound; .PHI. is a substituted aryl or heteroaryl system that is already present within the parent drug compound or is specifically added to the parent drug compound via A; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is either also already present within the parent drug compound or is specifically added to the parent drug compound via connection to .PHI.; X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via connection to R; and, R' is an added alkyl, alkenyl, or aralkyl group either branched or unbranched containing from 1 to 10 carbons, other common leaving group, or a structural element already present as an inherent portion of the parent drug compound.

- Therapeutic article including a personal care composition and methods of making the therapeutic article

A therapeutic article includes a skin contact layer having a plurality of fibers forming a plurality of point-bearing surfaces configured for wear against a user's skin; a personal care composition disposed proximate the fibers; an external layer attached to the skin contact layer; and an intermediate layer interposed between the skin contact layer and the external layer, the intermediate layer being configured to activate the personal care composition, the external layer being configured to direct the activated personal care composition through the skin contact layer to treat the user.

- Medical Devices and Applications of Polyhydroxyalkanoate Polymers

Devices formed of or including biocompatible polyhydroxyalkanoates are provided with controlled degradation rates, preferably less than one year under physiological conditions. Preferred devices include sutures, suture fasteners, meniscus repair devices, rivets, tacks, staples, screws (including interference screws), bone plates and bone plating systems, surgical mesh, repair patches, slings, cardiovascular patches, orthopedic pins (including bone filling augmentation material), adhesion barriers, stents, guided tissue repair/regeneration devices, articular cartilage repair devices, nerve guides, tendon repair devices, atrial septal defect repair devices, pericardial patches, bulking and filling agents, vein valves, bone marrow scaffolds, meniscus regeneration devices, ligament and tendon grafts, ocular cell implants, spinal fusion cages, skin substitutes, dural substitutes, bone graft substitutes, bone dowels, would dressings, and hemostats. The polyhydroxyalkanoates can contain additives, be formed of mixtures of monomers or include pendant groups or modifications in their backbones, or can be chemically modified, all to alter the degradation rats. The polyhydroxyalkanoate compositions also provide favorable mechanical properties, biocompatibility, and degradation times within desirable time frames under physiological conditions.

- Process for preparing a high stability microcapsule product and method for using same

The present invention is directed to a process for preparing a capsule product through the increase in the polymerization cure temperature and cure time during the capsule-making process. The microcapsule products prepared according the process of the present invention exhibit enhanced retention of active materials in consumer products which promote instability.

- Process for Preparing a High Stability Microcapsule Product and Method for Using Same

The present invention is directed to a process for preparing a capsule product through the increase in the polymerization cure temperature and cure time during the capsule-making process. The microcapsule products prepared according the process of the present invention exhibit enhanced retention of active materials in consumer products which promote instability.

- Multicomponent packaging with static micromixer

The packaging system has two storage chambers for separately storing two components and a static micromixer for mixing them to prepare a formulation. The static micromixer is provided with plural disks (1) arranged in a stack. Each disk (1) has at least one inlet opening (2) for a feed stream, which is connected via a linking channel (3) with at least one outlet opening (4) for outflow of the feed stream into a mixing zone (5). The linking channel (3) is divided into two or more part channels (7) by microstructure units (6). Each part channel has a respective width that is smaller than a width of the mixing zone (5). A method of in-situ preparation of a formulation by mixing the components in the packaging system is also described.

- Skincare compositions

There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises a cosmetically acceptable skincare composition in the form of a hydroalcoholic gel dispersion, the composition comprising salicylic acid or a salt thereof and a gelling agent in the form of a copolymer of acryloyl dimethyl tauric acid or a salt thereof. The compositions may be useful to cleanse the skin and the prophylactic or remedial treatment of acne.

- Substituted hydrocarbyl functional siloxanes-silicone resin

Sunscreen compositions containing a hydrocarbyl functional organopolysiloxane are disclosed. The hydrocarbyl functional organopolysiloxane contains at least one siloxy unit of the formula --R.sup.2OCH.sub.2CH.sub.2OH, where R.sup.2 is a divalent hydrocarbon group containing 2 to 6 carbon atoms. The inclusion of the hydrocarbyl functional organopolysiloxane in the sunscreen composition improves the sun-protection factor (SPF) of the sunscreen component and various personal, medical and household care compositions containing the sunscreen composition.

- Synthesis of a nitroxide antioxidant and methods of use in cosmetic and dermatological compositions

The present invention provides a dermatological and/or cosmetic composition which includes a methoxycinnamate, and a cyclic nitroxide. The present invention further provides a method of synthesizing photo absorbing-antioxidant compounds and their use in dermatological and/or cosmetic compositions. In addition, the present invention relates to the use of methoxycinnamate, and nitroxide compounds for the preparation of a composition for the dermatological and/or cosmetic treatment of skin.

- Photoprotective compositions containing a triazine derivative, an amide-based oil and a eutectic mixture of n-butylphthalimide/isopropylphthalimide

Stable, topically applicable cosmetic/dermatological photoprotective compositions contain: a) at least one 1,3,5-triazine compound, b) at least one oil containing in its structure at least one amide structural unit, and c) at least one eutectic mixture of n-butylphthalimide and of isopropylphthalimide, and have enhanced sun protection factors and cosmetic properties.

- TOPICAL SKIN CARE COMPOSITION CONTAINING REFINED PEANUT OIL

A vehicle containing refined peanut oil for topical use in skin care and for use in skin care therapeutics, and a process for making the vehicle and a composition and therapeutic composition made from that process.

- Ampholytic anionic copolymers

Ampholytic copolymers which contain a molar excess of anionogenic and/or anionic groups, polyelectrolyte complexes which contain such an ampholytic copolymer, cosmetic and pharmaceutical compositions which contain at least one such copolymer or polyelectrolyte complex and the use of these copolymers and polyelectrolyte complexes are described.

- Formulation assistants

The invention relates to the use of compounds of the formula (I), where R.sup.1, R.sup.2 and R.sup.3 may be identical or different and are selected from: straight-chain or branched C.sub.1- to C.sub.24-alkyl groups, straight-chain or branched C.sub.3- to C.sub.24-alkenyl groups, straight-chain or branched C.sub.1- to C.sub.24-hydroxyalkyl groups, where the hydroxyl group may be bonded to a primary or secondary carbon atom of the chain and furthermore the alkyl chain may also be interrupted by oxygen, and/or C.sub.3- to C.sub.10-cycloalkyl groups and/or C.sub.3- to C.sub.12-cycloalkenyl groups, where the rings may in each case also be bridged by (CH.sub.2).sub.n groups, where n=1 to 3, as formulation assistants for the preparation of cosmetic or dermatological compositions, to corresponding novel compounds, and to the preparation thereof.

- Penetration enhancing agent and method of its production from the hemp seeds

The conveying and absorption agent, preferably for the active substances of the pharmaceutical, dietetic, and cosmetic preparations, consists of the extract from the hemp seeds, obtained by action of carbon dioxide. Advantageously, the extract is a component of the fat or wax base of the pharmaceutical or cosmetic preparation, preferably composed of the propolis relieved of its pollen contents. According to the method of production of the conveying and absorption agent from the hemp seeds for the active substances of the pharmaceutical, dietetic, and cosmetic preparations, the hemp seeds are ground down to hemp flour, being then pressure-extracted with carbon dioxide to the hemp oil. The hemp seeds are ground down to fine-grain flour, which is then powered into the extraction cartridges that are inserted into the extractor. Extractor is then closed and the carbon dioxide is then driven into it at the temperature between 35.degree. C.-45.degree. C. and the pressure between 25 MPa and 35 MPa, advantageously 40.degree. C. and pressure 29 MPa. With the hemp oil extraction process slowed down, the carbon dioxide pressure in the extractor is reduced down to the ambient atmospheric pressure value and the hemp oil is separated from the carbon dioxide which is subsequently led away from the extractor to the reserve tank, where it will be stored in its supercritical condition. For removal of chlorophyll and waxes, 2%-35% in weight of the crushed silicon sand is mixed into the hemp oil extracted. Following the surface absorption, the crushed silicon sand is filtered out.

- Food composition comprising glucosamine

The present invention relates to an orally ingestible food or pet food composition or cosmetic composition containing glucosamine generated from plant materials through a drying process for the maintenance of joint health or prevention, alleviation and/or treatment of osteoarthritis, or the improvement of the skin quality and prevention or restoration of age-related alterations of skin. It also relates to the use of the composition in the manufacture of a nutritional product, a supplement, a treat, a medicament or a cosmetic product and methods for the maintenance of bone health, prevention, alleviation and/or treatment of osteoarthritis, improvement of the skin quality and prevention or restoration of age-related alterations of skin which comprises administering an effective amount of the composition.

- Control of proliferation and apoptosis in cancer cells

The invention includes a method of inhibiting or reducing cellular proliferation through the use of one or more agents that prevent the association or interaction of pp32 polypeptides with the hyperphosphorylated form of Retinoblastoma protein. The invention also discloses agents that are useful in preventing the association or interaction of pp32 polypeptides with the hyperphosphorylated form of Retinoblastoma protein. The invention also discloses screening assays that utilize pp32 polypeptide fragments to identify candidate agents useful in preventing the association or interaction of pp32 polypeptides with the hyperphosphorylated form of Retinoblastoma protein. The invention further discloses diseases and/or disorders for which the disclosed compositions and methods are useful.

- Layered dosage form for a medicated tampon assembly

A tampon adapted to deliver a therapeutic agent includes a tampon body having a distal end and a dosage form affixed to the distal end of the tampon body, the dosage form including a first active layer dispersible by a first mechanism, and an attachment layer dispersible by a second mechanism. Mechanisms include melting and dissolution.

- Polyethylene binding peptides and methods of use

Combinatorially generated peptides are provided that have binding affinity for polyethylene (PE). The peptides may be used to deliver benefit agents to various PE surfaces.

- Nylon binding peptides and methods of use

Combinatorially generated peptides are provided that have binding affinity for nylon (NY). The peptides may be used to deliver benefit agents to various NY surfaces.

- Substituted pyrazole compounds

Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.

- Jasmonate derivative compounds, pharmaceuticals compounds and methods of use thereof

The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers.

- Use of thermoplastic elastomers in a composition and compositions thereof

Compositions and methods for the formation of physically cross-linked thermoplastic elastomeric films are disclosed. The disclosed films are long-lasting, flexible, transfer resistant, and water-proof. The film-forming compositions comprise a thermoplastic elastomer, a tackifier resin, and a volatile solvent useful for formulating cosmetics, personal care products, and pharmaceutical compositions.

- Compositions and methods comprising magnetic particles for health use

The present invention provides a topical composition comprising a topical composition base and a plurality of magnetic particles. The topical composition can further comprise one or more active agents. The magnetic particles and/or active agent(s) can optionally be encapsulated and/or coated. Methods for making and using the topical composition are also provided.

- Aqueous-alcoholic depigmenting gels comprising mequinol and adapalene

Stable, topically applicable cosmetic/pharmaceutical skin depigmentation compositions contain a combination depigmentation effective amount of mequinol and adapalene, and optionally, at least one sunscreen, formulated as aqueous-alcoholic gels or gel-creams in topically applicable, physiologically acceptable media therefor.

- Foaming, color-changing topical composition and method of imparting a cosmetic effect

There is an anhydrous topical composition. The composition has a) an active ingredient; b) a base compound of a carbonate or bicarbonate salt of an alkali metal or an alkaline earth metal; c) an acid compound; and d) a cosmetically acceptable anhydrous vehicle. The base compound and the acid compound are reactable and are present in amounts sufficient to foam the topical composition when the topical composition is exposed to water. The topical composition changes color upon exposure to water. There is also a method for imparting a cosmetic effect to a topical surface.

- Antiperspirant compositions comprising at least one dispersion of cationic colloidal silica particles, antiperspirant product, and cosmetic process for treating perspiration

The present disclosure relates to the use of a dispersion of cationic colloidal particles of silica modified with a multivalent cation in a cosmetic composition, as an antiperspirant active agent. The present disclosure also relates to antiperspirant compositions comprising at least one dispersion of cationic colloidal particles of silica modified with a multivalent cation, as well as cosmetic processes for treating perspiration and body odor, employing the compositions disclosed herein.

- PREPARATIONS FOR TOPICAL SKIN USE AND TREATMENT

Topical preparations for release of an active agent to the skin are provided. The preparations have an internal phase dispersed within an external phase. The internal phase includes a hydrophilic carrier and an enzyme active agent. The external phase comprises a silicone matrix.

- Liposomal Nanowater-Containing Patch-Type Nanodermal Gel for Transdermal Delivery and Method for Preparing the Same

Disclosed herein is a patch-type nanodermal gel including liposomal nanowater, which can deliver cosmetically active substances, such as those functioning to moisturize the skin, into and through the skin stably and effectively. The patch-type cosmetic composition for transdermal deliver, based on nanodermal gel, comprises nanowater in an amount from 0.01 to 80.0% by weight; a skin-compatible polymer in an amount from 0.01 to 10.0% by weight; and a polyhydric alcohol in an amount from 5.0 to 20.0% by weight, based on the total weight of the nanodermal gel.

- Pharmacologic-functioning water and usage of the same

The present invention provides a new pharmacologic-functioning water demonstrating pharmacologic function without any side effects, and usage of the same. The pharmacologic-functioning water, which demonstrates pharmacologic function without any side effects and includes antioxidant-functioning water as an active principle containing hydrogen-dissolved water, which is made up of molecular hydrogen used as a substrate that is included in raw water, and a precious metal colloid, which is included in the hydrogen-dissolved water and catalyzes the breaking reaction of the molecular hydrogen into a product of atomic hydrogen, is used for preventing and/or treating diseases.

- TRANSFERRIN AND TRANSFERRIN-BASED COMPOSITIONS FOR DIABETES TREATMENT

Embodiments of the present invention use transferrin or active derivatives to control or stabilize abnormally elevated levels of blood glucose in mammals, particularly humans. Embodiments of the invention also provide methods for enhancing survival of islet .beta.-cells in vivo and in vitro. In other embodiments, transferrin or active derivatives are used in combination with anti-diabetic medicaments or performing an insulin elevating procedure. In yet another embodiment the invention includes administering transferrin or an active derivative to reduce weight loss induced by type 1 diabetic condition.

- Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same

Methods for chemical modification of hyaluronic acid, formation of amine or aldehyde functionalized hyaluronic acid, and the cross-linking thereof to form hydrogels are provided. Functionalized hyaluronic acid hydrogels of this invention can be polymerized in situ, are biodegradable, and can serve as a tissue adhesive, a tissue separator, a drug delivery system, a matrix for cell cultures, and a temporary scaffold for tissue regeneration.

- Six membered heteroaromatic inhibitors targeting resistant kinase mutations

A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.

- Use of piketprofen for the preparation of a pharmaceutical composition to treat rosacea

The present invention relates to the use of piketoprofen for the preparation of novel pharmaceutical compositions and more particularly dermatological compositions that are useful for treating rosacea.

- PH modulated films for delivery of actives

The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water; and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.

- Topical Pharmaceutical Foam Composition

A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an emulsion which contains an HFA propellant and one or more keratolytic agents. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent(s) may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. Either or both of the oil phase and the aqueous phase may contain one or more surfactants, emulsifiers, emulsion stabilizers, buffers, and/or other excipients. The foam is stable on the skin, for example, for at least 5 minutes at body temperature, preferably at least 20 minutes at body temperature, and disappears into the skin upon rubbing or after prolonged standing. In one embodiment, the formulation contains an HFA propellant which does not contain additional co-solvents or co-propellants. The formulations demonstrate reduced intensity of the odor and/or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.

- Method of treating skin needing hyaluronic acid treatment

A treatment regimen for treating skin subject to a cosmetic hyaluronic acid procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin requiring non-ablative procedure

A treatment regimen for treating skin subject to non-ablative procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin requiring radiofrequency procedure

A treatment regimen for treating skin subject to radiofrequency procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin requiring chemical peel procedure

A treatment regimen for treating skin subject to chemical peel procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin subject to or affected by aesthetic surgical procedures

A treatment regimen for treating skin subject to aesthetic surgical procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin needing collagen treatment

A treatment regimen for treating skin subject to a collagen procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin needing ablative treatment

A treatment regimen for treating skin subject to an ablative treatment involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin requiring hair removal procedure

A treatment regimen for treating skin subject to hair removal procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin needing botulinum toxin type a treatment

A treatment regimen for treating skin subject to a botulinum toxin type A cosmetic procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- COMPOSITION CONTAINING CONCAVE PARTICLES AND A DISPERSANT, PROCESSES AND USES

The present invention relates to a composition containing concave particles, at least one dispersant for these concave particles, and optionally porous particles. This composition is nonpulverulent. The present invention also relates to a treatment process employing this composition and to the uses of this composition, in particular for conferring a matt appearance on keratinous substances and/or for softening imperfections of the relief of the skin and/or for concealing microrelief features, wrinkles, fine lines and pores of the skin.

- Method of treating skin having incision from surgical procedures

A treatment regimen for treating skin in which an incision is made during a surgical procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin requiring microdermabrasion

A treatment regimen for treating skin subject to microdermabrasion involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Method of treating skin requiring skin cancer treatment

A treatment regimen for treating skin subject to skin cancer treatments involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Topical film compositions for delivery of actives

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a topical active agent.

- Pharmaceutical composition

The present invention is related to pharmaceutical compositions for the inhibition of metastases and treatment of cancer such as bladder carcinoma, colon cancer, endometrial cancer, hepatocellular carcinoma, leukemia, lymphoma, melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, soft tissue cancer, renal cancer, osteosarcoma, mesothelioma, myeloma multiple, bladder carcinoma and esophagcal cancer as well as the use of these pharmaceutical compositions for the treatment of said metastases and cancers. Another aspect of this invention are new antisense oligonucleotides inhibiting the formation of human interleukin 10 and their synthesis. A further aspect of this invention is the use IL-10 antisense oligonucleotides for the preparation of pharmaceutical compositions and for the treatment of cancer and metastases.

- Flavonoid complexes with cyclodextrins

The invention relates to complexes of certain flavonoid derivatives, of the formula I compositions which comprise such derivatives, corresponding processes for the preparation of the flavonoid derivatives or of compositions comprising same, and the use thereof, in particular for the care, preservation or improvement of the general state of the skin or hair. Formula (1), in which Z.sub.1 to Z.sub.4 and Z.sub.6 to Z.sub.10 each, independently of one another, denote H, OH, CH.sub.3COO, alkoxy, hydroxyalkoxy, mono- or oligoglycoside radicals and where the alkoxy and hydroxyalkoxy groups may be branched and unbranched and can have 1 to 18 C atoms. Formula (II) denotes, Z.sub.5 is a mono- or the oligoglycoside radical, where bonded to this glycoside radical, in each case via an --O-- group, is at least one radical selected from certain benzo molecule.

- Compounds for the inhibition of angiogenesis and use thereof

This invention is directed to compounds of structure (I). Particularly this invention is directed to compounds of structure (VIII) wherein the variables are defined as in the description. These compounds are integrin inhibitors and are useful in the treatment of diseases in which an inhibition of angiogenesis is desired.

- TRICYCLIC-BIS-ENONE DERIVATIVES AND METHODS OF USE THEREOF

Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.

- Cycloalkylidene compounds as modulators of estrogen receptor

The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.

- Method of treating skin requiring Intense Pulse Light (IPL) procedure

A treatment regimen for treating skin subject to an Intense Pulse Light procedure involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- Biochemical route to astaxanthin

The sequence of a nucleic acid isolated from a cDNA library of the flowering plant Adonis aestivalis is disclosed (SEQ ID NO: 1). This DNA sequence, referred to as AdKC28, encodes for a protein that acts in conjunction with proteins encoded by either one of two other closely-related Adonis aestivalis cDNAs, AdKeto1 and AdKeto2, to convert .beta.-carotene (.beta.,.beta.-carotene) into astaxanthin (3,3'-dihydroxy-4,4'-diketo-.beta.,.beta.-carotene). Together, these Adonis aestivalis cDNAs, when operably linked to promoters appropriate to the transgenic host, enable the production of astaxanthin and other carotenoids with 3-hydroxy-4-keto-.beta.-rings in a variety of host cells and organisms.

- Merchandising systems, methods of merchandising, and point-of-sale devices comprising micro-optics technology

A merchandising system, comprising: a consumer product. The merchandising system comprises at least one of the consumer product, packaging for the consumer product, and advertisement material pertaining to the consumer product. At least one merchandising system elements comprises indicia and/or an image that relates, or is analogous to, an attribute and/or targeted benefit of the consumer product. At least one merchandising system elements comprises a micro-optic structure capable of controlling the scatter of light impinging thereon so that the micro-optic structure reflects and/or transmits light in a field of view over which at least a portion of the indicia and/or image appears brighter relative to that outside the field of view.

- Merchandising systems, methods of mechandising, and point-of-sale devices comprising micro-optics technology

A merchandising system, comprising: a consumer product. The merchandising system comprises at least one of the consumer product, packaging for the consumer product, and advertisement material pertaining to the consumer product. At least one merchandising system elements comprises indicia and/or an image that relates, or is analogous to, an attribute and/or targeted benefit of the consumer product. At least one merchandising system elements comprises a micro-optic structure capable of controlling the scatter of light impinging thereon so that the micro-optic structure reflects and/or transmits light in a field of view over which at least a portion of the indicia and/or image appears brighter relative to that outside the field of view.

- Use of stinging cells/capsules for the delivery of active agents to keratinous substances

A composition of matter comprising an agent beneficial to a non-skin keratinous substance and at least one stinging capsule and methods of use are disclosed.

- Method of applying a composition

There is provided herein, in one specific embodiment, a method of applying a trisiloxane-containing composition to the surface of a substrate comprising: applying to a surface of a substrate a composition comprising a trisiloxane of the general formula (1): MDM (1) wherein M=R.sup.AR.sup.BR.sup.CSiO.sub.1/2, D=R.sup.DR.sup.FSiO.sub.1/2 in which R.sup.D and R.sup.F each independently is a monovalent, divalent or trivalent hydrocarbon radical possessing from 2 to 8 carbon atoms or a monovalent, divalent or trivalent hydrocarbon radical possessing from one to sixty carbon atoms other than from 2 to 8 carbon atoms, provided that at least one of R.sup.D and R.sup.F is a monovalent, divalent or trivalent hydrocarbon radical possessing from 2 to 8 carbon atoms, and R.sup.A, R.sup.B, R.sup.C each independently is a monovalent, divalent or trivalent hydrocarbon radical possessing from one to sixty carbon atoms other than from 2 to 8 carbon atoms.

- UV-radiation protectant compositions

A substantially aqueous composition comprising one or more particle encapsulated sunscreen active agents, at least one volatile additive, and at least one UV-radiation scattering agent, whereby the composition provides an SPF greater than 30.

- PENETRATING CARRIER, ANTI-FUNGAL COMPOSITION USING THE SAME AND METHOD FOR TREATMENT OF DERMATOPHYTES

A liquid carrier for topical administration is provided that contains a mineral oil, turpentine and, optionally, camphor, and optionally other terpenoid components containing pinene, and its use to provide an antifungal composition a mixture of antifungal essential oils and the carrier system, wherein the mixture of antifungal essential oils includes an effective amount of each of eucalyptus globulus, peppermint, cedarwood, and Manuka; along with the use of this composition in the topical treatment of fungal infection, particularly of the nail.

- Use of agents for the cosmetic treatment of keratin-containing material

The object of the present invention is the use of a compound of formula and of the salts thereof in an agent for repairing, strengthening and restructuring keratin-containing material and protecting such material from mechanical and chemical damage.

- Skin disinfectant composition and methods for using

A skin disinfectant composition is provided according to the invention. The skin disinfectant composition comprises an effective amount of a disinfectant active component to provide disinfectant properties to skin tissue, an effective amount of a skin bonding polymer component to hold the disinfectant active component to skin tissue so that the disinfectant active component becomes available on skin tissue to provide disinfectant properties, and water. A method of using a skin disinfectant composition is provided.

- IL-17A/F heterologous polypeptides and therapeutic uses thereof

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

- Methods for extending the replicative lifespan of cells

The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured cells can be used for a variety of applications including cell-based therapies such as bone marrow transplants, gene therapies, tissue engineering, and in vitro organogenesis.

- Hemostatic textile

The present invention is directed to a hemostatic textile, comprising: a material comprising a combination of glass fibers and one or more secondary fibers selected from the group consisting of silk fibers; ceramic fibers; raw or regenerated bamboo fibers; cotton fibers; rayon fibers; linen fibers; ramie fibers; jute fibers; sisal fibers; flax fibers; soybean fibers; corn fibers; hemp fibers; lyocel fibers; wool; lactide and/or glycolide polymers; lactide/glycolide copolymers; silicate fibers; polyamide fibers; feldspar fibers; zeolite fibers, zeolite-containing fibers, acetate fibers; and combinations thereof; the hemostatic textile capable of activating hemostatic systems in the body when applied to a wound. Additional cofactors such as thrombin and hemostatic agents such as RL platelets, RL blood cells; fibrin, fibrinogen, and combinations thereof may also be incorporated into the textile. The invention is also directed to methods of producing the textile, and methods of using the textile to stop bleeding.

- SOLUBILIZING SYSTEMS FOR FLAVORS AND FRAGRANCES

The present invention provides compositions and clear oil-in-water microemulsion containing up to 80% w/w of an oil, a surfactant system, a w/w oil/surfactant system ratio between 1 and 3, and a solubilizing-aid ingredient which is not a surfactant neither a VOC compound, the latter being present in an amount sufficient to ensure that the ratio oil/(surfactant+solubilizing-aid) is between 0.1 and 5. The present invention concerns also the articles and products associated with such compositions and microemulsions, and the methods to manufacture them.

- Dispersions

A solid composition comprising oil core aphrons dispersed in a solid surfactant.

- N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE

The present invention relates to an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof, the N-(phosphonoalkyl)-amino acid, related compound or derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, other than N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, a related compound or a derivative thereof in a form as a free acid, salt, partial salt, lactone, amide or ester, or in stereoisomeric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic administration to a mammalian subject, as well as a method of administering an effective amount of such a composition for alleviating or improving a condition, disorder, symptom or syndrome associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system.

- Use of low-dosage erythropoietin for stimulation of endothelial progenitor cells, for organ regeneration and for slowing the progression of end-organ damage

The present invention relates to the use of low-dosage erythropoietin for stimulation of physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulation of vasculogenesis, for therapy of diseases related to a dysfunction of endothelial progenitor cells, and for production of pharmaceutical compositions for treatment of such diseases as well as pharmaceutical compositions that include erythropoietin and other suitable active ingredients for stimulation of endothelial progenitor cells.

- Thiazole inhibitors targeting resistant kinase mutations

A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophbic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.

- ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein the substituents are as defined in the specification.

- Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain

Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

- Aqueous photoprotective compositions comprising hydrophilic metal oxide nanopigments and polyalkylene glycols of low molecular mass

Stable, reduced whitening photoprotective compositions contain: a) at least one aqueous phase, b) at least hydrophilic inorganic nanopigments based on metal oxides, in an amount ranging from 1% to 25% by weight, with respect to the total weight of the composition, and c) at least one polyalkylene glycol having a molecular mass of less than 8,000 g/mol, formulated into d) a topically applicable, physiologically acceptable medium therefor.

- Composition and method for treating hyperpigmented skin

An improved cosmetic and dermatological composition and a method for treating hyperpigmented skin is disclosed. The composition demonstrates an enhanced ability to lighten mammalian skin color, and is nontoxic and nonirritating. The composition comprises a hydroxycinnamic acid or a methoxycinnamic acid dissolved in a compound having one or more hydroxy groups, like a PEG-4 through PEG-20, a monoC.sub.1-4alkyl ether of an ethylene glycol, or a monoC.sub.1-4alkyl ether of a propylene glycol oligomer, and/or a silicone fluid.

- Method of treating skin requiring tattoo removal

A treatment regimen for treating skin subject to tattoo removal procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

- ANTIPERSPIRANT STICK COMPOSITIONS

Disclosed are antiperspirant stick compositions comprising specified amounts of antiperspirant active; carrier oil comprising volatile silicone oil and non-volatile masking oil; structurant comprising fatty alcohol and cosmetically acceptable wax having a melting point of 75 to 95.degree. C., a portion of wax comprises polyethylene in specified amounts. Also disclosed are methods of making such stick compositions, and methods of ameliorating perspiration by the topical application of such compositions to the skin.

- Skincare compositions and methods

There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises from 0.5 to 10% by weight of salicylic acid and from 0.5 to 10% of hydrogen peroxide, but is substantially free of other therapeutic agents selected from the group consisting of anti-microbial agents, anti-bacterial agents, anti-viral agents, anti-fungal agents, anthelmintic agents and anti-inflammatory agents. The composition is useful in the treatment of acne.

- Skin Whitening Methods and Compositions Based on Zeolite - Active Oxygen Donor Complexes

The present invention discloses certain complexes of anionic zeolites with active oxygen donor agents, such as organic or inorganic peroxides, and methods and compositions based on said complexes for skin whitening.

- HoxD3, HoxA3 and HoxB3 compositions and methods for improved wound healing

The present invention provides methods and compositions useful in localized transfer of genetic material or proteins. Moreover, the present invention provides methods and compositions for improving and/or controlling wound healing by applying a wound care device comprising HoxD3 and/or HoxA3 and/or HoxB3. In addition, the present invention provides methods and compositions for improved wound healing in subjects having impaired healing capabilities, such as diabetic and aged subjects.

- Extracts of houttuynia cordata and rubus coreanus and their composition for preventing and treating allergic diseases

The present invention relates to an extract of Houttuynia cordata and Rubus coreanus, and a composition for the prevention and treatment of allergic diseases, comprising the same. The inventive extract and the composition comprising the same have the effect of preventing and treating allergic diseases by inhibiting the degranulation and histamine release of mast cells. Also, they show no cytotoxicity and thus can be safely use in vivo.

- Compounds for the treatment of inflammatory disorders and microbial diseases

This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-.alpha. or combinations thereof.

- SUBSTITUTED BICYCLIC 8-PYRR0LIDINOXANTHINES, METHODS FOR THEIR PRODUCTION, PHARMACEUTICAL FORMULATIONS AND THEIR USE

Compounds for the treatment of elevated blood glucose levels and the physiological and metabolic disorders arising therefrom are disclosed and comprise novel substituted bicyclic 8-pyrrolidinoxanthines and their derivatives of formula l: wherein the various R groups are hereinafter defined. The present invention also comprises pharmaceutical compositions comprising them as well as processes for the preparation of these compounds. Particular blood glucose disorders treatable thereby include type-2 diabetes, insulin resistance, hyperglycemia, arteriosclerotic diseases and the like.

- Pleuromutilin derivatives, process for their preparation and uses thereof

Pleuromutilin compounds of the formula: are of use in antibacterial therapy.

- Stabilized derivatives of ascorbic aicd

Ascorbic acid derivatives of the general formula 1: wherein R<1> is a C2-C22 acyl group, an amino acid group, or a C1-C17 alkyl group; R<2> is ammonium or a metal cation; and each of R<3> or R<4>, independently, is hydrogen, a C2-C22 acyl group, an amino acid residue, or a C1-C17 alkyl group, are more stable than ascorbic acid and can be used as a source of vitamin C in pharmaceutical, nutraceutical and cosmetic compositions.

- Nonaqueous ascorbic acid compositions and methods for preparing same

A method for preparing a nonaqueous ascorbic acid composition in an alcohol solvent comprising ascorbic acid, a solubilization enhancer, and an oleaginous skin protectant is described. The amount of ascorbic acid dissolved in the nonaqueous composition in the presence of the solubilization enhancer is greater than the amount of ascorbic acid that would be soluble in the solvent in the absence of the solubilization enhancer. A nonaqueous composition comprises the dissolved ascorbic acid, solubilization enhancer, and homogenized oleaginous skin protectant.

- Transparent cosmetic microemulsion-based formulation containing an alpha-hydroxy-carboxylic acid

The invention relates to a clear, microemulsion-based cosmetic formulation with reduced stickiness, comprising at least one antiperspirant active ingredient and/or deodorant active ingredient and .alpha.-hydroxycarboxylic acid.

- Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same

The present invention relates to stem cells which exhibit increased sensitivity to a chemoattractant and, more particularly, to methods of generating and using them such as in clinical applications involving stem cell transplantation.

- Increasing of the resorption of substances via skin and mucous membranes

The invention relates to the increasing of the resorption of substances via skin and mucous membranes. The invention also relates to substances having an increased capability of being resorbed by skin and mucous membranes, and to pharmaceutical compositions containing substances of this type.

- Agents for preventing and treating disorders involving modulation of the RyR receptors

The present invention provides compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.

- STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS

The invention is directed sterile to compositions of glucocorticosteroids useful in the prophylaxis and chronic treatment of asthma and other allergic and inflammatory conditions in adults and pediatric patients.

- Antiperspirant compositions

Antiperspirant water in oil emulsions can suffer from inferior sensory properties, including wetness and/or slow "dry-down" and/or stickiness, even when the composition contains a polyhydric humectant, a known class of skin moisturiser. A balance of sensory properties can be achieved by formation of a base composition in the form of a water in oil emulsion in which the oil phase, preferably comprising 20 to 55% of the base composition, contains at least threshold proportions of both a volatile silicone and a sensory modifying oil, particularly selected from dicaprylyl ether and dicaprylyl carbonate, the sensory modifying oil advantageously being present in a weight ratio to the polyhydric humectant of from 3:4 to 4:1. Such compositions are particularly suitable for mixture with a liquifiable propellant to form aerosol compositions.

- High efficiency sunscreen composition particularly useful for wipes and sprays

A sunscreen composition, either impregnating a wipe substrate or comprising a sunscreen spray, wherein the composition comprises an oil phase dispersed stably as emulsion droplets in a water phase that contains i) a booster for the sun protection factor (SPF), comprising a combination of water-dispersible particulate materials, one of which is smectite clay, and a water-soluble or water-dispersible phenolic polymer; and ii) a water-soluble or water-dispersible polymer having a weak acid group, a weight average molecular weight of 1,000-100,000 Dalton, and an anionic charge density of no less than 4 milliequivalent per gram of the polymer; the said sunscreen composition meeting the following specifications: i) the in-vivo sun protection factor (SPF) is .gtoreq.1.8 times the weight percent of the sunscreen active(s) contained therein, based on the weight of the sunscreen composition; and ii) the shear thinning index of the composition is greater by 5% or higher with the weak acid polymer contained therein than without the polymer, the shear thinning index being defined as the ratio of viscosities of the sunscreen composition at 0.5 rpm and 20 rpm, measured on a Brookfield RVT viscometer at 25 .degree. C., using spindle 7, after cooling the composition to room temperature and storing it at that temperature for about 24 hours.

- Cosmetic and pharmaceutical uses of an extract of a plant belonging to the genus buchholzia

A cosmetic or dermopharmaceutical composition including an extract of a plant belonging to the genus Buchholzia and at least one auxiliary and/or additive is provided. A method for the cosmetic treatment of the skin or scalp and a method for the treatment of skin inflammation includes administering to a patient in need thereof a composition including an effective amount of a plant extract from a plant belonging to the genus Buchholzia.

- PATHOTROPIC TARGETED GENE DELIVERY SYSTEM FOR CANCER AND OTHER DISORDERS

Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.

- Stabilized single domain antibodies

The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

- Method for recovering a secondary plant metabolite

The present invention relates to a method for recovering a secondary plant metabolite from a seed material. The present invention further relates to a extract comprising the secondary plant metabolite, which extract is obtainable by a method according to the invention and to a foodstuff, cosmetic or medicament comprising such an extract.

- Compositions having improved soft focus effect properties

The invention relates to a composition, especially a cosmetic composition, containing at least one silicone elastomer and at least one encapsulated pigment, wherein the refractive index of the pigment is greater than the refractive index of the encapsulating material.

- Integrated Circuit Device

A commercially mass-produced, integrated circuit including: a solid substrate of one conductivity type; at least one solid material pocket of a different conductivity type having a side surface and positioned on a selected top surface of the substrate to thereby form a signal-translating, electronic rectifying barrier between the at least one solid material pocket and the selected top surface of the substrate; and a solid state material region adjoining the substrate, the electronic rectifying barrier, and the side surface of the at least one solid material pocket; wherein next to the electronic rectifying barrier the solid state material region has a lateral dimensional accuracy of better than a few hundred atomic layers.

- Cosmetic composition comprising porous particles incorporating optically active substances

An object of the invention is to offer an optical additive capable of adequately activating the effects of incorporated optically active substances, providing the base with such optical effects, having a suitable sensation and level of safety, and having exceptional cosmetic properties. A cosmetic composition comprising in a physiologically acceptable medium (a) silicium based porous particles having an aspect ratio of at least 2 and (b) an optically active substance incorporated into said porous particles is offered. The incorporated optically active substances are selected from among UV screening substances, fluorescent substances and photochromic substances.

- Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same

Compounds useful as agonists of A.sub.2A adenosine receptors are described. Also described is a cosmetically acceptable composition having an agonists of A.sub.2A adenosine receptors where the composition is suitable to apply to human skin to reduce the effects of melanin, resulting in skin whitening.

- Para-coumaric acid or para-hydroxycinnamic acid derivatives and their use in cosmetic or dermatological compositions

The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an --NH-- group; X and Y are identical and each represent a CH or CH.sub.2 group, as an active principle with depigmenting, free-radical-scavenging and/or antiinflammatory activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and/or antiinflammatory activity.

- Cosmetic composition

The present invention relates a cosmetic composition comprising: at least one pigment comprising: an elongated core, a red organic colorant coating at least partially the core, and at least one binder between the core and the organic colorant.

- Anti-aging treatment using copper and zinc compositions

Composition and methods for alleviating or eliminating age related skin conditions by providing an effective amount of one or more copper, zinc and copper-zinc compositions are disclosed. Treatment is accomplished through the use of topical compositions containing one or more copper or zinc salts and/or copper-zinc compounds or complexes, particularly copper-zinc malonate active ingredient.

- Soluble tgf-b type III receptor fusion proteins

Soluble fusion proteins of the TGF-.beta. type III receptor and novel methods for their production are disclosed herein for the first time. The fusion proteins of the invention competitively inhibit the binding of members of the TGF-.beta. superfamily to their cell-surface receptors. Also provided are methods for using these fusion proteins to modulate the biological activity of members of the TGF-.beta. superfamily under in vitro or in vivo conditions, and to prevent or treat a variety of pathophysiological conditions associated with overproduction of TGF-.beta. or mediated by altered signaling pathways of the inhibin/activin system.

- Stable Therapeutic Formulations

Compositions of and methods for formulating and delivering biologically active agent formulations having enhanced physical stability, and wherein deterioration from the presence of oxygen and/or water is minimized and/or controlled, to yield a stable formulation. The compositions of and methods for formulating and delivering biologically active agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-corneum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the biologically active agents.

- Formulation for topical non-invasive application in vivo

A formulation comprising molecular arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of said pores is smaller than the average penetrant diameter, provided that the prenetrants can transport agents or else enable agent permeation through the pores after penetrants have entered pores, characterized in that the formulation comprises at least one consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over, and retention at, the application area is enabled and/or at least one antioxidant in an amount that reduces the increase of oxidation index to less than 100% per 6 months and/or at least one microbiocide in an amount that reduces the bacterial count of 1 million germs added per g of total mass of the formulation to less than 100 in the case of aerobic bacteria, to less than 10 in the case of entero-bacteria, and to less than 1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days.

- Healthcare and cosmetic compositions containing nanodiamond

Nanodiamonds can be included in various compositions to take advantage of the ability of nanodiamond to reduce or prevent the formation of free radicals through administering the particles to a subject. Nanodiamonds can be administered through a variety of means to a tissue area of the subject, thus reducing or preventing the formation of free radicals and reducing the signs of ageing. The nanodiamonds may be incorporated into a composition that includes a variety of components including biologically or cosmetically acceptable carriers, dispersants, and additional active ingredients.

- Skin stabilizer preparation

A skin stabilizer system is provided which comprises separate compositions of a corticosteroid and sulfur. The compositions may be combined in any desired ratio by the user, and applied to the skin.

- Pharmaceutical and cosmetic composition against skin aging

Pharmaceutical and cosmetic compositions for the prevention of skin aging, containing phospholipid complexes of extracts of Vitis vinifera, and phospholipid complexes of standardized extract from Centella asiatica.

- Compositions and methods for the treatment of immune related diseases

The present invention relates to composition containing novel proteins and method of using those compositions for the dignosis and treatment of immune related diseases.

- Compositions and methods for the treatment of immune related diseases

The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.

- Regulation of mammalian keratinous tissue using skin care actives

Personal care compositions comprising skin and/or hair care actives. Such compositions are useful for regulating the condition of mammalian keratinous tissue needing such treatments, particularly skin lightening. In accordance with one embodiment, there is provided a personal care composition comprising a safe and effective amount of a first active selected from the group consisting of erythritol, p-cymen-7-ol, benzyl phenylacetate, 4-(4-methoxyphenyl)butan-2-one, ethoxyquin, tannic acid, gallic acid, octadecenedioic acid, p-cymen-5-ol, methyl sulfonyl methane, an avenathramide compound, and combinations thereof.

- Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents

The present invention relates generally to methods and compositions of treating disease characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering antiangiogenic agents in combination with chemotherapeutic agents. More specifically, the present invention relates to a methods and compositions of treating diseases characterized by abnormal cell proliferation and/or abnormal or undesirable angiogenesis by administering 2-methoxyestradiol, in combination with chemotherapeutic agents.

- Histone deacetylase inhibitor and process for producing the same

HDAC inhibitors represented by formula (1) show strong inhibitory activity against various subtypes of HDACs. The compounds of the present invention find utility as pharmaceutical agents for treating or preventing diseases associated with HDAC 1, 4, and 6. The methods for producing the compounds of the present invention enable easy and simple synthesis of various types of these compounds, and are expected to contribute to the development of HDAC inhibitors having novel properties and the like.

- Pyrimidine derivatives

A compound of Formula (I): or a pharmaceutically and/or veterinarily acceptable derivative thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.8 are as defined above.

- Galvanic Current Skin Treatment

The present invention relates to methods and systems for application of a substance and an electrical current to a biological tissue or surface. In one embodiment, the methods and systems include application of a substance and an electrical current to the surface or tissue such that the transport or absorption of the substance into the surface or tissue is enhanced for a period of time after the electrical current has been removed.

- ELECTROKINETIC SYSTEM AND METHOD FOR DELIVERING METHOTREXATE

The electrokinetic methotrexate delivery system includes at least one applicator having a multiplicity of non-conductive micro-needles carried on a non-conductive surface of the applicator. The opposite surface is formed of electrically conductive material for contact with an active electrode. The applicator includes a matrix containing a medicament, e.g., methotrexate, or a carrier therefor between the opposite surfaces. When the applicator is applied to the individual's skin with the micro-needles penetrating the skin, an electrical current is completed through the power source, the active electrode, methotrexate, or electrically conductive carrier therefor, the targeted treatment site, the individual's body, a ground electrode and the power supply, thereby electokinetically driving the medicament through the non-conductive micro-needles into the targeted treatment site.

- Spray-on formulations and methods for dermal delivery of drugs

The present invention is drawn to sprayable formulations, methods of drug delivery, and resultant solidified layers for dermal delivery of a drug. The formulation can include a drug, a non-volatile solvent system, a solidifying agent, and a propellant. The formulation can have an initial viscosity suitable to be expelled out of a pressurized or manual pump container and applied onto a skin surface as a layer. When applied to the skin, the formulation can form a solidified layer after at least a portion of the propellant is evaporated.

- Compositions and methods for dermally treating musculoskeletal pain

The present invention is drawn to solidifying formulations for dermal delivery of a drug for treating musculoskeletal pain, inflammation, joint pain, etc. The formulation can include a drug selected from certain drug classes, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the evaporation of at least some of the volatile solvent converts the formulation on the skin into a solidified layer and the non-volatile solvent system is capable of facilitating the topical delivery of the drug(s) at therapeutically effective rates over a sustained period of time.

- Agents for use on skin and/or hair containing quadruply substituted cyclohexene compounds

The invention relates to agents for use on skin or hair, particularly for increasing skin tanning and the synthesis of melanin in skin or hair. The invention contains, in particular, cosmetic or dermatological preparations containing quadruply substituted cyclohexene compounds. The use of the preparations leads to the induction and intensification of the tanning mechanisms of skin, the intensification of hair color and thus also to an intensification of the skin's and hair's intrinsic protection.

- Use of a compound modifying an interleukin 5, interleukin 6 and/or interleukin 10 secretion for preparing a pharmaceutical composition for rosacea treatment

The invention relates to the use of a compound which modifies, and advantageously inhibits, the secretion of at least one interleukin chosen from the group comprising IL-5, IL-6 and IL-10, for the preparation of a pharmaceutical composition for treating rosacea.

- Substances with a probiotic action used in deodorants

A method for promoting probiotic activity on the skin comprises contacting the skin with a probiotic effective amount of a substance having a probiotic effect selected from the group consisting of a plant extract, a glycerol monoalkyl ether, and a fatty acid ester or a combination of the plant extract and the glycerol monoalkyl ether whereby the growth of desired skin microbes is promoted and the growth of undesired skin microbes is inhibited.

- Film and film-forming compositions

The invention provides films and film forming compositions that can be applied onto a tissue surface. The film and the film forming composition comprise at least one polycarboxylated polymer and at least one polysaccharide.

- Compositions and methods for topical administration

Vanishing cream base compositions and vanishing cream compositions suitable for topical application of an active agent to an animal or plant comprising water, at least one alcohol, a polymeric thickening agent, a skin penetration enhancing compound, and an emulsifying agent are provided. Methods for the use and manufacture of such creams are also disclosed.

- Use of a topical medicament comprising riluzole

The present invention relates to the use of Riluzole if needed with suitable adjuvants and additives for the production of a medicament for the treatment of diseases characterized by hyperproliferation of keratinocytes and/or T cells, in particular psoriasis and neurodermatitis as well as compositions comprising Riluzole and use thereof.

- Prevention and treatment of complement-associated disorders

The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the prevention and treatment of complement-associated disorders, including complement-associated eye conditions, such as age-related macular degeneration (AMD) and choroidal neovascularization (CNV).

- Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs

The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and at least two solidifying agents. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

- Method for treating generalized and focal peripheral neuropathies

A composition providing cobalamine, cobalamine subtype or cobalamine analog as an effective agent for topical or transdermal administration to alleviate pain associated with a generalized or focal peripheral neuropathic condition, such as carpal tunnel syndrome.

- Method of preparing dendritic drugs

Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.

- Method for providing an active agent topically to the skin

A method of providing an active agent topically to the skin is provided and includes providing a topical preparation having an internal phase and an external phase, wherein the internal phase is dispersed within the external phase. The internal phase includes at least one hydrophilic carrier, at least one hydrophilic component, and at least one active agent, and the external phase comprises a silicone matrix. The topical preparation is placed in contact with the skin of a patient such that the active agent is released from the silicone matrix topically onto the skin of the patient.

- Cationic Steroid Antimicrobial Compositions and Methods of Use

The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

- Process for qualitative and/or quantitative determination of at least one molecule present on a solid surface

The invention concerns a method for qualitative and/or quantitative determination of at least one molecule present on a solid surface, in which a polysiloxane-based sorbent material is used.

- HETEROCYCLIC MODULATORS OF PPAR

The present invention relates to compounds and methods useful as modulators of Peroxisome Proliferator-Activated Receptors (PPARs) for treatment or prevention of disease.

- Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives

The present invention provides pharmaceutical compositions comprising quinazolinecarboxamide derivative, and certain novel quinazolinecarboxamide derivatives capable of inhibiting heparan sulfate-glycosaminoglycan (HS-GAGs) interactions with L-selectin, and useful in the prevention or treatment of various diseases, disorders and conditions mediated by HS-GAGs, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.

- Bi-aryl meta-pyrimidine inhibitors of kinases

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

- Novel benzo[D][1,3]-dioxol derivatives

The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.

- BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY

Systems and methods for synchronizing the administration of compounds with the human body's natural circadian rhythms and addiction rhythms to counteract symptoms when they are likely to be at their worst by using an automated and pre programmable transdermal or other drug administration system.

- Pharmaceutical composition

The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and/or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and/or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytoststatic active antibiotics, caphthotecine derivatives, anti estrogens, anti-androgens and analogs of gonadotropin releasing hormon.

- Personal care composition comprising dehydroacetate salts

Personal care composition comprising a dehydroacetate salt, and a dermatologically acceptable carrier, wherein the pH of said composition is about 7.0 and greater.

- Photostable sunscreen compositions comprising dibenzoylmethane compound UV-A filters and s-triazine compounds

Photostable sunscreen compositions containing at least one dibenzoylmethane compound UV-A screening agent and at least one particular s-triazine compound have improved effectiveness with respect to UV-A radiation.

- Personal care compositions

Personal care compositions comprising an active component, use of such compositions, and methods of marketing such compositions. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.

- Cosmetic composition with a volumizing effect

The present invention relates to a cosmetic composition for caring for and/or making up the skin and/or the lips, containing, in a physiologically acceptable medium, at least: one active agent comprising at least one glycol with a C.sub.4-C.sub.16 hydrocarbon-based chain and/or a hydroxylated ester resulting from the esterification of polyol and/or of C.sub.4-C.sub.16 carboxylic acid(s), and one additional agent chosen from essential oils, agents for promoting capillary circulation and temperature regulators, and mixtures thereof.

- Methods and kits for topical administration of hyaluronic acid

The present invention provides a method for treating the skin of a subject comprising (a) applying an HA liquid to an area of the skin, wherein the HA liquid comprises hyaluronic acid, hyaluronate, cosmetically acceptable salts of hyaluronic acid, intramolecular esters of hyaluronic acid and/or intermolecular esters of hyaluronic acid; (b) massaging a self-heating mask composition into the area of the skin for a duration sufficient to activate heat, wherein the self-heating mask composition comprises at least one silicoaluminate; (c) letting the self-heating mask composition set on the area of the skin to form a mask; (d) optionally massaging the mask into the area of the skin; (e) optionally removing the mask from the area of the skin; and thereafter (f) optionally applying another skin care product to the area of the skin. The present invention also provides a kit useful for skin treatment, wherein the kit comprises the HA liquid and the self-heating mask composition comprises at least one silicoaluminate.

- Methods and kits for topical administration of hyaluronic acid

The present invention provides a method for treating the skin of a subject comprising (a) applying an HA liquid to an area of the skin, wherein the HA liquid comprises hyaluronic acid, hyaluronate, cosmetically acceptable salts of hyaluronic acid, intramolecular esters of hyaluronic acid and/or intermolecular esters of hyaluronic acid; (b) massaging a self-heating mask composition into the area of the skin for a duration sufficient to activate heat, wherein the self-heating mask composition comprises at least one silicoaluminate; (c) letting the self-heating mask composition set on the area of the skin to form a mask; (d) optionally massaging the mask into the area of the skin; (e) optionally removing the mask from the area of the skin; and thereafter (f) optionally applying another skin care product to the area of the skin. The present invention also provides a kit useful for skin treatment, wherein the kit comprises the HA liquid and the self-heating mask composition comprises at least one silicoaluminate.

- Cleansing Compositions Containing Film

A composition comprising a cleanser base and a plurality of film pieces, wherein the composition has a moisture content of about 22% or less. Also, a method of making a composition, comprising the steps of combining pieces of film with a cleansing material to make a cleansing mixture, and forming the mixture into a product of desired shape and size. Also, A method of delivering an active material during cleansing, comprising cleansing with water and a composition, wherein the composition comprises a plurality of film pieces, said film pieces comprising an active material and a polymer selected from water-soluble polymers, water-dispersible polymers, and combinations thereof.

- Cosmetic herbal compositions

Herbal cosmetic skin care compositions formulated to combat conditions associated with oxidative stress are provided. The compositions contain effective amounts of one of several active agents, including an herbal agent derived from one or more of the plant species, as well as cosmetically acceptable carriers. Other agents that may be included are proteins, peptides, anti-inflammatory agents, and/or vasodilators. These cosmetic compositions find use in improving the appearance of aged or damaged skin.

- Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs

The present invention is drawn to adhesive solidifying formulations, and methods for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a polyvinyl alcohol. The solvent vehicle can include a volatile solvent system including water and an alcohol solvent, e.g., ethanol, propanol, and/or isopropanol, and a non-volatile solvent system including at least one non-volatile solvent which is compatible with polyvinyl alcohol. The formulation is formulated such that the water to polyvinyl alcohol weight ratio is in the range of from about 4:1 to about 1:1, and water to alcohol solvent weight ratio in the range of from about 0.33:1 to about 6:1.

- Cellulite skin treatment methods and compositions

Methods for treating cellulite-affected areas on a human body include applying, to affected skin areas, while dry, a skin scrub that includes certain oils, menthone glycerin acetal, and certain organic extracts, then removing the scrub, moistening the affected areas, and applying a skin cream that includes caffeine, certain organic extracts and oils, and menthone glycerin acetal.

- Compositions and methods for dermally treating infections

The present invention is drawn to solidifying adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug which can treat various skin infections, such as fungal, bacterial, and/or viral skin infections. The formulation can include an anti-infective drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent. The non-volatile solvent system can facilitate the delivery of the drug at therapeutically effective rates for sustained period of time. The non-volatile solvent system can also act as a plasticizer for the solidifying agent. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

- Method for reducing allergenicity in indoor spaces

According to this invention, allergenicity in an indoor space is reduced by denaturing allergens in allergen reservoirs that are capable of producing respiratory or skin reactions and physically removing the allergens from the allergen reservoirs in the indoor space. The allergen reservoirs may also be treated with pesticides and fungicides/fungistats to prevent reinfestation of house dust mites, molds and cockroaches.

- Hyphae-Specific Cell Wall Proteins Of Candida

Nucleic acids that code a cell wall protein required for the hyphal development of Candida; fragments of the nucleic acids; vectors containing the nucleic acids or nucleic acid fragments; host cells containing the vectors; cell wall proteins coded by the nucleic acids; antibodies directed against the proteins; methods for producing the cell wall proteins; methods for characterizing and/or for detecting the hyphal stage of Candida; methods for detecting a Candida infection; methods for identifying substances having a therapeutic effect against diseases caused by Candida; diagnostic and pharmaceutical compositions containing the nucleic acid, nucleic acids fragments, vectors, host cells, proteins and/or antibodies directed against the cell wall protein; kits for conducting in-vitro indentation of the cell wall proteins, and; to the use of the nucleic acids, vectors, proteins or antibodies for diagnosing and treating Candida-caused diseases, i.e., producing diagnostic or pharmaceutical compositions.

- Flux-enabling compositions and methods for dermal delivery of drugs

The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

- Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs

The present invention is drawn to adhesive formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can have a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least two non-volatile solvents. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

- Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs

The present invention is drawn to adhesive formulations and methods of drug delivery. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least two volatile solvents, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

- Compositions and methods for dermally treating neuropathic pain

The present invention is drawn to adhesive solidifying formulations for treating neuropathic pain. The formulation can include a drug suitable for treating neuropathic pain, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

- Compositions and methods for treating dermatitis or psoriasis

The present invention is drawn to adhesive solidifying formulations for treating skin disorders, such as dermatitis or psoriasis. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein the non-volatile solvent system is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

- Method of enhancing needleless transdermal powered drug delivery

A method is provided for enhancing the transdermal or intradermal delivery of a therapeutic agent using a needleless syringe drug delivery system. In one embodiment, the method entails first administering to a predetermined area of skin or mucosa particles comprising the therapeutic agent, a placebo and/or a permeation enhancing agent. A transdermal delivery device or occlusive dressing is then topically positioned over the area of skin or mucosa. In another embodiment, the method entails administering a formulation of particles wherein the formulation includes particles that contain a therapeutic agent and placebo particles.

- TEXTURED FILM WITH DEEP POCKETS

A thermoplastic film having a first surface defining pockets, each pocket having a depth and breadth and a bottom, the bottom is preferably textured and is thinner than the thickness of the first surface. Devices made from the film include one or more of a variety of materials contained within the pockets and a second layer overlying the first surface to cover the openings of the pockets. A process of making the film is also disclosed.

- Human sample matching system

Methods and apparatus for a human sample (S), analyzing the sample (S) and then determining a match with a member of the opposite sex is disclosed. In one embodiment, a customer purchases an AromaMatch.TM. Test Kit (14), which comprises a bottle of cleaning solution (20), a cotton ball (22) a sample patch (24), a sample bag (28) and a mailing envelope (30). The user (10) opens the kit (14), cleans a patch of skin somewhere on his or her body, and then applies the patch (24). After wearing the patch (24) for an appropriate time period, the patch (24) is removed, and placed in the sample bag (28). The user (10) writes his or her password on the sample bag (28), and then mails it in the return envelope (30). A laboratory analyzes the sample patch (24), and determines a set of genetic attributes (G1) that are associated with the sample (S). The user (10) receives an analysis report by mail, or views the results of the analysis on a website (18), such as www.AromaMatch.com. In another embodiment, a customized perfume is manufactured that is based on biological agents that are selected to match the set of genetic attributes identified by the analysis.

- Use Of Chemotherapeutic Agents

The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.

- Hepoxilins and modulators of ichthyin for treatment skin disorders

The present application relates to compositions and methods for treating skin disorders, dry skin, and protection of skin in inflammatory events. The present application more particularly discloses the identification of new genes and metabolic pathways involved in skin disorders, which provide novel targets and approaches for treating said disorders and for screening biologically active compounds. The present invention also provides various products and constructs, such as probes, primers, vectors, recombinant cells, which can be used to implement the above methods. The invention may be used to detect or treat various skin disorders, particularly dry and inflammatory skin disorders, in various subjects, including mammalian subjects, particularly human beings.

- COSMETIC SKINCARE APPLICATIONS EMPLOYING MINERAL-DERIVED TUBULES FOR CONTROLLED RELEASE

Compositions and methods pertaining to the topical treatment of skin are disclosed. The present invention relates to topical compositions for regulating the condition of skin, especially for regulating visible and/or tactile discontinuities in skin associated with skin aging, environmental affects and the like. One embodiment of the present invention relates to improving skin with compositions containing one or more non-volatile, slowly absorbed, liquid or semi-liquid organic substances (active agents) via controlled release of active agents associated with mineral-derived tubules such as halloysite nanotubules. For example, the active agents, in the form of organic substances may include vitamin compounds and glycerin, among others.

- Stable oil-in-water and water/oil/water multiple emulsions and hair treating compositions comprising them

The present invention provides an oil-in-water or water/oil/water multiple emulsion, or a mixture thereof, comprising (A) a organopolysiloxane elastomer crosslinked with polyether chains and (B) at least one thickener selected from the group of a polyacrylamide homo- or copolymer, a cellulose ether, a non-silicone cationic polymer or a thickening system comprising a mixture of from about 60% to about 67% of the thickening system of a copolymer of 2-propenoic acid with 2-propenamide, from about 27% to about 32% of the thickening system of the homopolymer of 2-methyl-1-propene and from about 5 to about 7% of the thickening system of poly(oxy-1,2-ethanediyl)-sorbitan-monododecanoate.

- Ionized compositions and methods of use therefore

This invention relates to methods for preparing an ionic composition suitable for use as a cosmetic product, products containing such compositions, and containers for containing and dispensing such products.

- PAWPAW and/or peach derived composition

There is provided a process for making a composition suitable for topical application comprising the steps of a) heating at least one fruit and/or vegetable pulp to up to a temperature in the range of about 40.degree. C. to 100.degree. C.; b) mixing between 1 and 40% w/w of a mild base with the heated fruit and/or vegetable pulp. There is also provided a fruit and/or vegetable derived composition suitable for topical application prepared by the above process. There is further provided a fruit and/or vegetable derived composition comprising at least one fruit and/or vegetable-derived pulp and a mild base, said composition having a pH in the range of about 7.5 to about 9.5.

- ANTI-AGEING COMPOSITION

The invention relates to a composition containing, in a physiologically acceptable medium, at least: hyaluronic acid and/or one of its salts; at least one extract of soybean proteins; and at least one compound of formula (I) as described herein. This composition is useful for preventing and/or decreasing the signs of skin ageing, in particular the loss of firmness and/or of elasticity of the skin.

- Carbohydrase Inhibitors Derived From Chestnut And Use Thereof

The present invention provides a plant-derived carbohydrase inhibitor, wherein the inhibitor is effective for preventing or alleviating diabetes, or preventing obesity, and foods, drinks, and medicines containing the same. The present invention is accomplished by use of an .alpha.-amylase inhibitor or an .alpha.-glucosidase inhibitor as a carbohydrase inhibitor that is extracted from astringent skins of a chestnut using ethanol or aqueous ethanol solution. The present invention can also be accomplished by adding the carbohydrase inhibitor to a food or medical composition as an active ingredient for delaying saccharide digestion or absorption, suppressing a rise in postprandial blood glucose levels or blood insulin levels, or preventing obesity.

- Morinda Citrifolia Leaf Juice And Leaf Extract Based Formulations

A method and composition for inhibiting certain enzymes, where such inhibition results in various health benefits is provided. More particularly, a method and composition using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4) PDE3 and PDE4; 5-Lipoxygenase (LOX) and 15-LOX; Xanthine Oxidase (XO); Gamma Amino Butyric Acid (GABA) and the growth of the second most common human skin cancer cell line, is provided. Moreover, the foregoing enzymatic inhibitions result in: alleviating pain and inflammation; treating prostate cancers; lowering cholesterol levels; counteracting Diabetes Type II; maintaining the highest possible integrity of cellular interactions in the brain resulting in an undisturbed neural function, (i.e., neuroprotection); ameliorating the effects of asthma and allergies; improving energy; improving insulin secretion; decreasing kidney stone accumulation; alleviating the effects of gout; minimizing convulsions related to epilepsy and other seizure disorders; and providing palliative effects to those addicted to drugs.

- Cleansing Wipes Having A Covalently Bound Oleophilic Coating, Their Use And Processes For Their Manufacture

A method is provided for forming an active material containing coating on a substrate. The substrate is suitably a wipe, cloth or sponge for household use, or a water-soluble household cleaning unit dose product. The method comprises the steps of: i) introducing one or more gaseous or atomised liquid and/or solid coating-forming materials which undergo chemical bond forming reactions within a plasma environment and one or more active materials which substantially do not undergo chemical bond forming reactions within a plasma environment, into an atmospheric or low pressure plasma discharge and/or an excited gas stream resulting therefrom, and ii) exposing the substrate to the resulting mixture of atomised coating-forming and at least one active material which are deposited onto the substrate surface to form a coating.